
<html lang="en"     class="pb-page"  data-request-id="2c9c3c78-acad-441d-89e3-93f5f0c7622b"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-13;requestedJournal:journal:jmcmar;article:article:10.1021/acs.jmedchem.9b02052;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer" /></meta><meta name="dc.Creator" content="Jay B.  Fell" /></meta><meta name="dc.Creator" content="John P.  Fischer" /></meta><meta name="dc.Creator" content="Brian R.  Baer" /></meta><meta name="dc.Creator" content="James F.  Blake" /></meta><meta name="dc.Creator" content="Karyn  Bouhana" /></meta><meta name="dc.Creator" content="David M.  Briere" /></meta><meta name="dc.Creator" content="Karin D.  Brown" /></meta><meta name="dc.Creator" content="Laurence E.  Burgess" /></meta><meta name="dc.Creator" content="Aaron C.  Burns" /></meta><meta name="dc.Creator" content="Michael R.  Burkard" /></meta><meta name="dc.Creator" content="Harrah  Chiang" /></meta><meta name="dc.Creator" content="Mark J.  Chicarelli" /></meta><meta name="dc.Creator" content="Adam W.  Cook" /></meta><meta name="dc.Creator" content="John J.  Gaudino" /></meta><meta name="dc.Creator" content="Jill  Hallin" /></meta><meta name="dc.Creator" content="Lauren  Hanson" /></meta><meta name="dc.Creator" content="Dylan P.  Hartley" /></meta><meta name="dc.Creator" content="Erik J.  Hicken" /></meta><meta name="dc.Creator" content="Gary P.  Hingorani" /></meta><meta name="dc.Creator" content="Ronald J.  Hinklin" /></meta><meta name="dc.Creator" content="Macedonio J.  Mejia" /></meta><meta name="dc.Creator" content="Peter  Olson" /></meta><meta name="dc.Creator" content="Jennifer N.  Otten" /></meta><meta name="dc.Creator" content="Susan P.  Rhodes" /></meta><meta name="dc.Creator" content="Martha E.  Rodriguez" /></meta><meta name="dc.Creator" content="Pavel  Savechenkov" /></meta><meta name="dc.Creator" content="Darin J.  Smith" /></meta><meta name="dc.Creator" content="Niranjan  Sudhakar" /></meta><meta name="dc.Creator" content="Francis X.  Sullivan" /></meta><meta name="dc.Creator" content="Tony P.  Tang" /></meta><meta name="dc.Creator" content="Guy P.  Vigers" /></meta><meta name="dc.Creator" content="Lance  Wollenberg" /></meta><meta name="dc.Creator" content="James G.  Christensen" /></meta><meta name="dc.Creator" content="Matthew A.  Marx" /></meta><meta name="dc.Description" content="Capping off an era marred by drug development failures and punctuated by waning interest and presumed intractability toward direct targeting of KRAS, new technologies and strategies are aiding in t..." /></meta><meta name="Description" content="Capping off an era marred by drug development failures and punctuated by waning interest and presumed intractability toward direct targeting of KRAS, new technologies and strategies are aiding in t..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 6, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b02052" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b02052" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b02052" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b02052" /></link>
        
    
    

<title>Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b02052" /></meta><meta property="og:title" content="Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0033.jpeg" /></meta><meta property="og:description" content="Capping off an era marred by drug development failures and punctuated by waning interest and presumed intractability toward direct targeting of KRAS, new technologies and strategies are aiding in the target’s resurgence. As previously reported, the tetrahydropyridopyrimidines were identified as irreversible covalent inhibitors of KRASG12C that bind in the switch-II pocket of KRAS and make a covalent bond to cysteine 12.  Using structure-based drug design in conjunction with a focused in vitro absorption, distribution, metabolism and excretion screening approach, analogues were synthesized to increase the potency and reduce metabolic liabilities of this series. The discovery of the clinical development candidate MRTX849 as a potent, selective covalent inhibitor of KRASG12C is described." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b02052"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02052">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b02052&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b02052&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b02052&amp;href=/doi/10.1021/acs.jmedchem.9b02052" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 6679-6693</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00785" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Featured Article</span><a href="/doi/10.1021/acs.jmedchem.9b01942" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of Cancer</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Jay B. Fell</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jay B. Fell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#54362635307a3231383814352626352d363d3b243c352639357a373b39"><span class="__cf_email__" data-cfemail="8be9f9eaefa5edeee7e7cbeaf9f9eaf2e9e2e4fbe3eaf9e6eaa5e8e4e6">[email protected]</span></a>. Phone: 303-386-1528.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jay+B.++Fell">Jay B. Fell</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5770-1225" title="Orcid link">http://orcid.org/0000-0002-5770-1225</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John P. Fischer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John P. Fischer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+P.++Fischer">John P. Fischer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brian R. Baer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brian R. Baer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brian+R.++Baer">Brian R. Baer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James F. Blake</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James F. Blake</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James+F.++Blake">James F. Blake</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Karyn Bouhana</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Karyn Bouhana</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Karyn++Bouhana">Karyn Bouhana</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David M. Briere</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David M. Briere</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Mirati Therapeutics, 9393 Towne Centre Drive, Suite 200, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+M.++Briere">David M. Briere</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Karin D. Brown</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Karin D. Brown</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Karin+D.++Brown">Karin D. Brown</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Laurence E. Burgess</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Laurence E. Burgess</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Laurence+E.++Burgess">Laurence E. Burgess</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Aaron C. Burns</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Aaron C. Burns</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Mirati Therapeutics, 9393 Towne Centre Drive, Suite 200, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Aaron+C.++Burns">Aaron C. Burns</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael R. Burkard</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael R. Burkard</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+R.++Burkard">Michael R. Burkard</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Harrah Chiang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Harrah Chiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Mirati Therapeutics, 9393 Towne Centre Drive, Suite 200, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Harrah++Chiang">Harrah Chiang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mark J. Chicarelli</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark J. Chicarelli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark+J.++Chicarelli">Mark J. Chicarelli</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Adam W. Cook</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Adam W. Cook</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Adam+W.++Cook">Adam W. Cook</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John J. Gaudino</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John J. Gaudino</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+J.++Gaudino">John J. Gaudino</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jill Hallin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jill Hallin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Mirati Therapeutics, 9393 Towne Centre Drive, Suite 200, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jill++Hallin">Jill Hallin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lauren Hanson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lauren Hanson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lauren++Hanson">Lauren Hanson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dylan P. Hartley</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dylan P. Hartley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dylan+P.++Hartley">Dylan P. Hartley</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Erik J. Hicken</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Erik J. Hicken</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Erik+J.++Hicken">Erik J. Hicken</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gary P. Hingorani</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gary P. Hingorani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gary+P.++Hingorani">Gary P. Hingorani</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ronald J. Hinklin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ronald J. Hinklin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ronald+J.++Hinklin">Ronald J. Hinklin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Macedonio J. Mejia</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Macedonio J. Mejia</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Macedonio+J.++Mejia">Macedonio J. Mejia</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peter Olson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peter Olson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Mirati Therapeutics, 9393 Towne Centre Drive, Suite 200, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Olson">Peter Olson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jennifer N. Otten</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jennifer N. Otten</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer+N.++Otten">Jennifer N. Otten</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Susan P. Rhodes</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Susan P. Rhodes</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Susan+P.++Rhodes">Susan P. Rhodes</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Martha E. Rodriguez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Martha E. Rodriguez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Martha+E.++Rodriguez">Martha E. Rodriguez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pavel Savechenkov</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pavel Savechenkov</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pavel++Savechenkov">Pavel Savechenkov</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Darin J. Smith</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Darin J. Smith</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Darin+J.++Smith">Darin J. Smith</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Niranjan Sudhakar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Niranjan Sudhakar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Mirati Therapeutics, 9393 Towne Centre Drive, Suite 200, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Niranjan++Sudhakar">Niranjan Sudhakar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Francis X. Sullivan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Francis X. Sullivan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Francis+X.++Sullivan">Francis X. Sullivan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tony P. Tang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tony P. Tang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tony+P.++Tang">Tony P. Tang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Guy P. Vigers</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Guy P. Vigers</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Guy+P.++Vigers">Guy P. Vigers</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lance Wollenberg</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lance Wollenberg</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lance++Wollenberg">Lance Wollenberg</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James G. Christensen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James G. Christensen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Mirati Therapeutics, 9393 Towne Centre Drive, Suite 200, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James+G.++Christensen">James G. Christensen</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Matthew A. Marx</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthew A. Marx</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Mirati Therapeutics, 9393 Towne Centre Drive, Suite 200, San Diego, California 92121, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#f29f93808a9fb29f9b8093869bdc919d9f"><span class="__cf_email__" data-cfemail="026f63707a6f426f6b7063766b2c616d6f">[email protected]</span></a>. Phone: 858-332-3558.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+A.++Marx">Matthew A. Marx</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2351-4787" title="Orcid link">http://orcid.org/0000-0003-2351-4787</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b02052&amp;href=/doi/10.1021%2Facs.jmedchem.9b02052" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 6679–6693</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 6, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>10 December 2019</li><li><span class="item_label"><b>Published</b> online</span>6 April 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 July 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b02052" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02052</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b02052"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">25222</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">50</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b02052" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jay&quot;,&quot;last_name&quot;:&quot;B. Fell&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;P. Fischer&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;R. Baer&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;F. Blake&quot;},{&quot;first_name&quot;:&quot;Karyn&quot;,&quot;last_name&quot;:&quot;Bouhana&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;M. Briere&quot;},{&quot;first_name&quot;:&quot;Karin&quot;,&quot;last_name&quot;:&quot;D. Brown&quot;},{&quot;first_name&quot;:&quot;Laurence&quot;,&quot;last_name&quot;:&quot;E. Burgess&quot;},{&quot;first_name&quot;:&quot;Aaron&quot;,&quot;last_name&quot;:&quot;C. Burns&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;R. Burkard&quot;},{&quot;first_name&quot;:&quot;Harrah&quot;,&quot;last_name&quot;:&quot;Chiang&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;J. Chicarelli&quot;},{&quot;first_name&quot;:&quot;Adam&quot;,&quot;last_name&quot;:&quot;W. Cook&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;J. Gaudino&quot;},{&quot;first_name&quot;:&quot;Jill&quot;,&quot;last_name&quot;:&quot;Hallin&quot;},{&quot;first_name&quot;:&quot;Lauren&quot;,&quot;last_name&quot;:&quot;Hanson&quot;},{&quot;first_name&quot;:&quot;Dylan&quot;,&quot;last_name&quot;:&quot;P. Hartley&quot;},{&quot;first_name&quot;:&quot;Erik&quot;,&quot;last_name&quot;:&quot;J. Hicken&quot;},{&quot;first_name&quot;:&quot;Gary&quot;,&quot;last_name&quot;:&quot;P. Hingorani&quot;},{&quot;first_name&quot;:&quot;Ronald&quot;,&quot;last_name&quot;:&quot;J. Hinklin&quot;},{&quot;first_name&quot;:&quot;Macedonio&quot;,&quot;last_name&quot;:&quot;J. Mejia&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Olson&quot;},{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;N. Otten&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;P. Rhodes&quot;},{&quot;first_name&quot;:&quot;Martha&quot;,&quot;last_name&quot;:&quot;E. Rodriguez&quot;},{&quot;first_name&quot;:&quot;Pavel&quot;,&quot;last_name&quot;:&quot;Savechenkov&quot;},{&quot;first_name&quot;:&quot;Darin&quot;,&quot;last_name&quot;:&quot;J. Smith&quot;},{&quot;first_name&quot;:&quot;Niranjan&quot;,&quot;last_name&quot;:&quot;Sudhakar&quot;},{&quot;first_name&quot;:&quot;Francis&quot;,&quot;last_name&quot;:&quot;X. Sullivan&quot;},{&quot;first_name&quot;:&quot;Tony&quot;,&quot;last_name&quot;:&quot;P. Tang&quot;},{&quot;first_name&quot;:&quot;Guy&quot;,&quot;last_name&quot;:&quot;P. Vigers&quot;},{&quot;first_name&quot;:&quot;Lance&quot;,&quot;last_name&quot;:&quot;Wollenberg&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;G. Christensen&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;A. Marx&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;06&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;6679-6693&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b02052&quot;},&quot;abstract&quot;:&quot;Capping off an era marred by drug development failures and punctuated by waning interest and presumed intractability toward direct targeting of KRAS, new technologies and strategies are aiding in the target’s resurgence. As previously reported, the tetrahydropyridopyrimidines were identified as irreversible covalent inhibitors of KRASG12C that bind in the switch-II pocket of KRAS and make a covalent bond to cysteine 12. Using structure-based drug design in conjunction with a focused in vitro absorption, distribution, metabolism and excretion screening approach, analogues were synthesized to increase the potency and reduce metabolic liabilities of this series. The discovery of the clinical development candidate MRTX849 as a potent, selective covalent inhibitor of KRASG12C is described.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02052&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02052" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02052&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02052" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02052&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02052" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b02052&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02052&amp;href=/doi/10.1021/acs.jmedchem.9b02052" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b02052" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b02052" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b02052%26sid%3Dliteratum%253Aachs%26pmid%3D32250617%26genre%3Darticle%26aulast%3DFell%26date%3D2020%26atitle%3DIdentification%2Bof%2Bthe%2BClinical%2BDevelopment%2BCandidate%2BMRTX849%252C%2Ba%2BCovalent%2BKRASG12C%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D13%26spage%3D6679%26epage%3D6693%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292143" title="Metabolism">Metabolism</a>,</li><li><a href="/action/doSearch?ConceptID=291675" title="Stability">Stability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/jmcmar.2020.63.issue-13/20200709/jmcmar.2020.63.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0033.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Capping off an era marred by drug development failures and punctuated by waning interest and presumed intractability toward direct targeting of KRAS, new technologies and strategies are aiding in the target’s resurgence. As previously reported, the tetrahydropyridopyrimidines were identified as irreversible covalent inhibitors of KRAS<sup>G12C</sup> that bind in the switch-II pocket of KRAS and make a covalent bond to cysteine 12.  Using structure-based drug design in conjunction with a focused in vitro absorption, distribution, metabolism and excretion screening approach, analogues were synthesized to increase the potency and reduce metabolic liabilities of this series. The discovery of the clinical development candidate <b>MRTX849</b> as a potent, selective covalent inhibitor of KRAS<sup>G12C</sup> is described.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div class="extra-info-sec articleNote"><h4><span></span> Note</h4><p class="last">This paper was published ASAP on April 6, 2020. Scheme 8 Reagents and Conditions were updated. The revised paper was reposted on April 10, 2020.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44524" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44524" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p"><i>KRAS</i> is the single most frequently mutated oncogene and the first of more than 700 genes to be causally implicated in human cancer (COSMIC).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Mutations in <i>KRAS</i> are prevalent amongst the top three most deadly cancer types in the United States: pancreatic (95%), colorectal (45%), and lung (35%).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Its frequent mutation across a spectrum of aggressive cancers has stimulated an intensive drug discovery effort to develop therapeutic strategies that block KRAS function for cancer treatment. Despite nearly four decades of research, a clinically viable KRAS cancer therapy has remained elusive largely because of its high affinity for GTP and lack of a well-defined binding pocket.<a onclick="showRef(event, 'ref3 ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6">(3−6)</a> However, recent findings have stimulated a new wave of activities to develop KRAS-targeted therapies.</div><div class="NLM_p">Capping off an era marred by drug development failures and punctuated by waning interest and presumed intractability toward direct targeting of KRAS, new technologies and strategies are aiding in the target’s resurgence.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> Central to this renewal is a single mutation: KRAS<sup>G12C</sup>, a well-validated driver mutation and the most frequent individual KRAS mutation in lung cancer.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Associated with poor prognosis and resistance to treatment, KRAS<sup>G12C</sup> represents both an extraordinary unmet clinical need and opportunity. This mutation has a causal role in 14% of lung adenocarcinomas (∼14,000 new US cases annually) and 5% of colorectal adenocarcinomas (∼5000 new US cases annually) and is present in smaller fractions of other cancers. Collectively, KRAS<sup>G12C</sup> mutations comprise a patient population with a worldwide annual incidence of greater than 100,000 individuals. A novel scientific basis for targeting KRAS<sup>G12C</sup> was recently described in a breakthrough article by Shokat and Wells, in which they identified a previously unknown allosteric pocket near the nucleotide binding site.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Small molecules binding to this pocket can inhibit signaling through KRAS by locking the protein in its inactive GDP-bound state.<a onclick="showRef(event, 'ref10 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13">(10−13)</a> Although targeting this site with covalent, small-molecule inhibitors was a clear advancement, it was also evident that the molecules identified required significant optimization to achieve drug-like potency and pharmaceutical properties.</div><div class="NLM_p">As previously reported, compound <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) is an irreversible covalent inhibitor of KRAS<sup>G12C</sup> that binds in the switch-II pocket of KRAS and makes a covalent bond to cysteine 12.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Inhibitor <b>1</b> showed robust target engagement in a PK/PD experiment using MIA PaCa-2 tumor bearing mice when dosed IP. In a related tumor growth inhibition (TGI) experiment, compound <b>1</b> demonstrated rapid regressions with cures when dosed as low as 30 mg/kg IP once a day. While providing a valuable tool compound, inhibitor <b>1</b> demonstrated clearance (CL) of 46 mL/min/kg following a 3 mg/kg IV dose to CD-1 mice and oral bioavailability of 2.4% with a 100 mg/kg PO dose. The pharmacokinetic limitations of <b>1</b> necessitated several iterations of optimization to identify a tractable clinical candidate. Described in this paper are the insights that led to the discovery of the clinical candidate <b>MRTX849</b>.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structural comparison of compound <b>1</b> to clinical development candidate <b>MRTX849</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54768" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54768" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In order to advance the tetrahydropyridopyrimidine series of covalent KRAS<sup>G12C</sup> inhibitors, it was necessary to develop an understanding of the metabolic liabilities of <b>1</b> that contributed to high CL and low bioavailability in CD-1 mice. Compound <b>1</b> was incubated with mouse hepatocytes, and the metabolites were identified by liquid chromatography mass spectrometry (LCMS) with relative concentrations being estimated based on peak area in the corresponding <i>A</i><sub>290nm</sub> chromatogram (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The metabolism of naphthol is well-documented,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and it was not surprising that the hydroxyl moiety was the major metabolic liability for compound <b>1</b> with 76% of the identified metabolites being <i>O</i>-glucuronides (M1, M2, M6, and M7) or <i>O</i>-sulfate (M3). Glutathione (GSH) conjugation of the acrylamide also appeared to play an important role, 50% of the metabolites (M1, M2, M4, and M5) contained this modification.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Metabolites of Compound <b>1</b> Identified in Incubations with Mouse Hepatocytes</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0024.gif" alt="" id="GRAPHIC-d7e606-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">metabolite</th><th class="colsep0 rowsep0" align="center">biotransformation(s)</th><th class="colsep0 rowsep0" align="center" char=".">% peak area</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">M1</td><td class="colsep0 rowsep0" align="left">dealkylation; glucuronide; GSH</td><td class="colsep0 rowsep0" align="char" char=".">8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">M2</td><td class="colsep0 rowsep0" align="left">glucuronide; GSH</td><td class="colsep0 rowsep0" align="char" char=".">18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">M3</td><td class="colsep0 rowsep0" align="left">sulfate</td><td class="colsep0 rowsep0" align="char" char=".">9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">M4</td><td class="colsep0 rowsep0" align="left">dealkylation; GSH</td><td class="colsep0 rowsep0" align="char" char=".">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">M5</td><td class="colsep0 rowsep0" align="left">GSH</td><td class="colsep0 rowsep0" align="char" char=".">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">M6</td><td class="colsep0 rowsep0" align="left">dealkylation; glucuronide</td><td class="colsep0 rowsep0" align="char" char=".">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">M7</td><td class="colsep0 rowsep0" align="left">glucuronide</td><td class="colsep0 rowsep0" align="char" char=".">27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Compound <b>1</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">4</td></tr></tbody></table></div></div><div class="NLM_p">Given the metabolite profile, it was predicted that removal of the hydroxyl moiety from compound <b>1</b> may decrease overall CL by reducing conjugative metabolism. As previously described,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> the naphthol ring of this class of inhibitors binds in a well-defined hydrophobic pocket formed by Val9, Met72, Phe78, Tyr96, Ile100, and Val103. In addition, the naphthyl hydroxyl forms a hydrogen bond to the carboxylate of Asp69. <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> describes a series of substituted indazoles that were designed as naphthol replacements that fill the hydrophobic pocket while maintaining a hydrogen bonding interaction to Asp69. The activity of these compounds, reported as IC<sub>50</sub> (nM), was determined in NCI-H358 cells by measuring inhibition of phospho-ERK after a 3 h incubation with the inhibitor. Because the intracellular drug disposition was unknown, the liabilities of conducting SAR studies using cellular data were recognized. The 5-methylindazole <b>2</b> displayed 1/10th of the cellular potency of compound <b>1</b>; this loss in potency was attributed to inadequate interactions with the protein. The 5-ethylindazole <b>3</b> and the 5-isopropylindazole <b>4</b> are equipotent to analogue <b>2</b> within variance of the assay. Through improved contact with the protein, both the 5-trifluoromethylindazole <b>5</b> and the 5,6-dimethylindazole <b>6</b> showed cellular IC<sub>50</sub>’s approximately five fold more potent than compound <b>2</b>. As the most active of the naphthol replacements, the substituted indazoles <b>5</b> and <b>6</b> were profiled in a series of metabolic stability and permeability assays. While the human hepatocyte and microsome stability data were promising, with a hepatic extraction ratio (ER) of <55%, these analogues exhibited low permeability and were potent P-gp efflux substrates with permeability efflux (PE) ratios of 75 and 88, respectively. These results prompted the exploration of an alternate strategy for progressing the project.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Exploration of Substituted Indazoles as Hydroxy Naphthyl Replacements<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0025.gif" alt="" id="GRAPHIC-d7e763-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0026.gif" alt="" id="gr24" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">NCI-H358 cellular pERK inhibition at 3 h.</p></div></div><div></div></div><div class="NLM_p">Because the indazole analogues designed as naphthol replacements did not achieve acceptable cellular permeability, the hydroxyl moiety was targeted for removal in an effort to improve both permeability as well as metabolic stability. The deshydroxy analogue <b>7</b> was synthesized (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), and the PK was evaluated in CD-1 mice. Following a 3 mg/kg IV dose of compound <b>7</b> to CD-1 mice (<i>n</i> = 3), CL was 25.6 mL/min/kg, the <i>t</i><sub>1/2</sub> was 0.908 h, and the volume of distribution (<i>V</i><sub>SS</sub>) was 0.996 L/kg (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Oral administration of a 10 mg/kg dose of <b>7</b> to mice (<i>n</i> = 3) resulted in a <i>C</i><sub>max</sub> of 0.131 μg/mL and AUC<sub>inf</sub> of 0.302 h·μg/mL, with 13.9% bioavailability. The lower CL and higher bioavailability of <b>7</b> relative to <b>1</b>, albeit at a different dose, validated the decision to remove the hydroxyl metabolic liability. The weak cellular activity of compound <b>7</b> toward KRAS<sup>G12C</sup>, IC<sub>50</sub> = 4400 ± 73 nM compared to 142 ± 12 nM for compound <b>1</b>, prompted a search for additional interactions with the protein to move the series into a progressable activity range.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0008.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Compound <b>1</b> and the deshydroxy analogue <b>7</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. PK of Compound <b>7</b> Dosed in CD-1 Mice</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose</th><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center" char=".">value</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3 mg/kg IV</td><td class="colsep0 rowsep0" align="left">CL (mL/min/kg)</td><td class="colsep0 rowsep0" align="char" char=".">25.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">0.908</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>V</i><sub>SS</sub> (L/kg)</td><td class="colsep0 rowsep0" align="char" char=".">0.996</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10 mg/kg PO</td><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μg/mL)</td><td class="colsep0 rowsep0" align="char" char=".">0.131</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">0.500</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AUC<sub>inf</sub> (h·μg/mL)</td><td class="colsep0 rowsep0" align="char" char=".">0.302</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="char" char=".">13.9</td></tr></tbody></table></div></div><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> illustrates the X-ray crystal structure of compound <b>7</b> bound to KRAS<sup>G12C</sup>. Notable in this structure is a bound water molecule complexed to Gly10 and Thr58 which is near the piperazine ring of compound <b>7</b>. This water molecule forms hydrogen bonds with the side chain hydroxyl of Thr58 (ca. 2.7 Å) and the carbonyl of Gly10 (3.0 Å), highlighted in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>. The water is also ca. 3.0 Å from the backbone NH of Gly10. Analysis of the proximal hydrogen bonding network suggested that displacement of this water could lead to a large potency increase.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> An appropriately substituted piperazine ring would have the correct trajectory to displace this bound water.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0009.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray crystal structure of compound <b>7</b> bound to KRAS<sup>G12C</sup> with 2.27 Å resolution, hydrogens added for clarity (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6USX">6USX</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> describes a series of analogues that was synthesized to probe the space occupied by the Gly10-bound water. Substituents were placed at either R<sub>1</sub> or R<sub>2</sub> while keeping the other positions on the piperazine unsubstituted. Compounds <b>8–11</b> are a set of R<sub>1</sub>- and R<sub>2</sub>-substituted hydroxy methyl and hydroxy ethyl analogues that were designed to displace the bound water and replace the hydrogen bonding interactions in the pocket. These compounds were equal or less potent than the unsubstituted compound <b>7</b> in the NCI-H358 cell assay. Analogue <b>12</b>, substituted at the R<sub>1</sub> position with CH<sub>2</sub>CN, showed a 300-fold increase in potency with a cellular IC<sub>50</sub> = 14 nM. The diastereomers of <b>12</b> were synthesized, and the <i>S</i>-diastereomer <b>12a</b> was determined to be ∼100× more potent than the <i>R</i>-diastereomer <b>12b</b>. In addition to binding, another factor that could contribute to increased potency of a covalent inhibitor is electrophile reactivity. For example, compound <b>7</b> was incubated with GSH at 37 °C and the percent parent remaining at 1 and 4 h was measured. From these data, the half-life (<i>t</i><sub>1/2</sub>), a relative measure of electrophile reactivity, was extrapolated to be 17 h. Compound <b>12a,</b> on the other hand, had a GSH <i>t</i><sub>1/2</sub> of 4 h, indicating that the electron withdrawing cyanomethyl substituent had the effect of increasing the reactivity of the acrylamide toward GSH. Interestingly, the opposite enantiomer <b>12b</b> also showed increased reactivity, GSH <i>t</i><sub>1/2</sub> = 1 h. However, unlike <b>12a</b> which was 400× more potent than <b>7</b>, <b>12b</b> with a cell IC<sub>50</sub> = 1020 nM was only 4 fold more potent than compound <b>7</b>. No increase in potency was observed with the cyanomethyl regioisomer <b>13</b>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Substituted Piperazines Designed To Displace KRAS<sup>G12C</sup> Gly10-Bound Water<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0027.gif" alt="" id="GRAPHIC-d7e1116-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0028.gif" alt="" id="gr25" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">NCI-H358 cellular pERK inhibition at 3 h.</p></div></div><div></div></div><div class="NLM_p">In addition to the potent cell activity, compound <b>12a</b> displayed favorable in vitro absorption, distribution, metabolism, and excretion (ADME) properties. This compound had 95% plasma protein binding such that the free fraction adjusted cell IC<sub>50</sub> was calculated to be 200 nM. Compound <b>12a</b> had measured solubility of 800 μg/mL in FaSSIF at pH 6.5. CL in microsome preparations was modest, with an ER of 45% and high in hepatocytes, with an ER of 90%. This compound displayed medium permeability with efflux (<i>P</i><sub>app</sub> (A to B) = 2.2 × 10<sup>–6</sup> cm/s, PE = 28) in the MDR LLCPK assay. Taken together, these data suggested that compound <b>12a</b> represented an interesting lead compound that warranted further investigation. Optimization of compound <b>12a</b> proceeded with substitution of the naphthalene moiety. <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> shows a surface view of <b>12a</b> bound to KRAS<sup>G12C</sup> that revealed a small pocket in the protein oriented from the 8-position of the naphthyl, highlighted with a blue arrow. A number of small hydrophobic groups were designed to fill this narrow hydrophobic cleft formed by residues Val9, Thr58, Met72, and Tyr96.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0010.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray crystal structure of compound <b>12a</b> bound to KRAS<sup>G12C</sup> with 2.03 Å resolution, surface pose (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6USZ">6USZ</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Following the synthetic route described in the <a class="ref internalNav" href="#sec2_1" aria-label="Chemistry">Chemistry</a> section, a series of analogues was synthesized to probe the vector from the naphthyl 8-position. The 8-substituted naphthyl compounds and their corresponding NCI-H358 cellular IC<sub>50</sub> values are shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. The methoxy and cyano analogues <b>14</b> and <b>15</b> were less potent compared to the proto analogue <b>12a</b>. 8-Ethyl naphthyl <b>16</b> and 8-trifluoromethyl naphthyl <b>17</b> displayed similar potency to the parent with single digit cellular IC<sub>50</sub> values. Finally, both the chloro and methyl substituted compounds <b>18</b> and <b>19</b> were more potent with cellular IC<sub>50</sub>’s of 1 nM.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Exploration of 8-Naphthyl Position<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0029.gif" alt="" id="GRAPHIC-d7e1225-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char="±">cellular IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">methoxy</td><td class="colsep0 rowsep0" align="char" char="±">22 ± 7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">cyano</td><td class="colsep0 rowsep0" align="char" char="±">64 ± 7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">ethyl</td><td class="colsep0 rowsep0" align="char" char="±">6 ± 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">trifluoromethyl</td><td class="colsep0 rowsep0" align="char" char="±">4 ± 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">chloro</td><td class="colsep0 rowsep0" align="char" char="±">1 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">methyl</td><td class="colsep0 rowsep0" align="char" char="±">1 ± 0.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">NCI-H358 cellular pERK inhibition at 3 h.</p></div></div></div><div class="NLM_p">Pharmacokinetics of the chloro and the methyl substituted compounds <b>18</b> and <b>19</b> were evaluated in CD-1 mice (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Oral administration of a 30 mg/kg dose of compound <b>18</b> to mice (<i>n</i> = 3) resulted in a <i>C</i><sub>max</sub> of 2.46 μg/mL and AUC<sub>inf</sub> of 2.27 h·μg/mL, with 16.9% bioavailability. Oral administration of a 30 mg/kg dose of compound <b>19</b> to mice (<i>n</i> = 3) resulted in a <i>C</i><sub>max</sub> of 1.66 μg/mL and AUC<sub>inf</sub> of 4.91 h·μg/mL, with 31.1% bioavailability. Given the cellular potency and favorable oral exposure observed in mice, compounds <b>18</b> and <b>19</b> were progressed into efficacy studies.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. PK of Compounds <b>18</b> and <b>19</b> Dosed in CD-1 Mice</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose</th><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center" char="."><b>18</b></th><th class="colsep0 rowsep0" align="center" char="."><b>19</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3 mg/kg IV</td><td class="colsep0 rowsep0" align="left">CL (mL/min/kg)</td><td class="colsep0 rowsep0" align="char" char=".">37.3</td><td class="colsep0 rowsep0" align="char" char=".">31.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">0.496</td><td class="colsep0 rowsep0" align="char" char=".">1.33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>V</i><sub>SS</sub> (L/kg)</td><td class="colsep0 rowsep0" align="char" char=".">0.867</td><td class="colsep0 rowsep0" align="char" char=".">1.91</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">30 mg/kg PO</td><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μg/mL)</td><td class="colsep0 rowsep0" align="char" char=".">2.46</td><td class="colsep0 rowsep0" align="char" char=".">1.66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">0.250</td><td class="colsep0 rowsep0" align="char" char=".">0.500</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AUC<sub>inf</sub> (h·μg/mL)</td><td class="colsep0 rowsep0" align="char" char=".">2.27</td><td class="colsep0 rowsep0" align="char" char=".">4.91</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="char" char=".">16.9</td><td class="colsep0 rowsep0" align="char" char=".">31.1</td></tr></tbody></table></div></div><div class="NLM_p">PK/PD studies were conducted to evaluate the pharmacodynamic response and to correlate drug exposure with target inhibition (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Compounds <b>18</b> and <b>19</b> were administered via oral gavage over a range of dose levels to NCI-H358 xenograft-bearing mice. Tumors and plasma were collected 6 h after a single dose. Compound <b>18</b> showed 70% KRAS<sup>G12C</sup> modification at 10 mg/kg, 89% protein modification at 30 mg/kg, and >90% modification at 100 mg/kg as determined by LCMS analysis of the tumor lysate. In comparison, compound <b>19</b> exhibited 20, 60, and 80% modification at the same doses. Given the similarities between these two compounds, there was no clear explanation for the differences seen with in vivo target engagement. However, this study demonstrated a dose-dependent increase in covalent modification of KRAS<sup>G12C</sup> that was proportional to the plasma concentration of the drug for the individual compounds.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0011.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. PK/PD of Compounds <b>18</b> and <b>19</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The antitumor activity of inhibitors <b>18</b> and <b>19</b> was evaluated in a MIA PaCa-2 xenograft TGI model (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). When tumors reached ∼350 mm<sup>3</sup>, the compounds were administered daily via oral gavage until study day 16. Treatment with either compound <b>18</b> or <b>19</b> at 30 mg/kg resulted in significant and rapid tumor regression with evidence of complete responses that were durable after cessation of dosing. Although longer timepoints were not assessed in the current study, it should be noted that outgrowth was observed with compound <b>19</b>, dosed PO at 30 mg/kg, beginning 20 days after dosing ended in a previously presented study.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0012.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Antitumor Efficacy of Compounds <b>18</b> and <b>19</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Considering the robust efficacy observed in mouse PK/PD and TGI experiments, compounds <b>18</b> and <b>19</b> were progressed into second species pharmacokinetic studies. Subsequent to a 3 mg/kg IV dose in beagle dogs, both compounds exhibited high CL, high volume of distribution, and a <i>t</i><sub>1/2</sub> of approximately 1 h. Following oral administration at a 10 mg/kg dose, these compounds exhibited 4% bioavailability with low plasma exposure, AUC<sub>inf</sub> ≤ 0.04 h·μg/mL (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Using the rodent and dog pharmacokinetic data, an allometric interspecies scaling approach described by Mahmood<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> was employed to predict human CL; values of 145 mL/min/kg (ER = 699%) and 121 mL/min/kg (ER = 588%) were calculated for <b>18</b> and <b>19</b>, respectively. The greater than liver blood flow<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> CL values that were measured in dogs and predicted in humans suggested that an extra-hepatic mechanism was contributing to the CL of compounds <b>18</b> and <b>19</b>.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. PK of Compounds <b>18</b> and <b>19</b> in Beagle Dogs</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose</th><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center" char="."><b>18</b></th><th class="colsep0 rowsep0" align="center" char="."><b>19</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3 mg/kg IV</td><td class="colsep0 rowsep0" align="left">CL (mL/min/kg)</td><td class="colsep0 rowsep0" align="char" char=".">225</td><td class="colsep0 rowsep0" align="char" char=".">151</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">0.826</td><td class="colsep0 rowsep0" align="char" char=".">0.966</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>V</i><sub>SS</sub> (L/kg)</td><td class="colsep0 rowsep0" align="char" char=".">7.91</td><td class="colsep0 rowsep0" align="char" char=".">6.16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10 mg/kg PO</td><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μg/mL)</td><td class="colsep0 rowsep0" align="char" char=".">0.0163</td><td class="colsep0 rowsep0" align="char" char=".">0.0178</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>t</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">0.833</td><td class="colsep0 rowsep0" align="char" char=".">1.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AUC<sub>inf</sub> (h·μg/mL)</td><td class="colsep0 rowsep0" align="char" char=".">0.0319</td><td class="colsep0 rowsep0" align="char" char=".">0.0395</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="char" char=".">4.12</td><td class="colsep0 rowsep0" align="char" char=".">3.67</td></tr></tbody></table></div></div><div class="NLM_p">Based on these observations and literature reports regarding the CL of targeted covalent inhibitors from Shibata and Chiba<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and Leung,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> it was likely that <b>18</b> and <b>19</b> were metabolized by either direct reaction with GSH or by GST-mediated GSH conjugation. To understand the mechanism of GSH conjugation onto the acrylamide, a diverse set of compounds from the tetrahydropyridopyrimidine series was subjected to reaction with GSH in phosphate buffer at 37 °C. A similar experiment using liver cytosol preparations plus GSH to capture GST/GSH-dependent conjugation also was run.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> A lack of correlation between the two data sets, represented by the line of unity in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b02052/suppl_file/jm9b02052_si_001.pdf" class="ext-link">Supporting Information</a> for data), and a lower <i>t</i><sub>1/2</sub> toward GSH conjugation in liver cytosol compared to reactivity in buffer, suggested that the compounds were susceptible to GST-mediated GSH conjugation.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0013.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Comparison of inherent GSH reactivity to GST-mediated GSH metabolism in the human liver cytosol for a diverse set of tetrahydropyridopyrimidines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further characterization of the GST isoforms responsible for GSH conjugation was performed. Confirmation of GSTA1-1-mediated GSH conjugation in the human liver cytosol was obtained. A linear correlation, <i>R</i><sup>2</sup> = 0.76 between the liver cytosol preparation plus GSH and GSTA1-1 plus GSH in buffer, is shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b02052/suppl_file/jm9b02052_si_001.pdf" class="ext-link">Supporting Information</a> for data).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0014.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Correlation of CL values for the tetrahydropyridopyrimidine series between GSTA1-1-mediated metabolism and human liver cytosol.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In a similar fashion, GSTP1-1 was identified as the primary isoform responsible for mediated GSH conjugation in human whole blood (HWB). As shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a> (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b02052/suppl_file/jm9b02052_si_001.pdf" class="ext-link">Supporting Information</a> for data), the HWB stability assay provided a good correlation, <i>R</i><sup>2</sup> = 0.66, to GST/GSH-dependent CL and was adopted as the primary metabolic stability assay.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0015.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Correlation of CL values for the tetrahydropyridopyrimidine series between GSTP1-1-mediated metabolism and HWB stability.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As previously reported by Xia<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and more recently by Zhao,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> a substituted acrylamide electrophile can produce a potent covalent inhibitor with less reactivity toward GSH compared to the unsubstituted counterpart. Considering the greater target engagement observed with compound <b>18</b> compared to compound <b>19</b> in the previously described PK/PD experiment, a set of analogues designed around inhibitor <b>18</b> was synthesized with substituted acrylamides. Shown in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>, the reference unsubstituted compound <b>18</b> was a 1 nM cellular inhibitor with measured WB stability of 5/2/14 h across species (mouse/dog/human). Compound <b>20</b> contained a 2-fluoro acrylamide substituent; this substitution resulted in a decrease in cell potency but with a concomitant improvement in WB stability to >50 h across species. The 2-methoxy analogue <b>21</b> was inactive in the cell assay. The 3-substituted analogues, <b>22</b> and <b>23</b>, had cellular IC<sub>50</sub> < 10 nM. However, although they showed improved stability in the WB assay relative to compound <b>18</b>, these compounds exhibited shorter half-lives than the 2-fluoro inhibitor <b>20</b>.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Substituted Electrophiles to Attenuate Reactivity<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0030.gif" alt="" id="GRAPHIC-d7e1926-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0031.gif" alt="" id="gr26" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">NCI-H358 cellular pERK inhibition at 3 h.</p></div></div><div></div></div><div class="NLM_p">As a result of its much reduced GST-mediated GSH conjugation, compound <b>20</b> (<b>MRTX849</b>) was further characterized in vitro and advanced into in vivo efficacy studies. Calculated and measured properties of <b>MRTX849</b> are shown in <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>. Highlighting in vitro ADME, <b>MRTX849</b> showed moderate permeability with an AB value of 4.7 × 10<sup>–6</sup> cm/s and displayed efflux in the MDR-LLCPK transfected line. Moderate stability in hepatocytes and microsomes was observed across the species tested, and the whole blood <i>t</i><sub>1/2</sub> was greater than 50 h in all species.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Properties of <b>MRTX849</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0032.gif" alt="" id="GRAPHIC-d7e1970-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MW/Clog <i>P</i>/PSA (Å<sup>2</sup>)</td><td class="colsep0 rowsep0" align="left">604/5.8/87</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCI-H358 cellular IC<sub>50</sub> @ 3 h (nM)</td><td class="colsep0 rowsep0" align="left">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MIA PaCa-2 cellular IC<sub>50</sub> @ 24 h (nM)</td><td class="colsep0 rowsep0" align="left">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">permeability AB 10<sup>–6</sup> cm/s, PE</td><td class="colsep0 rowsep0" align="left">4.7, 56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hepatocyte ER % (m, d, h)</td><td class="colsep0 rowsep0" align="left">61, 36, 50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">microsome ER % (m, d, h)</td><td class="colsep0 rowsep0" align="left">57, 39, 56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">whole blood stability <i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma protein binding % (m, h)</td><td class="colsep0 rowsep0" align="left">99.0, 98.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FaSSIF solubility pH 6.5 μg/mL</td><td class="colsep0 rowsep0" align="left">568</td></tr></tbody></table></div></div><div class="NLM_p">Co-crystal structures generated throughout lead optimization of the tetrahydropyridopyrimidine series provided insight toward new analogue design. Key findings are illustrated by the high-resolution X-ray crystal structure of <b>MRTX849</b> bound to KRAS<sup>G12C</sup> shown in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>. The interatomic distance of 1.65 Å between the Cys12 sulfur and the acrylamide β-carbon is consistent with a covalent bond. Key polar interactions include hydrogen bonds between the amine nitrogen of Lys16 and the acrylamide carbonyl (3.0 Å), the NE2 nitrogen of His95, and N-1 of the pyrimidine ring (2.9 Å). The C-2 pyrrolidine forms a salt-bridge with the carboxylate of Glu62, N–O distance of 2.8 Å. The cyanomethyl substituent displaces the Gly10 bound water and forms a hydrogen bond to the backbone NH of Gly10 (N–N distance 3.3 Å). Interestingly, displacement of the water via the cyanomethyl substituent also causes the chi1 angle of Thr58 to rotate from ca. 65° in compound <b>7</b> to −53° in <b>MRTX849</b>, and the side chain hydroxyl forms an H-bond with the backbone carbonyl of Val8, most likely due to loss of the H-bond with water. The methyl of Thr58 provides for more hydrophobic contacts with this class of inhibitors. The 8-chloronaphthyl fills the lipophilic pocket as previously discussed. Other key hydrophobic interactions are identical to those previously noted.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0002.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. X-ray crystal structure of <b>MRTX849</b> bound to KRAS<sup>G12C</sup> with 1.94 Å resolution, hydrogens added for clarity (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UT0">6UT0</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The kinetics of KRAS<sup>G12C</sup> modification by <b>MRTX849</b> were evaluated to understand how the reversible affinity (<i>K</i><sub>I</sub>), the rate of inactivation (<i>k</i><sub>inact</sub>), and the overall potency (<i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub>) compare with other KRAS<sup>G12C</sup> covalent inhibitors. Following treatment of KRAS<sup>G12C</sup> with <b>MRTX849</b>, the rates of target engagement (<i>k</i><sub>obs</sub>) were determined by LCMS measurement of the pepsin-derived Cys12-containing peptide fragments (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). The <i>k</i><sub>inact</sub> and <i>K</i><sub>I</sub> values determined from three separate experiments were 0.13 ± 0.01 s<sup>–1</sup> and 3.7 ± 0.5 μM, respectively. The <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> value for <b>MRTX849</b> was calculated to be 35 ± 0.3 mM<sup>–1</sup> s<sup>–1</sup> compared to the KRAS<sup>G12C</sup> inhibitors ARS-1620 (1.1 mM<sup>–1</sup> s<sup>–1</sup>)<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and AMG 510 (9.9 mM<sup>–1</sup> s<sup>–1</sup>)<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> found in the literature.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0003.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> determination for <b>MRTX849</b>. Data represent the mean <i>k</i><sub>obs</sub> measured from three experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The selectivity of <b>MRTX849</b> toward Cys12 of KRAS<sup>G12C</sup> was evaluated in NCI-H358 cells. Guided by the methodology described by Patricelli,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> a thiol-reactive probe was used to profile the cysteine residues in the proteome with and without 3 h treatment of 1 μM <b>MRTX849</b>. The results of this experiment, represented in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, show the treated versus control peptide ratio plotted for the 5702 identified peptides. The peptide-containing Cys12 of KRAS<sup>G12C</sup> had a peptide ratio of 0.03 following treatment with <b>MRTX849</b>, indicating nearly complete engagement of the intended target. Lysine-tRNA ligase (gene = <i>KARS</i>) was the only off target protein that was identified in this study. These data demonstrated that <b>MRTX849</b> showed highly specific modification of KRAS<sup>G12C</sup> in the NCI-H358 proteome at a concentration of 1 μM.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0004.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. <b>MRTX849</b>-targeted proteins identified by MS-based proteomic cysteine profiling.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In a complementary chemical proteomics experiment, the specificity of <b>MRTX849</b> was characterized utilizing the alkyne-containing click probe analogue <b>24</b> (cellular IC<sub>50</sub> = 140 ± 34 nM) to bait the protein targets (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). This experiment had the potential to identify lower abundance protein targets in comparison to the global cysteine reactivity experiment.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Of the 463 proteins that were identified and quantitated, only KRAS<sup>G12C</sup> significantly decreased in response to 1 μM <b>MRTX849</b> treatment, again confirming a high degree of selectivity for KRAS<sup>G12C</sup> (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>).</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0005.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Click chemistry target identification in NCI-H358 cells using compound <b>24</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The progression of the covalent KRAS<sup>G12C</sup> inhibitor <b>MRTX849</b> into pharmacokinetic studies in mouse, rat, and dog is detailed in <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>. Key intravenous and oral pharmacokinetic parameters were determined using a noncompartmental approach and were calculated for these species. Results from this analysis indicated that improved WB stability translated into increased in vivo stability and exposure with the 2-fluoro acrylamide <b>MRTX849</b> when compared to analogue <b>18</b>.</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Single Dose IV and PO Mean Pharmacokinetic Parameters of <b>MRTX849</b> Across Animal Species</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose</th><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center" char=".">mouse</th><th class="colsep0 rowsep0" align="center" char=".">rat</th><th class="colsep0 rowsep0" align="center" char=".">dog</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3 mg/kg IV</td><td class="colsep0 rowsep0" align="left">CL (mL/min/kg)</td><td class="colsep0 rowsep0" align="char" char=".">19.9</td><td class="colsep0 rowsep0" align="char" char=".">44.2</td><td class="colsep0 rowsep0" align="char" char=".">29.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">1.51</td><td class="colsep0 rowsep0" align="char" char=".">2.57</td><td class="colsep0 rowsep0" align="char" char=".">7.56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>V</i><sub>SS</sub> (L/kg)</td><td class="colsep0 rowsep0" align="char" char=".">2.02</td><td class="colsep0 rowsep0" align="char" char=".">20.7</td><td class="colsep0 rowsep0" align="char" char=".">17.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">30 mg/kg PO</td><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μg/mL)</td><td class="colsep0 rowsep0" align="char" char=".">2.41</td><td class="colsep0 rowsep0" align="char" char=".">0.209</td><td class="colsep0 rowsep0" align="char" char=".">0.252</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">1.00</td><td class="colsep0 rowsep0" align="char" char=".">2.67</td><td class="colsep0 rowsep0" align="char" char=".">4.00</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AUC<sub>inf</sub> (h·μg/mL)</td><td class="colsep0 rowsep0" align="char" char=".">15.9</td><td class="colsep0 rowsep0" align="char" char=".">2.67</td><td class="colsep0 rowsep0" align="char" char=".">4.47</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="char" char=".">62.9</td><td class="colsep0 rowsep0" align="char" char=".">29.7</td><td class="colsep0 rowsep0" align="char" char=".">25.9</td></tr></tbody></table></div></div><div class="NLM_p">The moderate-to-high oral bioavailability observed across species, <i>F</i> = 25.9–62.9%, suggested the potential for similar oral bioavailability in human studies. Predicted human CL for <b>MRTX849</b> using an allometric scaling approach<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> indicated a CL value of 19 mL/min/kg, 7.6-fold lower predicted human CL value relative to compound <b>18</b>. The metabolism of <b>MRTX849</b> was characterized in hepatocytes across species (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02052/suppl_file/jm9b02052_si_001.pdf" class="ext-link">Supporting Information</a>). In comparison to compound <b>1</b>, <b>MRTX849</b> formed fewer GSH adducts and no glucuronides. Based on MSMS fragmentation data, all oxidations occurred on the methylpyrrolidine group, and two metabolites were confirmed with synthetic standards; M10 was the <i>N</i>-dimethyl pyrrolidine metabolite and M11 was the methylpyrrolidin-2-one metabolite. Metabolite profiles were similar between preclinical species and humans. However, GSH conjugation was relatively minor in human hepatocytes compared to other species, suggesting that human CL may be overestimated by simple allometry.</div><div class="NLM_p">PK/PD studies were conducted with <b>MRTX849</b> to evaluate the pharmacodynamic response and correlate drug exposure with target engagement. <b>MRTX849</b> was administered via oral gavage over a range of dose levels to NCI-H358 xenograft-bearing mice. Tumors and plasma were collected 6 h after a single dose. Shown in <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, the fraction of covalently modified KRAS<sup>G12C</sup> protein was proportional to the plasma concentration of <b>MRTX849</b>. This study demonstrated a dose-dependent increase in covalent modification of KRAS<sup>G12C</sup> by <b>MRTX849</b> with maximal modification achieved at a 100 mg/kg dose.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0006.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. PK/PD of <b>MRTX849</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The anti-tumor activity of <b>MRTX849</b> as evaluated in a MIA PaCa-2 xenograft model is shown in <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>. When tumors reached ∼350 mm<sup>3</sup>, <b>MRTX849</b> was dosed daily via oral gavage until study day 16. Tumor regressions were seen in the 10 mg/kg dose group with rapid rebound observed following the end of dosing. Treatment at 30 and 100 mg/kg resulted in significant and rapid tumor regression, with evidence of complete responses that were durable after cessation of dosing. All mice in the 100 mg/kg cohort remained tumor-free for the duration of the study, and 2 of 7 mice in the 30 mg/kg cohort remained tumor-free through study day 70. In addition, drug treatment was well-tolerated with no loss of body weight at any dose level. These studies indicated that <b>MRTX849</b> demonstrated dose-dependent anti-tumor efficacy over a well-tolerated dose range and that the maximally efficacious dose of <b>MRTX849</b> in tumor bearing mice was between 30 and 100 mg/kg/day.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0007.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Antitumor Efficacy of <b>MRTX849</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Chemistry</h3><div class="NLM_p">The synthesis of compound <b>1</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) commenced with the condensation of ethyl 1-benzyl-3-oxopiperidine-4-carboxylate and urea to form the bicyclic di-one core followed by chlorination with POCl<sub>3</sub> to provide 7-benzyl-2,4-dichloro-5,6,7,8-tetrahydropyrido[3,4-<i>d</i>]pyrimidine <b>25</b>. A two-step sequence to install the piperazine substituent at C4 and then the ether at C2 began with S<sub>N</sub>Ar reaction between the dichloro core and <i>N</i>-BOC piperazine in dimethyl sulfoxide (DMSO) at 50 °C. This S<sub>N</sub>Ar product was subjected to a coupling reaction under Buchwald conditions<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> with (<i>S</i>)-prolinol using RuPhos/Pd<sub>2</sub>dba<sub>3</sub> as the catalyst to afford <i>tert</i>-butyl (<i>S</i>)-4-(7-benzyl-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-<i>d</i>]pyrimidin-4-yl)piperazine-1-carboxylate <b>26</b>. <i>N</i>-Benzyl group deprotection under hydrogenation conditions followed by introduction of the naphthyl moiety by Buchwald amination with 3-(benzyloxy)-1-bromonaphthalene gave intermediate <b>27</b>. Global deprotection and acylation with acryloyl anhydride resulted in the desired product <b>1</b>.</div><figure id="sch1" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compound <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) (i) urea, NaOEt/EtOH, 80 °C, 21 h, 62%; (ii) POCl<sub>3</sub>, 110 °C, 12 h, 60%; (b) (i) Boc-piperazine, DIEA, DMSO, 55 °C, 10 h, 80%; (ii) (<i>S</i>)-(1-methylpyrrolidin-2-yl)methanol, BINAP, Pd(OAc)<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, tol. 110 °C, 6 h, 90%; (c) (i) Pd(OH)<sub>2</sub>, H<sub>2,</sub> MeOH, 40 °C, 24 h, 94%; (ii) 3-(benzyloxy)-1-bromonaphthalene, RuPhos, Pd<sub>2</sub>(dba)<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, tol., 110 °C, 70%; (d) (i) Pd/C, H<sub>2</sub>, MeOH; (ii) HCl, MeCN, 0.5 h; (iii) acryloyl anhydride, DCM, DIEA, −50 °C, 12%.</p></p></figure><div class="NLM_p">The synthesis of compounds <b>2–6</b> followed the same synthetic route as was used for compound <b>1</b>. Advanced intermediate <b>26</b> was deprotected by hydrogenation, then subjected to Buchwald amination reactions with the appropriately functionalized THP protected indazole using RuPhos/Pd<sub>2</sub>dba<sub>3</sub> as the catalyst to give the nitrogen-arylated product (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Deprotection of both indazole and piperazine nitrogens was achieved by treatment with a solution of TFA in DCM. Installation of the acrylamide warhead using acryloyl anhydride gave the fully elaborated analogues. In addition, a similar synthetic sequence, substituting 1-bromonaphthalene for 3-(benzyloxy)-1-bromonaphthalene, was used to generate compound <b>7</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch2" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Representative Synthetic Route to the Indazole Analogues <b>2–6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) (i) Pd(OH)<sub>2</sub>, H<sub>2</sub>, MeOH, 40 °C, 24 h, 94%; (ii) bromo-5-methyl-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazole, RuPhos, Pd<sub>2</sub>(dba)<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, tol., 110 °C, 12 h, 70%; (b) (i) TFA, DCM, 1 h; (ii) acryloyl anhydride, DCM, DIEA, −40 °C, 49%.</p></p></figure><figure id="sch3" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compound <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) (i) Pd(OH)<sub>2</sub>, H<sub>2</sub>, MeOH, 40 °C, 24 h, 94%; (ii) 1-bromonaphthalene, Pd<sub>2</sub>(dba)<sub>3</sub>, RuPhos, Cs<sub>2</sub>CO<sub>3</sub>, tol., 90 °C, 8 h, 87%; (b) (i) HCl, MeCN, HCl/dioxane, 30 min, 0 °C; (ii) acryloyl anhydride, DCM, DIEA, −40 °C, 10 min, 14% over 2 steps.</p></p></figure><div class="NLM_p">An alternate synthetic approach was devised for the synthesis of the substituted piperazines <b>8–13</b> that allowed for late stage diversification at C4. Following the route shown in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>, the synthesis of compound <b>12a</b> began with selective derivatization at C4 by treatment of intermediate <b>25</b> with sodium methoxide in methanol. The C2 prolinol side chain was installed using a Buchwald coupling that was followed by benzyl hydrogenolysis to give compound <b>28</b> in good yield. Installation of the naphthyl ring system was accomplished by Buchwald amination with 1-bromonaphthalene to give (<i>S</i>)-4-methoxy-2-((1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-<i>d</i>]pyrimidine. Deprotection of this intermediate using a mixture of ethane thiol and sodium hydride in DMF followed by triflate formation with triflic anhydride and triethyl amine at reduced temperature gave compound <b>29</b>. The substituted piperazine was installed by S<sub>N</sub>Ar reaction of <b>29</b> with 2-piperazin-2-ylacetonitrile giving rise to the penultimate intermediate. Warhead attachment onto the piperazine nitrogen was accomplished by reaction with acryloyl anhydride, and subsequent separation of the diastereomers by chiral SCF chromatography gave <b>12a</b> and <b>12b</b>. Although the general approach to the synthesis of compounds <b>8–13</b> was the same as compound <b>12a</b>, modifications to the S<sub>N</sub>Ar reaction to install the substituted piperazine and final protecting group manipulations were necessary (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b02052/suppl_file/jm9b02052_si_001.pdf" class="ext-link">Supporting Information</a> for details).</div><figure id="sch4" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Representative Synthesis of Substituted Piperazines <b>8–13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) NaOMe/MeOH 0 → 25 °C, 30 min, 92%; (b) (<i>S</i>)-(1-methylpyrrolidin-2-yl)methanol, BINAP, Pd(OAc)<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, tol., 110 °C, 8 h, 83%; (c) Pd(OH)<sub>2</sub>/C, H<sub>2,</sub> MeOH, 40 °C 48 h, 90%; (d) 1-bromonaphthalene, Pd<sub>2</sub>(dba)<sub>3</sub>, RuPhos, Cs<sub>2</sub>CO<sub>3</sub>, tol., 90 °C, 12 h, 64%; (e) (i) EtSH, NaH, DMF, 1 h (ii) DCM, TEA, 4 Å MS, Tf<sub>2</sub>O, −40 °C, 22%; (f) (i) (<i>S</i>)-2-(piperazin-2-yl)acetonitrile, DIEA, DMA; (ii) acryloyl anhydride, DCM, DIEA, 0 °C, 1 h; (iii) SCF separation.</p></p></figure><div class="NLM_p">Shown in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a> is a convergent sequence to derivatize the 8-position of the naphthyl ring system while maintaining a Boc-protecting group at the piperazine nitrogen prior to warhead installation. The protecting group exchange at the nitrogen of ethyl 1-benzyl-3-oxo-piperidine-4-carboxylate from benzyl to Cbz was accomplished using a deprotection/reprotection sequence. Bicyclic ring formation was performed by treatment of 1-benzyl 4-ethyl 3-oxopiperidine-1,4-dicarboxylate with methyl carbamimidothioate. Triflate formation at C4 was accomplished by reaction of the C4 OH with triflic anhydride at reduced temperature to give <b>30</b>. S<sub>N</sub>Ar reaction upon treatment of <b>30</b> with (<i>S</i>)-2-(piperazin-2-yl)acetonitrile followed by protection of the free piperazine NH using Boc anhydride under standard conditions gave intermediate <b>31</b>. <i>m</i>-CPBA oxidation of the thiomethyl group at C2, S<sub>N</sub>Ar with (<i>S</i>)-prolinol and sodium <i>t</i>-butoxide and removal of the Cbz group under hydrogenation conditions provided <b>32</b>. Naphthyl installation, Boc-deprotection, and acrylamide formation were achieved as previously described to afford compound <b>19</b>.</div><figure id="sch5" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of 8-Substituted Naphthyl <b>14–17</b> and <b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) (i) H<sub>2</sub>, Pd(OH)<sub>2</sub>, MeOH, 40 °C; (ii) CbzCl, DCM DIEA, 0 °C 36%; (b) (i) methyl carbamimidothioate, NaOMe/MeOH, 30 °C, 12 h, 85%; (ii) DCM, TEA, Tf<sub>2</sub>O, −40 °C, 67%; (c) (i) (<i>S</i>)-2-(piperazin-2-yl)acetonitrile, DIEA, DMA, 80 °C, 83%; (d) (i) <i>m</i>-CPBA, DCM, 30 min, 89%; (ii) (<i>S</i>)-(1-methylpyrrolidin-2-yl)methanol, NaOtBu, tol., 0 °C, 6 h, 61%; (iii) Pd/C, H<sub>2</sub>, MeOH, 40 °C, 24 h, 71%; (e) (i) 8-methyl, 1-bromonaphthalene, XantPhos, Pd<sub>2</sub>(dba)<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, tol., 100 °C, 5 h, 59%; (ii) HCl diox/ACN, 30 min; (f) acryloyl anhydride, DCM, DIEA, −40 °C, 24%.</p></p></figure><div class="NLM_p">An alternative strategy, detailed in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>, was devised for the formation of the 8-chloro substituted compound <b>18</b>. In a synthesis similar to that described for compound <b>12a</b>; <b>27</b> was treated under Buchwald amination conditions with 1-bromo-8-chloronaphthalene to give the N-arylated product. Demethylation at the C4 position and subsequent triflate formation provided <b>32</b>. Introduction of the chiral (<i>S</i>)-2-(piperazin-2-yl)acetonitrile by S<sub>N</sub>Ar reaction and warhead installation gave <b>18</b>.</div><figure id="sch6" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compound <b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) Pd<sub>2</sub>(dba)<sub>3</sub>, RuPhos, Cs<sub>2</sub>CO<sub>3</sub>, tol. 90 °C, 12 h, 53%; (b) (i) EtSH, NaH, DMF, 60 °C, 1.5 h, 94%; (ii) Tf<sub>2</sub>O, TEA, 4 Å MS, DCM, −40 °C, 30 min, 22%; (c) (<i>S</i>)-2-(piperazin-2-yl)acetonitrile, DIEA, DMA, rt, 15 min, 44%; (d) acryloyl chloride, DCM −40 °C, 10 min, 36%.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a> depicts the synthesis of compound <b>20</b> from the advanced intermediate <b>34</b> using T3P<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> as the coupling reagent to facilitate formation of the amide linkage with the acid coupling partner. Compounds <b>21–22</b> were synthesized in a similar fashion.</div><figure id="sch7" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of the Clinical Candidate <b>20</b> (<b>MRTX849</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) 2-Fluoroprop-2-enoic acid, T3P, TEA, 0 °C, 30 min, 29%.</p></p></figure><div class="NLM_p">Synthesis of the click probe <b>24</b> was initiated by treatment of ethyl 1-benzyl-3-oxopiperidine-4-carboxylate with methyl carbamimidothioate and sodium ethoxide in ethanol to form the bicyclic ring system. Activation of the 4-position with POCl<sub>3</sub>, S<sub>N</sub>Ar with (<i>S</i>)-2-(piperazin-2-yl)acetonitrile and subsequent protection of the free amine with Boc anhydride gave intermediate <b>35</b>. Benzyl deprotection of compound <b>35</b> followed by Buchwald amination using XantPhos and Pd<sub>2</sub>(dba)<sub>3</sub> provided compound <b>36</b>. Oxidation of the thiomethyl substituent, displacement of the sulfoxide with (<i>S</i>)-(1-(pent-4-yn-1-yl)pyrrolidin-2-yl)methanol, and a two-step deprotection/acylation sequence yielded click probe <b>24</b> (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>).</div><figure id="sch8" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Click Chemistry Probe <b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions. (a) (i) ethyl 1-benzyl-3-oxopiperidine-4-carboxylate, NaOEt, EtOH; (ii) POCl<sub>3</sub>, CHCl<sub>3</sub>, 80 °C, 12 h, 71% over 2 steps; (b) (<i>S</i>)-2-(piperazin-2-yl)acetonitrile, DIEA, DMA, 80 °C, 3 h; Boc<sub>2</sub>O, 80 °C, 1 h, 85%; (c) (i) ACE-Cl, DCE, DIEA, 1 h, 0 °C; MeOH, 70 °C, 1 h, 82%; (ii) 8-chloro,1-bromonaphthalene, 4 Å MS, XantPhos, Pd<sub>2</sub>(dba)<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, tol., 110 °C, 12 h, 66%; (d) (i) <i>m</i>-CPBA, DCM, 30 min.; (ii) (<i>S</i>)-(1-(pent-4-yn-1-yl)pyrrolidin-2-yl)methanol, NaOtBu, tol., 4 Å MS, 0 °C, 30 min., 64%; (e) (i) TFA, DCM; (ii) 2-fluoroprop-2-enoic acid, EtOAc, T3P, TEA, 0 °C, 30 min., 24%.</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56567" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56567" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Insights leading to the discovery of the development candidate <b>MRTX849</b> began with the finding that removal of the hydroxyl moiety from <b>1</b> resulted in a five-fold improvement in oral bioavailability. Optimization of the deshydroxy analogue <b>7</b> to increase potency was predicated on the important observation that a bound water molecule was complexed to Gly10 and Thr58 in the crystal structure of <b>7</b> complexed to KRAS<sup>G12C</sup>. Analysis of the proximal hydrogen bonding network suggested that displacement of this water could lead to a dramatic increase in potency. A series of analogues designed and synthesized to displace the Gly10 water culminated in the cyanomethyl-substituted piperazine <b>12a</b>. The NCI-H358 cellular IC<sub>50</sub> of 10 nM represented a 400× potency boost for this inhibitor compared to compound <b>7</b>. Based on the GSH reactivity data of these compounds and <b>12b</b>, the large increase in potency was attributed to the displacement of the bound water molecule and the formation of new hydrogen bonding interactions with KRAS<sup>G12C</sup> rather than an overt increase in electrophile reactivity. Further optimization of <b>12a</b> yielded the 8-chloro analogue <b>18</b> with a cellular IC<sub>50</sub> value of 1 nM. Following oral administration at 10 mg/kg to beagle dogs, compound <b>18</b> showed 4% bioavailability and insufficient projected human exposure to inhibit KRAS<sup>G12C</sup>. A third key finding for the program was realized from a set of in vitro GSH conjugation experiments which were run in the presence of GST isoforms that confirmed that the tetrahydropyridopyrimidine compounds were undergoing GST-mediated GSH-conjugation. In order to minimize GSH metabolism, the development candidate <b>MRTX849</b> employed a 2-fluoroacrylamide warhead imparting whole blood stability of >50 h <i>t</i><sub>1/2</sub> across species while maintaining tractable cellular potency (IC<sub>50</sub> = 5–14 nM). Metabolism studies of <b>MRTX849</b> in hepatocytes showed that GSH conjugation of the 2-fluoroacrylamide was reduced compared to previous analogues containing the unsubstituted acrylamide. Favorable in vitro ADME and physical properties of <b>MRTX849</b> translated into moderate to high bioavailability of 26–63% across species tested. In a PK/PD experiment dosed at 10, 30, and 100 mg/kg to NCI-H358 tumor bearing mice, <b>MRTX849</b> demonstrated dose-dependent protein modification with nearly maximal effect at the highest doses. This compound was evaluated in a MIA PaCa-2 xenograft model orally administered at 10, 30, and 100 mg/kg QD for 16 days with continued post-treatment monitoring for a total of 70 days. <b>MRTX849</b> treatment in this study resulted in significant and rapid tumor regression with evidence of durable complete responses. The animals that were dosed at 100 mg/kg remained tumor-free for the duration of the 70-day monitoring period. Additionally, exquisite selectivity for KRAS<sup>G12C</sup> was observed in complimentary proteomics experiments: a biotin-streptavidin pull down study and a click probe experiment using a compound closely related to <b>MRTX849</b>. In conclusion, <b>MRTX849</b> is a potent, selective, orally bioavailable, irreversible covalent inhibitor of KRAS<sup>G12C</sup> with robust target engagement consistent with durable complete responses in tumor-bearing mice.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64288" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64288" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> General Chemistry Methods</h3><div class="NLM_p last">All final compounds were purified to ≥95% purity by either high-performance liquid chromatography (HPLC) or supercritical fluid chromatography (SFC) and were characterized by proton NMR, carbon NMR, and high-resolution mass spectrometry as described below. All chemicals were purchased from commercial suppliers and used as received unless otherwise indicated. Proton nuclear magnetic resonance (<sup>1</sup>H NMR) spectra were recorded on Bruker AVANCE 400 MHz spectrometers. Chemical shifts are expressed in δ ppm and are calibrated to the residual solvent peak: proton (CDCl<sub>3,</sub> 7.27 ppm). Coupling constants (<i>J</i>), when given, are reported in hertz. Multiplicities are reported using the following abbreviations: s = singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, m = multiplet (range of multiplet is given), br = broad signal, and dt = doublet of triplets. Carbon nuclear magnetic resonance (<sup>13</sup>C NMR) spectra were recorded using a Bruker AVANCE HD spectrometer at 100 MHz. Chemical shifts are reported in parts per million (ppm) and are calibrated to the solvent peak: carbon (CDCl<sub>3</sub>, 77.23 ppm). All final compounds were purified by reverse phase HPLC or SFC. The purity for test compounds was determined by HPLC on a LC-20AB Shimadzu instrument. HPLC conditions were as follows: Kinetex C18 LC Column 4.6 × 50 mm, 5 μm, 10–80% MECN (0.0375% TFA) in water (0.01875% TFA), 4 min run, flow rate 1.5 mL/min, UV detection (λ = 220, 215, 254 nm) or XBridge C18, 2.1 × 50 mm, 5 μm, 10–80% MECN in water buffered with 0.025% ammonia, 4 min run, flow rate 0.8 mL/min, UV detection (λ = 220, 215, 254 nm). The mass spectra were obtained using LCMS on a LCMS-2020 Shimadzu instrument using electrospray ionization (ESI). LCMS conditions were as follows: Kinetex EVO C18 30 × 2.1 mm, 5 μm, 5–95% MECN (0.0375% TFA) in water (0.01875% TFA), 1.5 min run, flow rate 1.5 mL/min, UV detection (λ = 220, 254 nm), or Kinetex EVO C18 2.1 × 30 mm, 5 μm, 5–95% MECN in water buffered with 0.025% ammonia, 1.5 min run, flow rate 1.5 mL/min, UV detection (λ = 220, 254 nm). High-resolution mass measurements were carried out on an Agilent 1290LC & 6530Q-TOF series with ESI. Melting point data were recorded on a Mettler Toledo MP70 [start temperature = 65 °C, end temperature = 255 °C, rate (°C/min) = 3.0]. Optical rotation data were recorded on an Anton Paar MCP500 [length = 1 dm, sodium lamp, λ (nm) = 589, temperature = 25 °C]. The SFC purity for test compounds was determined with a Shimadzu LC-30ADsf.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Cell-Based Phospho-ERK Assay</h3><div class="NLM_p last">All experiments were performed under standard conditions (37 °C and 5% CO<sub>2</sub>). IC<sub>50</sub> values were calculated by dose response curve fitting using a four-parameter method. NCI-H358 cells harboring the KRAS<sup>G12C</sup> mutation were seeded in 96-well plates in RPMI supplemented with 10% fetal bovine serum. Plates were incubated overnight. After incubation of cells with an inhibitor for 3 h, cells were washed once with phosphate-buffered saline (PBS), fixed with 3.8% formaldehyde, and permeabilized with ice cold methanol. The plates were then incubated with Li-Cor blocking buffer. Subsequently, phosphorylation of ERK was assessed by an in-cell western method by incubating with primary antibodies against GAPDH (mouse) and phospho-ERK (rabbit). The plates were then incubated with fluorescent secondary antibodies specific for mouse or rabbit. The plates were imaged on a Li-Cor fluorescent plate reader at 680 and 800 nm wavelengths. The phospho-ERK signal was normalized to the GAPDH signal, and POC values were generated.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Cocrystal Structures</h3><div class="NLM_p">KRAS isoform 4B, residues 1:169, was cloned into <i>Escherichia coli</i> with all 3 native cysteines mutated to other residues (C512S, C80L, and C118S) and residue G12 mutated to C. A 6-His tag and a TEV-cleavage site were added to the N-terminus. This is the same KRAS<sup>G12C</sup> “Lite” construct described in Ostrem et al.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a><i>KRAS</i> protein was expressed in BL21 (DE3) cells and purified by IMAC and ResourceQ chromatography. The 6-His tag was removed by cleavage overnight with TEV protease. In order to ensure complete loading with GDP, the KRAS protein at approximately 500 μM was incubated with 15 mM ethylenediaminetetraacetic acid (EDTA) for 1 h, and 25 mM MgGDP plus 50 mM MgCl<sub>2</sub> was then added and incubated for 1 h. The KRAS protein was further purified over a Superdex 75 sizing column. KRAS protein at approximately 260 μM was incubated with a 4-fold molar excess of compound and monitored by mass spectrometry until >95% of the protein was modified by the compound. The protein was then separated from the excess compound on a PD-10 column and concentrated to 16 mg/mL. The protein–ligand complex was crystallized at 20 °C in hanging drops using 2 μL protein + 2 μL precipitant. The precipitant was 32% PEG 4K, 0.1 M NaOAc (unbuffered) and 8% 2-propanol. Crystals were cryoprotected with 15% glycerol and flash frozen. Data were collected in-house on a Rigaku FR-E generator and Pilatus 1M detector.</div><div class="NLM_p last">The structures were solved using the CCP4 suite (<a href="https://www.ccp4.ac.uk/" class="extLink">https://www.ccp4.ac.uk/</a>) and Coot (<a href="https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/" class="extLink">https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/</a>). Coordinates have been deposited with PDB accession numbers. Compound <b>7</b><a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6USX">6USX</a>. Compound <b>12a</b><a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6USZ">6USZ</a>. <b>MRTX849</b><a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UTO">6UTO</a>.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Computational Modeling</h3><div class="NLM_p last">Computational modeling of various inhibitors and illustrations were performed with the Maestro suite of programs available from Schrödinger, LLC, New York, NY, 2019.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> In Vivo Studies</h3><div class="NLM_p last">All mouse studies were conducted in compliance with all applicable regulations and guidelines of the Institutional Animal Care and Use Committee (IACUC) from the National Institutes of Health (NIH). Mice were maintained under pathogen-free conditions, and food and water were provided ad libitum. 6–8 week-old, female, athymic nude-<i>Foxn1</i><sup><i>nu</i></sup> mice (Envigo, San Diego) were injected subcutaneously with either NCI-H358 or MIA PaCa-2 cells in 100 μL of PBS and Matrigel matrix in the right hind flank with 5.0 × 10<sup>6</sup> cells (Corning #356237; Discovery Labware, MA) 50:50 cells/Matrigel. Mouse health was monitored daily, and caliper measurements began when tumors were palpable. Tumor volume measurements were determined utilizing the formula 0.5 × <i>L</i> × <i>W</i><sup>2</sup> in which <i>L</i> refers to length and <i>W</i> refers to the width of each tumor. When tumors reached an average tumor volume of ∼350 mm<sup>3</sup>, mice were randomized into treatment groups. Mice were treated by oral gavage with either vehicle consisting of 10% research grade Captisol (CyDex Pharmaceuticals, KS) in 50 mM citrate buffer pH 5.0 or study compound in vehicle at indicated doses. For efficacy studies, animals were orally administered study compound or vehicle and monitored daily, tumors were measured 3 times per week and body weights were measured 2 times per week. Study day on efficacy plots indicates the day after which compound treatment was initiated. For PK/PD studies, tumors and plasma were collected after a single dose at the time points and concentration range indicated.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Inherent GSH Reactivity</h3><div class="NLM_p last">Compounds (1 μM) were incubated at 37 °C for one and 4 h in KPB buffer with and without 5 mM GSH. At the end of the designated time point, samples were quenched with acetonitrile spiked with 40 mM NEM and 0.2 μM final concentration of labetalol (internal standard). Samples were centrifuged, and supernatants were analyzed by LC–MS/MS.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> KRAS<sup>G12C</sup> Target Engagement</h3><div class="NLM_p last">Tumor fragments were homogenized in 6 M guanidine–HCl, 50 mM <i>N</i>-(2-hydroxyethyl)piperazine-<i>N</i>′-ethanesulfonic acid (HEPES) (pH 7.5), and 5 mM TCEP. Following centrifugation, the protein concentration of the supernatant was determined using a Bradford assay. An internal standard (<sup>13</sup>C<sup>15</sup>N recombinant KRAS<sup>G12C</sup>) and 20 mM iodoacetamide were added to 200 μg of tumor protein in 200 μL of lysis buffer, and samples were incubated at 37 °C for 30 min in the dark. Following alkylation, 100 μL of the reaction was exchanged into 1 M guanidine–HCl, 50 mM HEPES (pH 7.5), using a 96-well Zeba spin plate. Proteins were digested with 1 μg of trypsin/Lys-C mix at 37 °C for 18 h. Peptides were desalted using a C18 spin plate, and the solvent was removed by evaporation. Peptides were solubilized in 0.1% formic acid, 5% acetonitrile, 95% water, for LCMS analysis. A targeted method on a Sciex TripleTOF instrument was used to monitor the Cys-12-containing KRAS<sup>G12C</sup> peptide, an internal reference peptide, as well as the corresponding isotope-labeled peptides. KRAS<sup>G12C</sup> engagement was calculated as previously reported.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Allometric Scaling</h3><div class="NLM_p">Scaling of predicted CL in humans was conducted by an allometric equation relating the body weight of the mouse, rat, monkey, and dog versus CL measured in IV PK experiments. The following functional form of the equation<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_m001.gif" alt="" id="_i34" /></img></span>where CL is the IV predicted CL, <i>W</i> is the body weight of the organism, <i>a</i> is the coefficient of the allometric equation, and <i>b</i> is the exponent of the allometric equation. The equation is then transformed logarithmically to<span class="NLM_disp-formula" id="ueq2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_m002.gif" alt="" id="_i35" /></img></span></div><div class="NLM_p last">In this form of the equation, log <i>a</i> is equivalent to the <i>y</i>-intercept and <i>b</i> is equivalent to the slope based on a log–log plot of log CL versus log <i>W</i>. The following body weights were assumed for the mouse (0.02 kg), rat (0.3 kg), monkey (5 kg), and dog (10 kg) and were log transformed and plotted against the log of IV CL. A human body weight of 70 kg was assumed, and slope and intercept values described from the linear regression of the log CL versus log <i>WT</i> of the mouse, rat, monkey, and dog were used to predict log CL in the human.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Stability—Liver Cytosol Supplemented with GSH</h3><div class="NLM_p last">Compounds (1 μM) were incubated at 37 °C for 30 min in a 1 mg/mL liver cytosol, supplemented with 5 mM GSH in KPB buffer. At the end of the designated time point, samples were quenched with acetonitrile spiked with 40 mM NEM and 0.2 μM concentration of labetalol (internal standard). Samples were centrifuged, and supernatants were analyzed by LC–MS/MS.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Whole Blood Stability</h3><div class="NLM_p last">Compounds (5 μM) were incubated at 37 °C for 30, 60, and 240 min in a 1:1 (v/v) blood and PBS, pH 7.4. Diluted blood was preincubated for 15 min at 37 °C and 100% humidity before the reactions were initiated with the dosing of the compound. At the end of each designated time point, the red blood cells were lysed 1:1 with water, mixed at 600 rpm for 1 min, and stopped with acetonitrile containing 0.625 μM labetalol (internal standard). Samples were centrifuged, and supernatants were analyzed by LC–MS/MS.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Measurement of <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub></h3><div class="NLM_p last">Recombinant KRAS<sup>G12C</sup> “Lite” (C51S/C80L/C118S) was reacted with a range of <b>MRTX849</b> concentrations in 25 mM HEPES (pH 7.0), 150 mM NaCl, 5 mM MgCl<sub>2</sub>, 10 mM octyl β-glucopyranoside, and 0.5 mM TCEP, for 0–45 s, at room temperature. At each time-point, the reaction was quenched with 50 mM HCl, and 0.25 μg of pepsin was added. KRAS<sup>G12C</sup> was digested for 4 h at 37 °C, and the resulting Cys-12-containing peptide was analyzed by LCMS. The percent of modified KRAS<sup>G12C</sup> at each time-point was calculated from the 0 s control sample for each concentration of <b>MRTX849</b>, and <i>k</i><sub>obs</sub> was subsequently calculated from the slope of the ln(POC) versus time data. Rate versus concentration data fit the Michaelis–Menten equation.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Metabolite Identification in Hepatocytes</h3><div class="NLM_p last">Cryopreserved hepatocytes from mouse, rat, dog, and human were thawed and diluted to a viable cell density of 1 × 10<sup>6</sup> cells/mL using Dulbecco’s modified Eagle medium. <b>MRTX849</b> (10 μM) was added to 1 mL of each hepatocyte suspension, and samples were incubated at 37 °C for 2 h. Metabolism was quenched with the addition of 1% formic acid, samples were centrifuged, and the supernatant was loaded onto a 3cc Oasis HLB cartridge. <b>MRTX849</b> and metabolites were washed with 5% methanol in water and eluted with 100% methanol. The solvent was evaporated under a stream of nitrogen gas, and metabolites were reconstituted with 150 μL of 30:70 acetonitrile/water (v/v). Metabolites were separated on a Gemini NX-C18 column and detected by absorbance at 290 nm and mass spectrometry. Relative amounts of metabolites were determined by <i>A</i><sub>290nm</sub> peak intensity, and the biotransformation was characterized by the associated <i>m</i>/<i>z</i> and MSMS fragmentation patterns.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> NCI-H358 Proteome Cysteine Selectivity Assay</h3><div class="NLM_p last">NCI-H358 cells were treated with 3 μM <b>MRTX849</b> for 3 h and then lysed with 1% NP-40-containing buffer and sonication. Cell extracts were treated with 5 mM iodoacetamide desthiobiotin for 1 h at room temperature. Proteins were precipitated with acetone and resuspended in a buffer containing 6 M guanidine–HCl, 50 mM HEPES, pH 7.5, and 5 mM TCEP and incubated for 15 min at 65 °C. Following treatment with iodoacetamide and buffer exchange into 1 M guanidine-HCl, 50 mM HEPES (pH 7.5), proteins were digested with trypsin/Lys-C overnight. Desthiobiotinylated peptides were enriched using streptavidin agarose and eluted with 50% acetonitrile and 0.1% TFA. The solvent was removed by evaporation and peptides were resuspended in 0.1% formic acid, 5% acetonitrile, and in water. Samples were analyzed on a Sciex 6600 TripleTOF instrument. Protein Pilot 5 was used to identify peptides labeled with desthiobiotin from data-dependent MS/MS scans and relative quantitation (<b>MTRX849</b>-treated vs control) was conducted using SWATH analysis.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Click Chemistry Target Identification</h3><div class="NLM_p last">Two flasks of NCI-H358 cells (60 million cells/T225 flask) in the RPMI 1640 SILAC light media were treated with DMSO as the control, and two flasks of cells in the RPMI 1640 SILAC heavy media (<sup>13</sup>C<sub>6</sub>-lysine, <sup>13</sup>C<sub>6</sub>,<sup>15</sup>N<sub>4</sub>-arginine) were treated with 1 μM <b>MRTX849</b> for 3 h at 37 °C. All cells were then treated with 2 μM compound 24 for 3 h at 37 °C. Cells were then lysed with 50 mM HEPES, 150 NaCl, 0.5% Triton-X 100, 1 mM EDTA, 1 mM EGTA, and HALT protease inhibitor cocktail, for 5 min, probe sonicated, and centrifuged, and the supernatant was filtered with a 45 μm syringe filter. For each replicate, 4 mg of protein in “light”’ lysate was combined with 4 mg of protein in “heavy” lysate for sample processing. Proteins were isolated using chloroform/methanol precipitation, resuspended in 0.18% sodium dodecyl sulfate (SDS) in 50 mM HEPES pH 7.5, and ‘clicked’ to azide agarose by incubating with 5 mM ascorbate, 1 mM CuSO<sub>4</sub>, and 2 mM BTTAA, for 2.5 h at room temperature. Resin-bound proteins were treated with 10 mM DTT for 40 min and then with 20 mM iodoacetamide for 30 min and washed with (1) 100 mM Tris, pH 8.0, 250 mM NaCl, 1% SDS, 5 mM EDTA, (2) 8 M urea, 100 mM Tris, pH 8.0, and (3) 20% acetonitrile in water. Trypsin/Lys-C (1 μg) was added to the protein-bound resin, suspended in 20 mM Tris pH 8.0, 2 mM CaCl<sub>2</sub>, 10% acetonitrile, and incubated for 18 h at 37 °C. Eluted peptides were desalted on C18 spin columns, solvent was removed by evaporation, and peptides were resuspended in 0.1% formic acid, 5% acetonitrile, and in water for LCMS analysis. Samples were analyzed on a Sciex 6600 TripleTOF instrument. Protein Pilot 5 was used to identify peptides from data-dependent MS/MS scans of an unlabeled sample, and relative quantitation (MTRX849-treated vs control) was conducted using SWATH analysis of the SILAC samples.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42"><a href="/doi/suppl/10.1021/acs.jmedchem.9b02052" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17318" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17318" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b02052?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02052</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthetic experimental procedures, NMR spectra of final compounds, GSH reactivity data, metabolism of <b>MRTX849</b>, KRAS<sup>G12C</sup> target engagement, measurement of <i>K</i><sub>inact</sub>/<i>K</i><sub>I</sub>, metabolite identification in hepatocytes, NCI-H358 proteome cysteine selectivity assay, and click chemistry target identification and proteome selectivity and click chemistry target identification quantified protein list (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02052/suppl_file/jm9b02052_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02052/suppl_file/jm9b02052_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02052/suppl_file/jm9b02052_si_001.pdf">jm9b02052_si_001.pdf (7.92 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02052/suppl_file/jm9b02052_si_002.csv">jm9b02052_si_002.csv (2.39 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b02052" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64878" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64878" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jay B. Fell</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5770-1225" title="Orcid link">http://orcid.org/0000-0002-5770-1225</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c1a3b3a0a5efa7a4adad81a0b3b3a0b8a3a8aeb1a9a0b3aca0efa2aeac"><span class="__cf_email__" data-cfemail="14766675703a7271787854756666756d767d7b647c756679753a777b79">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew A. Marx</span> - <span class="hlFld-Affiliation affiliation">Mirati Therapeutics, 9393 Towne Centre Drive, Suite 200, San Diego, California 92121, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2351-4787" title="Orcid link">http://orcid.org/0000-0003-2351-4787</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3a575b4842577a5753485b4e5314595557"><span class="__cf_email__" data-cfemail="0b666a7973664b6662796a7f6225686466">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John P. Fischer</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian R. Baer</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James F. Blake</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karyn Bouhana</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David M. Briere</span> - <span class="hlFld-Affiliation affiliation">Mirati Therapeutics, 9393 Towne Centre Drive, Suite 200, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karin D. Brown</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laurence E. Burgess</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aaron C. Burns</span> - <span class="hlFld-Affiliation affiliation">Mirati Therapeutics, 9393 Towne Centre Drive, Suite 200, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael R. Burkard</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Harrah Chiang</span> - <span class="hlFld-Affiliation affiliation">Mirati Therapeutics, 9393 Towne Centre Drive, Suite 200, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark J. Chicarelli</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adam W. Cook</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John J. Gaudino</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jill Hallin</span> - <span class="hlFld-Affiliation affiliation">Mirati Therapeutics, 9393 Towne Centre Drive, Suite 200, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lauren Hanson</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dylan P. Hartley</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Erik J. Hicken</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gary P. Hingorani</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ronald J. Hinklin</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Macedonio J. Mejia</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Olson</span> - <span class="hlFld-Affiliation affiliation">Mirati Therapeutics, 9393 Towne Centre Drive, Suite 200, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer N. Otten</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan P. Rhodes</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martha E. Rodriguez</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pavel Savechenkov</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Darin J. Smith</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Niranjan Sudhakar</span> - <span class="hlFld-Affiliation affiliation">Mirati Therapeutics, 9393 Towne Centre Drive, Suite 200, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francis X. Sullivan</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tony P. Tang</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guy P. Vigers</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lance Wollenberg</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc, 3200 Walnut Street, Boulder, Colorado 80301, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James G. Christensen</span> - <span class="hlFld-Affiliation affiliation">Mirati Therapeutics, 9393 Towne Centre Drive, Suite 200, San Diego, California 92121, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i44">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54540" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54540" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We would like to thank the IDSU chemistry team from WuXi AppTec in Wuhan, China for their valuable contributions to this work. We are particularly grateful to Tao Guo, Duan Liu, Jie Qu, Yanchun Shen, Kunzhou Yang, Feng Zhao, and Yaolong Zhang.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">AUC<sub>inf</sub></td><td class="NLM_def"><p class="first last">area under the curve extrapolated to infinity</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum concentration</p></td></tr><tr><td class="NLM_term"><i>F</i></td><td class="NLM_def"><p class="first last">bioavailability</p></td></tr><tr><td class="NLM_term">FaSSIF</td><td class="NLM_def"><p class="first last">fasted state simulated intestinal fluid</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">LCMS</td><td class="NLM_def"><p class="first last">liquid chromatography mass spectrometry</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">PPB</td><td class="NLM_def"><p class="first last">plasma protein binding</p></td></tr><tr><td class="NLM_term">SWATH</td><td class="NLM_def"><p class="first last">sequential windowed acquisition of all theoretical fragment ions</p></td></tr><tr><td class="NLM_term">SILAC</td><td class="NLM_def"><p class="first last">stable isotope labeling with amino acids in cell culture</p></td></tr><tr><td class="NLM_term">TCEP</td><td class="NLM_def"><p class="first last">tris(2-carboxyethyl)phosphine hydrochloride</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>max</sub></td><td class="NLM_def"><p class="first last">time at <i>C</i><sub>max</sub></p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i46">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82212" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82212" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 29 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bos, J.</span></span> <span> </span><span class="NLM_article-title">Ras oncogenes in human cancer: a review</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">4682</span>– <span class="NLM_lpage">4689</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=2547513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADyaL1MXltlWksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1989&pages=4682-4689&author=J.+Bos&title=Ras+oncogenes+in+human+cancer%3A+a+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Ras oncogenes in human cancer:  a review</span></div><div class="casAuthors">Bos, Johannes L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4682-9</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">A review with 98 refs. with emphasis on current knowledge of the role mutant ras genes play in human tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-UKTWAA6IXLVg90H21EOLACvtfcHk0liODucvLdq-WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXltlWksL4%253D&md5=248025343f490785d0272d4b5e636df2</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBos%26aufirst%3DJ.%26atitle%3DRas%2520oncogenes%2520in%2520human%2520cancer%253A%2520a%2520review%26jtitle%3DCancer%2520Res.%26date%3D1989%26volume%3D49%26spage%3D4682%26epage%3D4689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jarvis, L.</span></span> <span> </span><span class="NLM_article-title">Have drug hunters finally cracked KRAS?</span>. <i>Chem. Eng. News</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">33</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2016&pages=28-33&author=L.+Jarvis&title=Have+drug+hunters+finally+cracked+KRAS%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJarvis%26aufirst%3DL.%26atitle%3DHave%2520drug%2520hunters%2520finally%2520cracked%2520KRAS%253F%26jtitle%3DChem.%2520Eng.%2520News%26date%3D2016%26volume%3D94%26spage%3D28%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">John, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohmen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feuerstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittinghofer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goody, R. S.</span></span> <span> </span><span class="NLM_article-title">Kinetics of interaction of nucleotides with nucleotide-free H-ras p21</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">6058</span>– <span class="NLM_lpage">6065</span>, <span class="refDoi"> DOI: 10.1021/bi00477a025</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00477a025" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADyaK3cXktF2lt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1990&pages=6058-6065&author=J.+Johnauthor=R.+Sohmenauthor=J.+Feuersteinauthor=R.+Linkeauthor=A.+Wittinghoferauthor=R.+S.+Goody&title=Kinetics+of+interaction+of+nucleotides+with+nucleotide-free+H-ras+p21&doi=10.1021%2Fbi00477a025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetics of interaction of nucleotides with nucleotide-free H-ras p21</span></div><div class="casAuthors">John, Jacob; Sohmen, Roland; Feuerstein, Juergen; Linke, Rosita; Wittinghofer, Alfred; Goody, Roger S.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">6058-65</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">A method is described for the convenient prepn. of substantial quantities of nucleotide-free H-ras p21 protein or of 1:1 complexes with nucleotides other than GDP.  The nucleotide-free protein was used for kinetic studies of the binding of GDP and GTP, making use of the fluorescent analogs 3'-(methylanthraniloyl)-2'-deoxy-GDP and -GTP.  Stopped-flow studies have led to the formulation of a 2-step binding mechanism for both GDP and GTP, involving initial rapid but weak binding of the nucleotide followed by a relatively slow (10-20 s-1 at 25°; 3-5 s-1 at 5°) quasi-irreversible isomerization reaction.  By use of a nonequil. competition method, guanosine and GMP have been shown to interact weakly but significantly with p21 (dissocn. consts. of 153 and 29 μM, resp.).  The presence of guanosine or GMP at the active site of p21 leads to a marked stabilization of p21 against denaturation when compared with the nucleotide- and nucleoside-free protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ_yMxte1CZrVg90H21EOLACvtfcHk0lgMcV_zVnObDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXktF2lt7o%253D&md5=069c7f0ba9b6691bd6368b8a079161a9</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fbi00477a025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00477a025%26sid%3Dliteratum%253Aachs%26aulast%3DJohn%26aufirst%3DJ.%26aulast%3DSohmen%26aufirst%3DR.%26aulast%3DFeuerstein%26aufirst%3DJ.%26aulast%3DLinke%26aufirst%3DR.%26aulast%3DWittinghofer%26aufirst%3DA.%26aulast%3DGoody%26aufirst%3DR.%2BS.%26atitle%3DKinetics%2520of%2520interaction%2520of%2520nucleotides%2520with%2520nucleotide-free%2520H-ras%2520p21%26jtitle%3DBiochemistry%26date%3D1990%26volume%3D29%26spage%3D6058%26epage%3D6065%26doi%3D10.1021%2Fbi00477a025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matikas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mistriotis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgoulias, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotsakis, A.</span></span> <span> </span><span class="NLM_article-title">Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity</span>. <i>Crit. Rev. Oncol. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2016.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1016%2Fj.critrevonc.2016.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=28109399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A280%3ADC%252BC1c7nvFersg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2017&pages=1-12&author=A.+Matikasauthor=D.+Mistriotisauthor=V.+Georgouliasauthor=A.+Kotsakis&title=Targeting+KRAS+mutated+non-small+cell+lung+cancer%3A+A+history+of+failures+and+a+future+of+hope+for+a+diverse+entity&doi=10.1016%2Fj.critrevonc.2016.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity</span></div><div class="casAuthors">Matikas Alexios; Mistriotis Dimitrios; Georgoulias Vasilios; Kotsakis Athanasios</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lung cancer remains the leading cause of cancer-related deaths in both men and women.  However, the discovery of several oncogenic driver mutations and the development of immune checkpoint inhibitors resulted in improved clinical outcomes for most patients.  Although activating KRAS mutations are the most common recurring molecular events in lung adenocarcinoma, little progress has been made during the past decades with no new agents being approved for this indication.  The elucidation of the underlying biology of this diverse patient subgroup offers great potential and renewed hope regarding the rational development, rigorous evaluation and subsequent approval of novel targeted agents and combinations which will effectively suppress compensatory escape routes and the emergence of resistance, issues that have plagued previous attempts.  Here, we review in a structured manner all aspects of KRAS positive non-small cell lung cancer, including the molecular biology, clinicopathologic characteristics, the prognostic and predictive value of KRAS mutations, as well as previous and contemporary approaches towards the treatment of this elusive target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQYoTBLJyPLwhWfpMXQLRstfW6udTcc2ebgYUk4JQxdArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7nvFersg%253D%253D&md5=1a6d423366e389c294cf507f378e0096</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2016.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2016.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DMatikas%26aufirst%3DA.%26aulast%3DMistriotis%26aufirst%3DD.%26aulast%3DGeorgoulias%26aufirst%3DV.%26aulast%3DKotsakis%26aufirst%3DA.%26atitle%3DTargeting%2520KRAS%2520mutated%2520non-small%2520cell%2520lung%2520cancer%253A%2520A%2520history%2520of%2520failures%2520and%2520a%2520future%2520of%2520hope%2520for%2520a%2520diverse%2520entity%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2017%26volume%3D110%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.critrevonc.2016.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Vega, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armenia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatila, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitriadow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantheti, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saghafinia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foltz, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shmulevich, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heins, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochoa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandoth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahceci, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dervishi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dogrusoz, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laird, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Way, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iavarone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazar, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammer, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tward, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Allen, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherniack, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciriello, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, N.</span></span> <span> </span><span class="NLM_article-title">Oncogenic signaling pathways in the cancer genone atlas</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">337</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1016%2Fj.cell.2018.03.035" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2018&pages=321-337&author=F.+Sanchez-Vegaauthor=M.+Minaauthor=J.+Armeniaauthor=W.+K.+Chatilaauthor=A.+Lunaauthor=K.+C.+Laauthor=S.+Dimitriadowauthor=D.+L.+Liuauthor=H.+S.+Kanthetiauthor=S.+Saghafiniaauthor=D.+Chakravartyauthor=F.+Daianauthor=Q.+Gaoauthor=M.+H.+Baileyauthor=W.+W.+Liangauthor=S.+M.+Foltzauthor=I.+Shmulevichauthor=L.+Dingauthor=Z.+Heinsauthor=A.+Ochoaauthor=B.+Grossauthor=J.+Gaoauthor=H.+Zhangauthor=R.+Kundraauthor=C.+Kandothauthor=I.+Bahceciauthor=L.+Dervishiauthor=U.+Dogrusozauthor=W.+Zhouauthor=H.+Shenauthor=P.+W.+Lairdauthor=G.+P.+Wayauthor=C.+S.+Greeneauthor=H.+Liangauthor=Y.+Xiaoauthor=C.+Wangauthor=A.+Iavaroneauthor=A.+H.+Bergerauthor=T.+G.+Bivonaauthor=A.+J.+Lazarauthor=G.+D.+Hammerauthor=T.+Giordanoauthor=L.+N.+Kwongauthor=G.+McArthurauthor=C.+Huangauthor=A.+D.+Twardauthor=M.+J.+Frederickauthor=F.+McCormickauthor=M.+Meyersonauthor=E.+M.+Van+Allenauthor=A.+D.+Cherniackauthor=G.+Cirielloauthor=C.+Sanderauthor=N.+Schultz&title=Oncogenic+signaling+pathways+in+the+cancer+genone+atlas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Vega%26aufirst%3DF.%26aulast%3DMina%26aufirst%3DM.%26aulast%3DArmenia%26aufirst%3DJ.%26aulast%3DChatila%26aufirst%3DW.%2BK.%26aulast%3DLuna%26aufirst%3DA.%26aulast%3DLa%26aufirst%3DK.%2BC.%26aulast%3DDimitriadow%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DD.%2BL.%26aulast%3DKantheti%26aufirst%3DH.%2BS.%26aulast%3DSaghafinia%26aufirst%3DS.%26aulast%3DChakravarty%26aufirst%3DD.%26aulast%3DDaian%26aufirst%3DF.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DBailey%26aufirst%3DM.%2BH.%26aulast%3DLiang%26aufirst%3DW.%2BW.%26aulast%3DFoltz%26aufirst%3DS.%2BM.%26aulast%3DShmulevich%26aufirst%3DI.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DHeins%26aufirst%3DZ.%26aulast%3DOchoa%26aufirst%3DA.%26aulast%3DGross%26aufirst%3DB.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DKundra%26aufirst%3DR.%26aulast%3DKandoth%26aufirst%3DC.%26aulast%3DBahceci%26aufirst%3DI.%26aulast%3DDervishi%26aufirst%3DL.%26aulast%3DDogrusoz%26aufirst%3DU.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DLaird%26aufirst%3DP.%2BW.%26aulast%3DWay%26aufirst%3DG.%2BP.%26aulast%3DGreene%26aufirst%3DC.%2BS.%26aulast%3DLiang%26aufirst%3DH.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DIavarone%26aufirst%3DA.%26aulast%3DBerger%26aufirst%3DA.%2BH.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26aulast%3DLazar%26aufirst%3DA.%2BJ.%26aulast%3DHammer%26aufirst%3DG.%2BD.%26aulast%3DGiordano%26aufirst%3DT.%26aulast%3DKwong%26aufirst%3DL.%2BN.%26aulast%3DMcArthur%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DTward%26aufirst%3DA.%2BD.%26aulast%3DFrederick%26aufirst%3DM.%2BJ.%26aulast%3DMcCormick%26aufirst%3DF.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DVan%2BAllen%26aufirst%3DE.%2BM.%26aulast%3DCherniack%26aufirst%3DA.%2BD.%26aulast%3DCiriello%26aufirst%3DG.%26aulast%3DSander%26aufirst%3DC.%26aulast%3DSchultz%26aufirst%3DN.%26atitle%3DOncogenic%2520signaling%2520pathways%2520in%2520the%2520cancer%2520genone%2520atlas%26jtitle%3DCell%26date%3D2018%26volume%3D172%26spage%3D321%26epage%3D337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simanshu, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissley, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, F.</span></span> <span> </span><span class="NLM_article-title">Ras proteins and their regulators in human disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.06.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1016%2Fj.cell.2017.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=28666118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSqsLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2017&pages=17-33&author=D.+K.+Simanshuauthor=D.+V.+Nissleyauthor=F.+McCormick&title=Ras+proteins+and+their+regulators+in+human+disease&doi=10.1016%2Fj.cell.2017.06.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">RAS Proteins and their regulators in human disease</span></div><div class="casAuthors">Simanshu, Dhirendra K.; Nissley, Dwight V.; McCormick, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-33</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  RAS proteins are binary switches, cycling between ON and OFF states during signal transduction.  These switches are normally tightly controlled, but in RAS-related diseases, such as cancer, RASopathies, and many psychiatric disorders, mutations in the RAS genes or their regulators render RAS proteins persistently active.  The structural basis of the switch and many of the pathways that RAS controls are well known, but the precise mechanisms by which RAS proteins function are less clear.  All RAS biol. occurs in membranes: a precise understanding of RAS' interaction with membranes is essential to understand RAS action and to intervene in RAS-driven diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoH9cHufj4FLVg90H21EOLACvtfcHk0ljEFsD1ev_BUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSqsLfP&md5=638a0c0efac88f2873c352715e332a92</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DSimanshu%26aufirst%3DD.%2BK.%26aulast%3DNissley%26aufirst%3DD.%2BV.%26aulast%3DMcCormick%26aufirst%3DF.%26atitle%3DRas%2520proteins%2520and%2520their%2520regulators%2520in%2520human%2520disease%26jtitle%3DCell%26date%3D2017%26volume%3D170%26spage%3D17%26epage%3D33%26doi%3D10.1016%2Fj.cell.2017.06.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ledford, H.</span></span> <span> </span><span class="NLM_article-title">Cancer: The Ras renaissance</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>520</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.1038/520278a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1038%2F520278a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=25877186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsF2gsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=520&publication_year=2015&pages=278-280&author=H.+Ledford&title=Cancer%3A+The+Ras+renaissance&doi=10.1038%2F520278a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer: The Ras renaissance</span></div><div class="casAuthors">Ledford, Heidi</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">520</span>
        (<span class="NLM_cas:issue">7547</span>),
    <span class="NLM_cas:pages">278-280</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Thirty years of pursuit have failed to yield a drug to take on one of the deadliest families of cancer-causing proteins.  Now some researchers are taking another shot.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9ZmQoGf5hfbVg90H21EOLACvtfcHk0ljEFsD1ev_BUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsF2gsb0%253D&md5=bb8dc94e579a028675392e3002b61684</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2F520278a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F520278a%26sid%3Dliteratum%253Aachs%26aulast%3DLedford%26aufirst%3DH.%26atitle%3DCancer%253A%2520The%2520Ras%2520renaissance%26jtitle%3DNature%26date%3D2015%26volume%3D520%26spage%3D278%26epage%3D280%26doi%3D10.1038%2F520278a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span> <span> </span><span class="NLM_article-title">Drugging RAS: Know the enemy</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">1158</span>– <span class="NLM_lpage">1163</span>, <span class="refDoi"> DOI: 10.1126/science.aam7622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1126%2Fscience.aam7622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=28302824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktFOmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2017&pages=1158-1163&author=B.+Papkeauthor=C.+J.+Der&title=Drugging+RAS%3A+Know+the+enemy&doi=10.1126%2Fscience.aam7622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging RAS: Know the enemy</span></div><div class="casAuthors">Papke, Bjoern; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">6330</span>),
    <span class="NLM_cas:pages">1158-1163</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  The three RAS oncogenes make up the most frequently mutated gene family in human cancer.  The well-validated role of mutationally activated RAS genes in driving cancer development and growth has stimulated comprehensive efforts to develop therapeutic strategies to block mutant RAS function for cancer treatment.  Disappointingly, despite more than three decades of research effort, clin. effective anti-RAS therapies have remained elusive, prompting a perception that RAS may be undruggable.  However, with a greater appreciation of the complexities of RAS that thwarted past efforts, and armed with new technologies and directions, the field is experiencing renewed excitement that mutant RAS may finally be conquered.  Here the authors summarize where these efforts stand.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhrMhg-D4EM7Vg90H21EOLACvtfcHk0lgSrE23ylMUxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktFOmtrY%253D&md5=ce9da51019033a624c765ef2507bac2e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1126%2Fscience.aam7622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aam7622%26sid%3Dliteratum%253Aachs%26aulast%3DPapke%26aufirst%3DB.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DDrugging%2520RAS%253A%2520Know%2520the%2520enemy%26jtitle%3DScience%26date%3D2017%26volume%3D355%26spage%3D1158%26epage%3D1163%26doi%3D10.1126%2Fscience.aam7622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ostrem, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sos, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>503</i></span>,  <span class="NLM_fpage">548</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1038/nature12796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1038%2Fnature12796" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=24256730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGqs7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=503&publication_year=2013&pages=548-551&author=J.+M.+Ostremauthor=U.+Petersauthor=M.+L.+Sosauthor=J.+A.+Wellsauthor=K.+M.+Shokat&title=K-Ras+%28G12C%29+inhibitors+allosterically+control+GTP+affinity+and+effector+interactions&doi=10.1038%2Fnature12796"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions</span></div><div class="casAuthors">Ostrem, Jonathan M.; Peters, Ulf; Sos, Martin L.; Wells, James A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">503</span>
        (<span class="NLM_cas:issue">7477</span>),
    <span class="NLM_cas:pages">548-551</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Somatic mutations in the small GTPase K-Ras are the most common activating lesions found in human cancer, and are generally assocd. with poor response to std. therapies.  Efforts to target this oncogene directly have faced difficulties owing to its picomolar affinity for GTP/GDP and the absence of known allosteric regulatory sites.  Oncogenic mutations result in functional activation of Ras family proteins by impairing GTP hydrolysis.  With diminished regulation by GTPase activity, the nucleotide state of Ras becomes more dependent on relative nucleotide affinity and concn.  This gives GTP an advantage over GDP and increases the proportion of active GTP-bound Ras.  Here we report the development of small mols. that irreversibly bind to a common oncogenic mutant, K-Ras(G12C).  These compds. rely on the mutant cysteine for binding and therefore do not affect the wild-type protein.  Crystallog. studies reveal the formation of a new pocket that is not apparent in previous structures of Ras, beneath the effector binding switch-II region.  Binding of these inhibitors to K-Ras(G12C) disrupts both switch-I and switch-II, subverting the native nucleotide preference to favor GDP over GTP and impairing binding to Raf.  Our data provide structure-based validation of a new allosteric regulatory site on Ras that is targetable in a mutant-specific manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokkgcVXuBn_rVg90H21EOLACvtfcHk0lgSrE23ylMUxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGqs7jO&md5=27c1e7d8ef6b7e4b2919e9f00a073923</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature12796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12796%26sid%3Dliteratum%253Aachs%26aulast%3DOstrem%26aufirst%3DJ.%2BM.%26aulast%3DPeters%26aufirst%3DU.%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DWells%26aufirst%3DJ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DK-Ras%2520%2528G12C%2529%2520inhibitors%2520allosterically%2520control%2520GTP%2520affinity%2520and%2520effector%2520interactions%26jtitle%3DNature%26date%3D2013%26volume%3D503%26spage%3D548%26epage%3D551%26doi%3D10.1038%2Fnature12796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ostrem, J. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design</span>. <i>Nat. Rev. Drug Discov.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">771</span>– <span class="NLM_lpage">785</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1038%2Fnrd.2016.139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=27469033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Gisb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=771-785&author=J.+M.+L.+Ostremauthor=K.+M.+Shokat&title=Direct+small-molecule+inhibitors+of+KRAS%3A+from+structural+insights+to+mechanism-based+design&doi=10.1038%2Fnrd.2016.139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design</span></div><div class="casAuthors">Ostrem, Jonathan M. L.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">771-785</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">KRAS is the most frequently mutated oncogene in human cancer.  In addn. to holding this distinction, unsuccessful attempts to target this protein have led to the characterization of RAS as 'undruggable'.  However, recent advances in technol. and novel approaches to drug discovery have renewed hope that a direct KRAS inhibitor may be on the horizon.  In this Review, we provide an in-depth anal. of the structure, dynamics, mutational activation and inactivation, and signalling mechanisms of RAS.  From this perspective, we then consider potential mechanisms of action for effective RAS inhibitors.  Finally, we examine each of the many recent reports of direct RAS inhibitors and discuss promising avenues for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBobrhZLF3V7Vg90H21EOLACvtfcHk0lgSrE23ylMUxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Gisb%252FK&md5=b0832c7ef45cc0555e11c59baccc5abd</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.139%26sid%3Dliteratum%253Aachs%26aulast%3DOstrem%26aufirst%3DJ.%2BM.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DDirect%2520small-molecule%2520inhibitors%2520of%2520KRAS%253A%2520from%2520structural%2520insights%2520to%2520mechanism-based%2520design%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discov.%26date%3D2016%26volume%3D15%26spage%3D771%26epage%3D785%26doi%3D10.1038%2Fnrd.2016.139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janes, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babbar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firdaus, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darjania, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, Y. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarieh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ely, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucharski, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brehmer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanak, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu-Lowe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patricelli, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">578</span>– <span class="NLM_lpage">589.e17</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2018.01.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1016%2Fj.cell.2018.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=29373830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislyisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2018&pages=578-589.e17&author=M.+R.+Janesauthor=J.+Zhangauthor=L.-S.+Liauthor=R.+Hansenauthor=U.+Petersauthor=X.+Guoauthor=Y.+Chenauthor=A.+Babbarauthor=S.+J.+Firdausauthor=L.+Darjaniaauthor=J.+Fengauthor=J.+H.+Chenauthor=S.+Liauthor=S.+Liauthor=Y.+O.+Longauthor=C.+Thachauthor=Y.+Liuauthor=A.+Zariehauthor=T.+Elyauthor=J.+M.+Kucharskiauthor=L.+V.+Kesslerauthor=T.+Wuauthor=K.+Yuauthor=Y.+Wangauthor=Y.+Yaoauthor=X.+Dengauthor=P.+P.+Zarrinkarauthor=D.+Brehmerauthor=D.+Dhanakauthor=M.+V.+Lorenziauthor=D.+Hu-Loweauthor=M.+P.+Patricelliauthor=P.+Renauthor=Y.+Liu&title=Targeting+KRAS+mutant+cancers+with+a+covalent+G12C-specific+inhibitor&doi=10.1016%2Fj.cell.2018.01.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor</span></div><div class="casAuthors">Janes, Matthew R.; Zhang, Jingchuan; Li, Lian-Sheng; Hansen, Rasmus; Peters, Ulf; Guo, Xin; Chen, Yuching; Babbar, Anjali; Firdaus, Sarah J.; Darjania, Levan; Feng, Jun; Chen, Jeffrey H.; Li, Shuangwei; Li, Shisheng; Long, Yun O.; Thach, Carol; Liu, Yuan; Zarieh, Ata; Ely, Tess; Kucharski, Jeff M.; Kessler, Linda V.; Wu, Tao; Yu, Ke; Wang, Yi; Yao, Yvonne; Deng, Xiaohu; Zarrinkar, Patrick P.; Brehmer, Dirk; Dhanak, Dashyant; Lorenzi, Matthew V.; Hu-Lowe, Dana; Patricelli, Matthew P.; Ren, Pingda; Liu, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">578-589.e17</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">KRASG12C was recently identified to be potentially druggable by allele-specific covalent targeting of Cys 12 in vicinity to an inducible allosteric switch II pocket (S-IIP).  Success of this approach requires active cycling of KRASG12C between its active-GTP and inactive-GDP conformations as accessibility of the S-IIP is restricted only to the GDP-bound state.  This strategy proved feasible for inhibiting mutant KRAS in vitro; however, it is uncertain whether this approach would translate to in vivo.  Here, the authors describe structure-based design and identification of ARS-1620, a covalent compd. with high potency and selectivity for KRASG12C.  ARS-1620 achieves rapid and sustained in vivo target occupancy to induce tumor regression.  The authors use ARS-1620 to dissect oncogenic KRAS dependency and demonstrate that monolayer culture formats significantly underestimate KRAS dependency in vivo.  This study provides in vivo evidence that mutant KRAS can be selectively targeted and reveals ARS-1620 as representing a new generation of KRASG12C-specific inhibitors with promising therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVmv4KAl4_dLVg90H21EOLACvtfcHk0lgBx6icp0CFCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislyisb8%253D&md5=d0883bde981b51e41a794179ffae87be</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DJanes%26aufirst%3DM.%2BR.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.-S.%26aulast%3DHansen%26aufirst%3DR.%26aulast%3DPeters%26aufirst%3DU.%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DBabbar%26aufirst%3DA.%26aulast%3DFirdaus%26aufirst%3DS.%2BJ.%26aulast%3DDarjania%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DY.%2BO.%26aulast%3DThach%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZarieh%26aufirst%3DA.%26aulast%3DEly%26aufirst%3DT.%26aulast%3DKucharski%26aufirst%3DJ.%2BM.%26aulast%3DKessler%26aufirst%3DL.%2BV.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DBrehmer%26aufirst%3DD.%26aulast%3DDhanak%26aufirst%3DD.%26aulast%3DLorenzi%26aufirst%3DM.%2BV.%26aulast%3DHu-Lowe%26aufirst%3DD.%26aulast%3DPatricelli%26aufirst%3DM.%2BP.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DTargeting%2520KRAS%2520mutant%2520cancers%2520with%2520a%2520covalent%2520G12C-specific%2520inhibitor%26jtitle%3DCell%26date%3D2018%26volume%3D172%26spage%3D578%26epage%3D589.e17%26doi%3D10.1016%2Fj.cell.2018.01.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patricelli, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucharski, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ely, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firdaus, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babbar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state</span>. <i>Canc. Discov.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">329</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.cd-15-1105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1158%2F2159-8290.CD-15-1105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=26739882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVyru7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=316-329&author=M.+P.+Patricelliauthor=M.+R.+Janesauthor=L.-S.+Liauthor=R.+Hansenauthor=U.+Petersauthor=L.+V.+Kesslerauthor=Y.+Chenauthor=J.+M.+Kucharskiauthor=J.+Fengauthor=T.+Elyauthor=J.+H.+Chenauthor=S.+J.+Firdausauthor=A.+Babbarauthor=P.+Renauthor=Y.+Liu&title=Selective+inhibition+of+oncogenic+KRAS+output+with+small+molecules+targeting+the+inactive+state&doi=10.1158%2F2159-8290.cd-15-1105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State</span></div><div class="casAuthors">Patricelli, Matthew P.; Janes, Matthew R.; Li, Lian-Sheng; Hansen, Rasmus; Peters, Ulf; Kessler, Linda V.; Chen, Yuching; Kucharski, Jeff M.; Feng, Jun; Ely, Tess; Chen, Jeffrey H.; Firdaus, Sarah J.; Babbar, Anjali; Ren, Pingda; Liu, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">316-329</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">KRAS gain-of-function mutations occur in approx. 30% of all human cancers.  Despite more than 30 years of KRAS-focused research and development efforts, no targeted therapy has been discovered for cancers with KRAS mutations.  Here, we describe ARS-853, a selective, covalent inhibitor of KRASG12C that inhibits mutant KRAS-driven signaling by binding to the GDP-bound oncoprotein and preventing activation.  Based on the rates of engagement and inhibition obsd. for ARS-853, along with a mutant-specific mass spectrometry-based assay for assessing KRAS activation status, we show that the nucleotide state of KRASG12C is in a state of dynamic flux that can be modulated by upstream signaling factors.  These studies provide convincing evidence that the KRASG12C mutation generates a "hyperexcitable" rather than a "statically active" state and that targeting the inactive, GDP-bound form is a promising approach for generating novel anti-RAS therapeutics.  Significance: A cell-active, mutant-specific, covalent inhibitor of KRASG12C is described that targets the GDP-bound, inactive state and prevents subsequent activation.  Using this novel compd., we demonstrate that KRASG12C oncoprotein rapidly cycles bound nucleotide and responds to upstream signaling inputs to maintain a highly active state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJJA-9IIHeN7Vg90H21EOLACvtfcHk0lgBx6icp0CFCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVyru7s%253D&md5=41db2f02006e8f0be7a9bb47354addcd</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-1105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-1105%26sid%3Dliteratum%253Aachs%26aulast%3DPatricelli%26aufirst%3DM.%2BP.%26aulast%3DJanes%26aufirst%3DM.%2BR.%26aulast%3DLi%26aufirst%3DL.-S.%26aulast%3DHansen%26aufirst%3DR.%26aulast%3DPeters%26aufirst%3DU.%26aulast%3DKessler%26aufirst%3DL.%2BV.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DKucharski%26aufirst%3DJ.%2BM.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DEly%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DFirdaus%26aufirst%3DS.%2BJ.%26aulast%3DBabbar%26aufirst%3DA.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DSelective%2520inhibition%2520of%2520oncogenic%2520KRAS%2520output%2520with%2520small%2520molecules%2520targeting%2520the%2520inactive%2520state%26jtitle%3DCanc.%2520Discov.%26date%3D2016%26volume%3D6%26spage%3D316%26epage%3D329%26doi%3D10.1158%2F2159-8290.cd-15-1105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lito, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">604</span>– <span class="NLM_lpage">608</span>, <span class="refDoi"> DOI: 10.1126/science.aad6204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1126%2Fscience.aad6204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=26841430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhsl2jt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2016&pages=604-608&author=P.+Litoauthor=M.+Solomonauthor=L.-S.+Liauthor=R.+Hansenauthor=N.+Rosen&title=Allele-specific+inhibitors+inactivate+mutant+KRAS+G12C+by+a+trapping+mechanism&doi=10.1126%2Fscience.aad6204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism</span></div><div class="casAuthors">Lito, Piro; Solomon, Martha; Li, Lian-Sheng; Hansen, Rasmus; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">6273</span>),
    <span class="NLM_cas:pages">604-608</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">It is thought that KRAS oncoproteins are constitutively active because their guanosine triphosphatase (GTPase) activity is disabled.  Consequently, drugs targeting the inactive or GDP-bound conformation are not expected to be effective.  We describe a mechanism that enables such drugs to inhibit KRASG12C signaling and cancer cell growth.  Inhibition requires intact GTPase activity and occurs because drug-bound KRASG12C is insusceptible to nucleotide exchange factors and thus trapped in its inactive state.  Indeed, mutants completely lacking GTPase activity and those promoting exchange reduced the potency of the drug.  Suppressing nucleotide exchange activity downstream of various tyrosine kinases enhanced KRASG12C inhibition, whereas its potentiation had the opposite effect.  These findings reveal that KRASG12C undergoes nucleotide cycling in cancer cells and provide a basis for developing effective therapies to treat KRASG12C-driven cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK3AbqEZO6k7Vg90H21EOLACvtfcHk0lgBx6icp0CFCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhsl2jt78%253D&md5=22a47908ac0146822ecf19f5d0c952de</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscience.aad6204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aad6204%26sid%3Dliteratum%253Aachs%26aulast%3DLito%26aufirst%3DP.%26aulast%3DSolomon%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DL.-S.%26aulast%3DHansen%26aufirst%3DR.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DAllele-specific%2520inhibitors%2520inactivate%2520mutant%2520KRAS%2520G12C%2520by%2520a%2520trapping%2520mechanism%26jtitle%3DScience%26date%3D2016%26volume%3D351%26spage%3D604%26epage%3D608%26doi%3D10.1126%2Fscience.aad6204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhana, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briere, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkard, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chicarelli, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudino, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicken, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinklin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mejia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savechenkov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudhakar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigers, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecca, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of tetrahydropyridopyrimidines as irreversible covalent inhibitors of KRAS-G12C with in vivo activity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1230</span>– <span class="NLM_lpage">1234</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00382</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00382" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFagurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1230-1234&author=J.+B.+Fellauthor=J.+P.+Fischerauthor=B.+R.+Baerauthor=J.+Ballardauthor=J.+F.+Blakeauthor=K.+Bouhanaauthor=B.+J.+Brandhuberauthor=D.+M.+Briereauthor=L.+E.+Burgessauthor=M.+R.+Burkardauthor=H.+Chiangauthor=M.+J.+Chicarelliauthor=K.+Davidsonauthor=J.+J.+Gaudinoauthor=J.+Hallinauthor=L.+Hansonauthor=K.+Heeauthor=E.+J.+Hickenauthor=R.+J.+Hinklinauthor=M.+A.+Marxauthor=M.+J.+Mejiaauthor=P.+Olsonauthor=P.+Savechenkovauthor=N.+Sudhakarauthor=T.+P.+Tangauthor=G.+P.+Vigersauthor=H.+Zeccaauthor=J.+G.+Christensen&title=Discovery+of+tetrahydropyridopyrimidines+as+irreversible+covalent+inhibitors+of+KRAS-G12C+with+in+vivo+activity&doi=10.1021%2Facsmedchemlett.8b00382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity</span></div><div class="casAuthors">Fell, Jay B.; Fischer, John P.; Baer, Brian R.; Ballard, Joshua; Blake, James F.; Bouhana, Karyn; Brandhuber, Barbara J.; Briere, David M.; Burgess, Laurence E.; Burkard, Michael R.; Chiang, Harrah; Chicarelli, Mark J.; Davidson, Kevin; Gaudino, John J.; Hallin, Jill; Hanson, Lauren; Hee, Kenneth; Hicken, Erik J.; Hinklin, Ronald J.; Marx, Matthew A.; Mejia, Macedonio J.; Olson, Peter; Savechenkov, Pavel; Sudhakar, Niranjan; Tang, Tony P.; Vigers, Guy P.; Zecca, Henry; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1230-1234</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">KRAS is the most frequently mutated driver oncogene in human cancer, and KRAS mutations are commonly assocd. with poor prognosis and resistance to std. treatment.  The ability to effectively target and block the function of mutated KRAS has remained elusive despite decades of research.  Recent findings have demonstrated that directly targeting KRAS-G12C with electrophilic small mols. that covalently modify the mutated codon 12 cysteine is feasible.  We have discovered a series of tetrahydropyridopyrimidines as irreversible covalent inhibitors of KRAS-G12C with in vivo activity.  The PK/PD and efficacy of compd. 13 will be highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGs80kLXd9TbVg90H21EOLACvtfcHk0ljVxbvPTmYntg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFagurfP&md5=f40ea2037c92c98dd84e907ebdcb4af6</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00382%26sid%3Dliteratum%253Aachs%26aulast%3DFell%26aufirst%3DJ.%2BB.%26aulast%3DFischer%26aufirst%3DJ.%2BP.%26aulast%3DBaer%26aufirst%3DB.%2BR.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DBouhana%26aufirst%3DK.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DBriere%26aufirst%3DD.%2BM.%26aulast%3DBurgess%26aufirst%3DL.%2BE.%26aulast%3DBurkard%26aufirst%3DM.%2BR.%26aulast%3DChiang%26aufirst%3DH.%26aulast%3DChicarelli%26aufirst%3DM.%2BJ.%26aulast%3DDavidson%26aufirst%3DK.%26aulast%3DGaudino%26aufirst%3DJ.%2BJ.%26aulast%3DHallin%26aufirst%3DJ.%26aulast%3DHanson%26aufirst%3DL.%26aulast%3DHee%26aufirst%3DK.%26aulast%3DHicken%26aufirst%3DE.%2BJ.%26aulast%3DHinklin%26aufirst%3DR.%2BJ.%26aulast%3DMarx%26aufirst%3DM.%2BA.%26aulast%3DMejia%26aufirst%3DM.%2BJ.%26aulast%3DOlson%26aufirst%3DP.%26aulast%3DSavechenkov%26aufirst%3DP.%26aulast%3DSudhakar%26aufirst%3DN.%26aulast%3DTang%26aufirst%3DT.%2BP.%26aulast%3DVigers%26aufirst%3DG.%2BP.%26aulast%3DZecca%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DDiscovery%2520of%2520tetrahydropyridopyrimidines%2520as%2520irreversible%2520covalent%2520inhibitors%2520of%2520KRAS-G12C%2520with%2520in%2520vivo%2520activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D1230%26epage%3D1234%26doi%3D10.1021%2Facsmedchemlett.8b00382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berenbom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, L.</span></span> <span> </span><span class="NLM_article-title">Biochemical Studies of Toxic Agents. 3. The Isolation of 1- and 2-Naphthyl-sulphuric acid and 1- and 2-naphthylglucaronide from the urine of rats dosed with 1- and 2-naphthol</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">1951</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1042/bj0490165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1042%2Fbj0490165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=14858304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADyaG38XjsFWl" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1951&pages=165-169&author=M.+Berenbomauthor=L.+Young&title=Biochemical+Studies+of+Toxic+Agents.+3.+The+Isolation+of+1-+and+2-Naphthyl-sulphuric+acid+and+1-+and+2-naphthylglucaronide+from+the+urine+of+rats+dosed+with+1-+and+2-naphthol&doi=10.1042%2Fbj0490165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical studies of toxic agents. III. The isolation of 1- and 2-naphthylsulfuric acid and 1- and 2-naphthylglucuronide from the urine of rats dosed with 1- and 2-naphthol</span></div><div class="casAuthors">Berenbom, M.; Young, L.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">1951</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">165-9</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    </div><div class="casAbstract">cf. C.A. 45, 764a.  Rats were injected subcutaneously with 1- and 2-naphthol.  The substances pass out into the urine, and are also conjugated and excreted as the corresponding H2SO4 and glucuronide compounds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkN9FLUzdPJ7Vg90H21EOLACvtfcHk0ljVxbvPTmYntg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG38XjsFWl&md5=8b904c9981da86dc81d0ce290c662061</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1042%2Fbj0490165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj0490165%26sid%3Dliteratum%253Aachs%26aulast%3DBerenbom%26aufirst%3DM.%26aulast%3DYoung%26aufirst%3DL.%26atitle%3DBiochemical%2520Studies%2520of%2520Toxic%2520Agents.%25203.%2520The%2520Isolation%2520of%25201-%2520and%25202-Naphthyl-sulphuric%2520acid%2520and%25201-%2520and%25202-naphthylglucaronide%2520from%2520the%2520urine%2520of%2520rats%2520dosed%2520with%25201-%2520and%25202-naphthol%26jtitle%3DBiochem.%2520J.%26date%3D1951%26volume%3D49%26spage%3D165%26epage%3D169%26doi%3D10.1042%2Fbj0490165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirado-Rives, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span> <span> </span><span class="NLM_article-title">Energetics of displacing water molecules from protein binding sites: consequences for ligand optimization</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">15403</span>– <span class="NLM_lpage">15411</span>, <span class="refDoi"> DOI: 10.1021/ja906058w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja906058w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFOiu7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=15403-15411&author=J.+Michelauthor=J.+Tirado-Rivesauthor=W.+L.+Jorgensen&title=Energetics+of+displacing+water+molecules+from+protein+binding+sites%3A+consequences+for+ligand+optimization&doi=10.1021%2Fja906058w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Energetics of Displacing Water Molecules from Protein Binding Sites: Consequences for Ligand Optimization</span></div><div class="casAuthors">Michel, Julien; Tirado-Rives, Julian; Jorgensen, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">15403-15411</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A strategy in drug design is to consider enhancing the affinity of lead mols. with structural modifications that displace water mols. from a protein binding site.  Because success of the approach is uncertain, clarification of the assocd. energetics was sought in cases where similar structural modifications yield qual. different outcomes.  Specifically, free-energy perturbation calcns. were carried out in the context of Monte Carlo statistical mechanics simulations to investigate ligand series that feature displacement of ordered water mols. in the binding sites of scytalone dehydratase, p38-αMAP kinase, and EGFR kinase.  The change in affinity for a ligand modification is found to correlate with the ease of displacement of the ordered water mol.  However, as in the EGFR example, the binding affinity may diminish if the free-energy increase due to the removal of the bound water mol. is not more than compensated by the addnl. interactions of the water-displacing moiety.  For accurate computation of the effects of ligand modifications, a complete thermodn. anal. is shown to be needed.  It requires identification of the location of water mols. in the protein-ligand interface and evaluation of the free-energy changes assocd. with their removal and with the introduction of the ligand modification.  Direct modification of the ligand in free-energy calcns. is likely to trap the ordered mol. and provide misleading guidance for lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoULCMKgzc8SLVg90H21EOLACvtfcHk0ljVxbvPTmYntg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFOiu7%252FI&md5=598676ea350be074bc2adea75eae9948</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fja906058w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja906058w%26sid%3Dliteratum%253Aachs%26aulast%3DMichel%26aufirst%3DJ.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26atitle%3DEnergetics%2520of%2520displacing%2520water%2520molecules%2520from%2520protein%2520binding%2520sites%253A%2520consequences%2520for%2520ligand%2520optimization%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D15403%26epage%3D15411%26doi%3D10.1021%2Fja906058w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marx, M.</span>; <span class="NLM_string-name">Baer, B. R.</span>; <span class="NLM_string-name">Ballard, J.</span>; <span class="NLM_string-name">Blake, J. F.</span>; <span class="NLM_string-name">Bouhana, K.</span>; <span class="NLM_string-name">Briere, D. M.</span>; <span class="NLM_string-name">Burgess, L. E.</span>; <span class="NLM_string-name">Burkard, M. R.</span>; <span class="NLM_string-name">Chiang, H.</span>; <span class="NLM_string-name">Chicarelli, M. J.</span>; <span class="NLM_string-name">Christensen, J. G.</span>; <span class="NLM_string-name">Cook, A. W.</span>; <span class="NLM_string-name">Fischer, J. P.</span>; <span class="NLM_string-name">Hallin, J.</span>; <span class="NLM_string-name">Mejia, M. J.</span>; <span class="NLM_string-name">Olson, P.</span>; <span class="NLM_string-name">Rodriguez, M.</span>; <span class="NLM_string-name">Savenchenkov, P.</span>; <span class="NLM_string-name">Sudhakar, N.</span>; <span class="NLM_string-name">Tang, T. P.</span>; <span class="NLM_string-name">Vigers, G. P.</span>; <span class="NLM_string-name">Fell, J. B.</span></span> <span> </span><span class="NLM_article-title">Structure based drug discovery of MRTX1257, a selective, covalent KRAS G12C inhibitor with oral activity in animal models of cancer</span>.  <i>AACR Targeting RAS-Driven Cancers</i>, <span class="NLM_year">2018</span>, <span class="NLM_publisher-loc">San Diego CA</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=M.+Marx&author=B.+R.+Baer&author=J.+Ballard&author=J.+F.+Blake&author=K.+Bouhana&author=D.+M.+Briere&author=L.+E.+Burgess&author=M.+R.+Burkard&author=H.+Chiang&author=M.+J.+Chicarelli&author=J.+G.+Christensen&author=A.+W.+Cook&author=J.+P.+Fischer&author=J.+Hallin&author=M.+J.+Mejia&author=P.+Olson&author=M.+Rodriguez&author=P.+Savenchenkov&author=N.+Sudhakar&author=T.+P.+Tang&author=G.+P.+Vigers&author=J.+B.+Fell&title=Structure+based+drug+discovery+of+MRTX1257%2C+a+selective%2C+covalent+KRAS+G12C+inhibitor+with+oral+activity+in+animal+models+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DMarx%26aufirst%3DM.%26atitle%3DStructure%2520based%2520drug%2520discovery%2520of%2520MRTX1257%252C%2520a%2520selective%252C%2520covalent%2520KRAS%2520G12C%2520inhibitor%2520with%2520oral%2520activity%2520in%2520animal%2520models%2520of%2520cancer%26jtitle%3DAACR%2520Targeting%2520RAS-Driven%2520Cancers%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17a"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hallin, J.</span>; <span class="NLM_string-name">Aranda, R.</span>; <span class="NLM_string-name">Baer, B. R.</span>; <span class="NLM_string-name">Burkard, M. R.</span>; <span class="NLM_string-name">Calinisan, A.</span>; <span class="NLM_string-name">Chiang, H.</span>; <span class="NLM_string-name">Engstrom, L. D.</span>; <span class="NLM_string-name">Fell, J. B.</span>; <span class="NLM_string-name">Marx, M. A.</span>; <span class="NLM_string-name">Olson, P.</span>; <span class="NLM_string-name">Christensen, J. G.</span></span> <span> </span><span class="NLM_article-title">Insight towards therapeutic susceptibility of KRAS mutant cancers from MRTX1257; A prototype selective inhibitor of KRAS G12C</span>.  <i>AACR Targeting RAS-Driven Cancers</i>, <span class="NLM_year">2018</span>, <span class="NLM_publisher-loc">San Diego CA</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=J.+Hallin&author=R.+Aranda&author=B.+R.+Baer&author=M.+R.+Burkard&author=A.+Calinisan&author=H.+Chiang&author=L.+D.+Engstrom&author=J.+B.+Fell&author=M.+A.+Marx&author=P.+Olson&author=J.+G.+Christensen&title=Insight+towards+therapeutic+susceptibility+of+KRAS+mutant+cancers+from+MRTX1257%3B+A+prototype+selective+inhibitor+of+KRAS+G12C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DHallin%26aufirst%3DJ.%26atitle%3DInsight%2520towards%2520therapeutic%2520susceptibility%2520of%2520KRAS%2520mutant%2520cancers%2520from%2520MRTX1257%253B%2520A%2520prototype%2520selective%2520inhibitor%2520of%2520KRAS%2520G12C%26jtitle%3DAACR%2520Targeting%2520RAS-Driven%2520Cancers%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahmood, I.</span></span> <span> </span><span class="NLM_article-title">Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development</span>. <i>Adv. Drug Deliv. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1177</span>– <span class="NLM_lpage">1192</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2007.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1016%2Fj.addr.2007.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=17826864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1amsL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2007&pages=1177-1192&author=I.+Mahmood&title=Application+of+allometric+principles+for+the+prediction+of+pharmacokinetics+in+human+and+veterinary+drug+development&doi=10.1016%2Fj.addr.2007.05.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development</span></div><div class="casAuthors">Mahmood, Iftekhar</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1177-1192</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The concept of correlating pharmacokinetic parameters with body wt. (termed as pharmacokinetic interspecies scaling) from different animal species has become a useful tool in drug development.  Interspecies scaling is based on the power function, where the body wt. of the species is plotted against the pharmacokinetic parameter of interest.  Clearance, vol. of distribution, and elimination half-life are the three most frequently extrapolated pharmacokinetic parameters.  The predicted pharmacokinetic parameter clearance can be used for estg. a first-in-human dose.  Over the years, many approaches have been suggested to improve the prediction of aforementioned pharmacokinetic parameters in humans from animal data.  A literature review indicates that there are different degrees of success with different methods for different drugs.  Interspecies scaling is also a very useful tool in veterinary medicine.  The knowledge of pharmacokinetics in veterinary medicine is important for dosage selection, particularly in the treatment of large animals such as horses, camels, elephants, or other large zoo animals.  Despite the potential for extrapolation error, the reality is that interspecies scaling is needed across many veterinary practice situations, and therefore will be used.  For this reason, it is important to consider mechanisms for reducing the risk of extrapolation errors that can seriously affect animal safety and therapeutic response.  Overall, although interspecies scaling requires continuous refinement and better understanding, the rationale approach of interspecies scaling has a lot of potential during the drug development process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrG8VANcfYx7Vg90H21EOLACvtfcHk0liQgYdtRb2J2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1amsL7F&md5=387ebd60e0e0573306734851ac5b05b9</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2007.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2007.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DMahmood%26aufirst%3DI.%26atitle%3DApplication%2520of%2520allometric%2520principles%2520for%2520the%2520prediction%2520of%2520pharmacokinetics%2520in%2520human%2520and%2520veterinary%2520drug%2520development%26jtitle%3DAdv.%2520Drug%2520Deliv.%2520Rev.%26date%3D2007%26volume%3D59%26spage%3D1177%26epage%3D1192%26doi%3D10.1016%2Fj.addr.2007.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, T.</span></span> <span> </span><span class="NLM_article-title">Physiological parameters in laboratory animals and humans</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1093</span>– <span class="NLM_lpage">1095</span>, <span class="refDoi"> DOI: 10.1023/a:1018943613122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1023%2Fa%3A1018943613122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=8378254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A280%3ADyaK3szptFaqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1993&pages=1093-1095&author=B.+Daviesauthor=T.+Morris&title=Physiological+parameters+in+laboratory+animals+and+humans&doi=10.1023%2Fa%3A1018943613122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Physiological parameters in laboratory animals and humans</span></div><div class="casAuthors">Davies B; Morris T</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1093-5</span>
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDDwka3A6hEYYPsCkJIw00fW6udTcc2eYPK4litaOVyrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3szptFaqsg%253D%253D&md5=094cdd17306b58cc17c8cf4fd5db9927</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1023%2Fa%3A1018943613122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252Fa%253A1018943613122%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DB.%26aulast%3DMorris%26aufirst%3DT.%26atitle%3DPhysiological%2520parameters%2520in%2520laboratory%2520animals%2520and%2520humans%26jtitle%3DPharm.%2520Res.%26date%3D1993%26volume%3D10%26spage%3D1093%26epage%3D1095%26doi%3D10.1023%2Fa%3A1018943613122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, M.</span></span> <span> </span><span class="NLM_article-title">The role of extrahepatic metabolism in the pharmacokinetics of the targeted covalent inhibitors afatinib, ibrutinib, and neratinib</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">384</span>, <span class="refDoi"> DOI: 10.1124/dmd.114.061424</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1124%2Fdmd.114.061424" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=25504185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1OmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=375-384&author=Y.+Shibataauthor=M.+Chiba&title=The+role+of+extrahepatic+metabolism+in+the+pharmacokinetics+of+the+targeted+covalent+inhibitors+afatinib%2C+ibrutinib%2C+and+neratinib&doi=10.1124%2Fdmd.114.061424"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The role of extrahepatic metabolism in the pharmacokinetics of the targeted covalent inhibitors afatinib, ibrutinib, and neratinib</span></div><div class="casAuthors">Shibata, Yoshihiro; Chiba, Masato</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">375-384, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Despite the fact that much progress has been made recently in the development of targeted covalent inhibitors (TCIs), their pharmacokinetics (PK) have not been well characterized in the light of extrahepatic clearance (CLextH) by glutathione (GSH)/glutathione S-transferase (GST)-dependent conjugation attributable to the unique electrophilic structure (e.g., acrylamide moiety) of TCI compds.  In the present study, CLextH values were examd. in rat, dog, and monkey to predict the contribution of CLextH to the PK of the TCIs afatinib, ibrutinib, and neratinib in humans.  Afatinib and neratinib both underwent extensive conjugation with GSH in buffer and cytosol fractions of liver and kidney, whereas ibrutinib showed much lower reactivity/susceptibility to GSH/GST-dependent conjugation.  The CLextH in each species was calcd. from the difference between obsd. total body clearance and predicted hepatic clearance (CLH) in cryopreserved hepatocytes suspended in 100% serum of the corresponding species.  The power-based simple allometry relating the CLextH for the unbound compd. to animal body wt. was applicable across species for afatinib and neratinib (R2 ≥ 0.9) but not for ibrutinib (R2 = 0.04).  The predicted AUC after oral administration of afatinib and neratinib agreed reasonably closely with reported values in phase I dose-escalation studies.  Comparisons of CLextH and CLH predicted that CLextH largely detd. the PK of afatinib (>90% as a proportion of total body clearance) and neratinib (∼34%) in humans.  The present method can serve as one of the tools for the optimization of PK in humans at the discovery stage for the development of TCI candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquWC6d6e6DU7Vg90H21EOLACvtfcHk0lgjGvO6haw83w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1OmsrY%253D&md5=eaac67ce7cea5f2432c5144922ba3dd2</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1124%2Fdmd.114.061424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.114.061424%26sid%3Dliteratum%253Aachs%26aulast%3DShibata%26aufirst%3DY.%26aulast%3DChiba%26aufirst%3DM.%26atitle%3DThe%2520role%2520of%2520extrahepatic%2520metabolism%2520in%2520the%2520pharmacokinetics%2520of%2520the%2520targeted%2520covalent%2520inhibitors%2520afatinib%252C%2520ibrutinib%252C%2520and%2520neratinib%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26spage%3D375%26epage%3D384%26doi%3D10.1124%2Fdmd.114.061424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelevitz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zientek, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banfield, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorarensen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span> <span> </span><span class="NLM_article-title">Clearance prediction of targeted covalent inhibitors by in vitro-in vivo extrapolation of hepatic and extrapatic clearance mechanisms</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1124/dmd.116.072983</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1124%2Fdmd.116.072983" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=27784718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlSksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=1-7&author=L.+Leungauthor=X.+Yangauthor=T.+J.+Strelevitzauthor=J.+Montgomeryauthor=M.+F.+Brownauthor=M.+A.+Zientekauthor=C.+Banfieldauthor=A.+M.+Gilbertauthor=A.+Thorarensenauthor=M.+E.+Dowty&title=Clearance+prediction+of+targeted+covalent+inhibitors+by+in+vitro-in+vivo+extrapolation+of+hepatic+and+extrapatic+clearance+mechanisms&doi=10.1124%2Fdmd.116.072983"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Clearance prediction of targeted covalent inhibitors by in vitro-in vivo extrapolation of hepatic and extrahepatic clearance mechanisms</span></div><div class="casAuthors">Leung, Louis; Yang, Xin; Strelevitz, Timothy J.; Montgomery, Justin; Brown, Matthew F.; Zientek, Michael A.; Banfield, Christopher; Gilbert, Adam M.; Thorarensen, Atli; Dowty, Martin E.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The concept of target-specific covalent enzyme inhibitors appears attractive from both an efficacy and a selectivity viewpoint considering the potential for enhanced biochem. efficiency assocd. with an irreversible mechanism.  Aside from potential safety concerns, clearance prediction of covalent inhibitors represents a unique challenge due to the inclusion of nontraditional metabolic pathways of direct conjugation with glutathione (GSH) or via GSH S-transferase-mediated processes.  In this article, a novel pharmacokinetic algorithm was developed using a series of Pfizer kinase selective acrylamide covalent inhibitors based on their in vitro-in vivo extrapolation of systemic clearance in rats.  The algorithmencompasses the use of hepatocytes as an in vitro model for hepatic clearance due to oxidative metab. and GSH conjugation, and the use of whole blood as an in vitro surrogate for GSH conjugation in extrahepatic tissues.  Initial evaluations with clin. covalent inhibitors suggested that the scaling algorithm developed from rats may also be useful for human clearance prediction when species-specific parameters, such as hepatocyte and blood stability and blood binding, were considered.  With careful consideration of clearance mechanisms, the described in vitro-in vivo extrapolation approach may be useful to facilitate candidate optimization, selection, and prediction of human pharmacokinetic clearance during the discovery and development of targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvIMBCrCxzNLVg90H21EOLACvtfcHk0lgjGvO6haw83w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlSksL4%253D&md5=8c8b918b087278b2025e0ae56a7abe37</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1124%2Fdmd.116.072983&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.116.072983%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DMontgomery%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DZientek%26aufirst%3DM.%2BA.%26aulast%3DBanfield%26aufirst%3DC.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DThorarensen%26aufirst%3DA.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26atitle%3DClearance%2520prediction%2520of%2520targeted%2520covalent%2520inhibitors%2520by%2520in%2520vitro-in%2520vivo%2520extrapolation%2520of%2520hepatic%2520and%2520extrapatic%2520clearance%2520mechanisms%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2017%26volume%3D45%26spage%3D1%26epage%3D7%26doi%3D10.1124%2Fdmd.116.072983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span> <span> </span><span class="NLM_article-title">A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9889</span>– <span class="NLM_lpage">9900</span>, <span class="refDoi"> DOI: 10.1021/jm5014659</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5014659" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKqu7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9889-9900&author=G.+Xiaauthor=W.+Chenauthor=J.+Zhangauthor=J.+Shaoauthor=Y.+Zhangauthor=W.+Huangauthor=L.+Zhangauthor=W.+Qiauthor=X.+Sunauthor=B.+Liauthor=Z.+Xiangauthor=C.+Maauthor=J.+Xuauthor=H.+Dengauthor=Y.+Liauthor=P.+Liauthor=H.+Miaoauthor=J.+Hanauthor=Y.+Liuauthor=J.+Shenauthor=Y.+Yu&title=A+chemical+tuned+strategy+to+develop+novel+irreversible+EGFR-TK+inhibitors+with+improved+safety+and+pharmacokinetic+profiles&doi=10.1021%2Fjm5014659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles</span></div><div class="casAuthors">Xia, Guangxin; Chen, Wenteng; Zhang, Jing; Shao, Jiaan; Zhang, Yong; Huang, Wei; Zhang, Leduo; Qi, Weixing; Sun, Xing; Li, Bojun; Xiang, Zhixiong; Ma, Chen; Xu, Jia; Deng, Hailin; Li, Yufeng; Li, Ping; Miao, Hong; Han, Jiansheng; Liu, Yanjun; Shen, Jingkang; Yu, Yongping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9889-9900</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Gatekeeper T790 M mutation in EGFR is the most prevalent factor underlying acquired resistance.  Acrylamide-bearing quinazoline derivs. are powerful irreversible inhibitors for overcoming resistance.  Nevertheless, concerns about the risk of nonspecific covalent modification have motivated the development of novel cysteine-targeting inhibitors.  In this paper, the authors demonstrate that fluoro-substituted olefins can be tuned to alter Michael addn. reactivity.  Incorporation of these olefins into the quinazoline templates produced potent EGFR inhibitors with improved safety and pharmacokinetic properties.  A lead compd. I was validated against EGFRWT, EGFRT790M as well as A431 and H1975 cancer cell lines.  Addnl., compd. I displayed a weaker inhibition against the EGFR-independent cancer cell line SW620 when compared with afatinib.  Oral administration of I at a dose of 30 mg/kg induced tumor regression in a murine-EGFRL858R/T790M driven H1975 xenograft model.  Also, I exhibited improved oral bioavailability and safety as well as favorable tissue distribution properties and enhanced brain uptake.  These findings provide the basis of a promising strategy toward the treatment of NSCLC patients with drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV-v8dZV3wkLVg90H21EOLACvtfcHk0ljm0kpbStqhlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKqu7vF&md5=bc5ffd322783971a898d5c0fa62d261c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm5014659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5014659%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DMiao%26aufirst%3DH.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DY.%26atitle%3DA%2520chemical%2520tuned%2520strategy%2520to%2520develop%2520novel%2520irreversible%2520EGFR-TK%2520inhibitors%2520with%2520improved%2520safety%2520and%2520pharmacokinetic%2520profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9889%26epage%3D9900%26doi%3D10.1021%2Fjm5014659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of AZD9291 derivatives as selective and potent EGFRL<sup>858R/T790M</sup> inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.11.069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1016%2Fj.ejmech.2018.11.069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=30530173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKqsrfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2019&pages=367-380&author=B.+Zhaoauthor=Z.+Xiaoauthor=J.+Qiauthor=R.+Luoauthor=Z.+Lanauthor=Y.+Zhangauthor=X.+Huauthor=Q.+Tangauthor=P.+Zhengauthor=S.+Xuauthor=W.+Zhu&title=Design%2C+synthesis+and+biological+evaluation+of+AZD9291+derivatives+as+selective+and+potent+EGFRL858R%2FT790M+inhibitors&doi=10.1016%2Fj.ejmech.2018.11.069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of AZD9291 derivatives as selective and potent EGFRL858R/T790M inhibitors</span></div><div class="casAuthors">Zhao, Bingbing; Xiao, Zhen; Qi, Jianguo; Luo, Rong; Lan, Zhou; Zhang, Yanzhuo; Hu, Xiaohan; Tang, Qidong; Zheng, Pengwu; Xu, Shan; Zhu, Wufu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">367-380</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Third-generation epidermal growth factor receptor (EGFR)L858R/T790M inhibitors are still the main drugs for the treatment of advanced non-small cell lung cancer (NSCLC), and these drugs have achieved remarkable clin. efficacy.  However, there are still many patients suffering from drug-resistant mutations and drug side effects caused by NSCLC.  In this study, guided by the mol. simulation, we applied a structure-based drug design strategy (SBDD) and optimized the structure to obtain a series of potent and selective EGFRL858R/T790M inhibitors.  The most potent compd. 18e demonstrated excellent kinase inhibitory activity and selectivity for EGFRL858R/T790M double mutants and the IC50 value reached nanomolar level.  The selectivity of 18e against wild-type EGFR was near to 200-fold.  In addn., compd. 18e also inhibited H1975 cells proliferation at G2/M phase and induced apoptosis at a concn. of 0.25 μM, which makes it more valuable for potential lung cancer research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8TnKdjpJ_mLVg90H21EOLACvtfcHk0ljm0kpbStqhlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKqsrfM&md5=c189aed9e39d21f36c80155ea2ea80a1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.11.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.11.069%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DXiao%26aufirst%3DZ.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DR.%26aulast%3DLan%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DQ.%26aulast%3DZheng%26aufirst%3DP.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DW.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520AZD9291%2520derivatives%2520as%2520selective%2520and%2520potent%2520EGFRL858R%252FT790M%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D163%26spage%3D367%26epage%3D380%26doi%3D10.1016%2Fj.ejmech.2018.11.069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babbar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">The reactivity driven biochemical mechanism of covalent KRAS(G12C) inhibitors</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1038/s41594-018-0061-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1038%2Fs41594-018-0061-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=29760531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKqu7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=454-462&author=R.+Hansenauthor=U.+Petersauthor=A.+Babbarauthor=Y.+Chenauthor=J.+Fengauthor=M.+R.+Janesauthor=L.-S.+Liauthor=P.+Renauthor=Y.+Liuauthor=P.+P.+Zarrinkar&title=The+reactivity+driven+biochemical+mechanism+of+covalent+KRAS%28G12C%29+inhibitors&doi=10.1038%2Fs41594-018-0061-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors</span></div><div class="casAuthors">Hansen, Rasmus; Peters, Ulf; Babbar, Anjali; Chen, Yuching; Feng, Jun; Janes, Matthew R.; Li, Lian-Sheng; Ren, Pingda; Liu, Yi; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">454-462</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Activating mutations in KRAS are among the most common tumor driver mutations.  Until recently, KRAS had been considered undruggable with small mols.; the discovery of the covalent KRASG12C inhibitors ARS-853 and ARS-1620 has demonstrated that it is feasible to inhibit KRAS with high potency in cells and animals.  Although the biol. activity of these inhibitors has been described, the biochem. mechanism of how the compds. achieve potent inhibition remained incompletely understood.  We now show that the activity of ARS-853 and ARS-1620 is primarily driven by KRAS-mediated catalysis of the chem. reaction with Cys12 in human KRASG12C, while the reversible binding affinity is weak, in the hundreds of micromolar or higher range.  The mechanism resolves how an induced, shallow and dynamic pocket not expected to support high-affinity binding of small mols. can nevertheless be targeted with potent inhibitors and may be applicable to other targets conventionally considered undruggable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrya_A4ZYnOu7Vg90H21EOLACvtfcHk0ljm0kpbStqhlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKqu7nL&md5=b3f9198f55998306f3b881c256be22a9</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fs41594-018-0061-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-018-0061-5%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DR.%26aulast%3DPeters%26aufirst%3DU.%26aulast%3DBabbar%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DJanes%26aufirst%3DM.%2BR.%26aulast%3DLi%26aufirst%3DL.-S.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DThe%2520reactivity%2520driven%2520biochemical%2520mechanism%2520of%2520covalent%2520KRAS%2528G12C%2529%2520inhibitors%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D454%26epage%3D462%26doi%3D10.1038%2Fs41594-018-0061-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Canon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiki, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapaport, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osgood, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volak, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houk, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fakih, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neil, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falchook, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henary, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvedson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cee, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipford, J. R.</span></span> <span> </span><span class="NLM_article-title">The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>575</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1038/s41586-019-1694-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1038%2Fs41586-019-1694-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=31666701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitV2hsb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=575&publication_year=2019&pages=217-223&author=J.+Canonauthor=K.+Rexauthor=A.+Y.+Saikiauthor=C.+Mohrauthor=K.+Cookeauthor=D.+Bagalauthor=K.+Gaidaauthor=T.+Holtauthor=C.+G.+Knutsonauthor=N.+Koppadaauthor=B.+A.+Lanmanauthor=J.+Wernerauthor=A.+S.+Rapaportauthor=T.+San+Miguelauthor=R.+Ortizauthor=T.+Osgoodauthor=J.-R.+Sunauthor=X.+Zhuauthor=J.+D.+McCarterauthor=L.+P.+Volakauthor=B.+E.+Houkauthor=M.+G.+Fakihauthor=B.+H.+O%E2%80%99Neilauthor=T.+J.+Priceauthor=G.+S.+Falchookauthor=J.+Desaiauthor=J.+Kuoauthor=R.+Govindanauthor=D.+S.+Hongauthor=W.+Ouyangauthor=H.+Henaryauthor=T.+Arvedsonauthor=V.+J.+Ceeauthor=J.+R.+Lipford&title=The+clinical+KRAS%28G12C%29+inhibitor+AMG+510+drives+anti-tumour+immunity&doi=10.1038%2Fs41586-019-1694-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity</span></div><div class="casAuthors">Canon, Jude; Rex, Karen; Saiki, Anne Y.; Mohr, Christopher; Cooke, Keegan; Bagal, Dhanashri; Gaida, Kevin; Holt, Tyler; Knutson, Charles G.; Koppada, Neelima; Lanman, Brian A.; Werner, Jonathan; Rapaport, Aaron S.; San Miguel, Tisha; Ortiz, Roberto; Osgood, Tao; Sun, Ji-Rong; Zhu, Xiaochun; McCarter, John D.; Volak, Laurie P.; Houk, Brett E.; Fakih, Marwan G.; O'Neil, Bert H.; Price, Timothy J.; Falchook, Gerald S.; Desai, Jayesh; Kuo, James; Govindan, Ramaswamy; Hong, David S.; Ouyang, Wenjun; Henary, Haby; Arvedson, Tara; Cee, Victor J.; Lipford, J. Russell</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">575</span>
        (<span class="NLM_cas:issue">7781</span>),
    <span class="NLM_cas:pages">217-223</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">KRAS is the most frequently mutated oncogene in cancer and encodes a key signalling protein in tumors1,2.  The KRAS(G12C) mutant has a cysteine residue that has been exploited to design covalent inhibitors that have promising preclin. activity3-5.  Here we optimized a series of inhibitors, using novel binding interactions to markedly enhance their potency and selectivity.  Our efforts have led to the discovery of AMG 510, which is, to our knowledge, the first KRAS(G12C) inhibitor in clin. development.  In preclin. analyses, treatment with AMG 510 led to the regression of KRASG12C tumors and improved the anti-tumor efficacy of chemotherapy and targeted agents.  In immune-competent mice, treatment with AMG 510 resulted in a pro-inflammatory tumor microenvironment and produced durable cures alone as well as in combination with immune-checkpoint inhibitors.  Cured mice rejected the growth of isogenic KRASG12D tumors, which suggests adaptive immunity against shared antigens.  Furthermore, in clin. trials, AMG 510 demonstrated anti-tumor activity in the first dosing cohorts and represents a potentially transformative therapy for patients for whom effective treatments are lacking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTHdBftQfnhbVg90H21EOLACvtfcHk0lgGpj_elfqjiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitV2hsb7F&md5=3819175980905976ba87ff545b9506e1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-1694-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-1694-1%26sid%3Dliteratum%253Aachs%26aulast%3DCanon%26aufirst%3DJ.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DSaiki%26aufirst%3DA.%2BY.%26aulast%3DMohr%26aufirst%3DC.%26aulast%3DCooke%26aufirst%3DK.%26aulast%3DBagal%26aufirst%3DD.%26aulast%3DGaida%26aufirst%3DK.%26aulast%3DHolt%26aufirst%3DT.%26aulast%3DKnutson%26aufirst%3DC.%2BG.%26aulast%3DKoppada%26aufirst%3DN.%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DWerner%26aufirst%3DJ.%26aulast%3DRapaport%26aufirst%3DA.%2BS.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DOrtiz%26aufirst%3DR.%26aulast%3DOsgood%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DJ.-R.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DVolak%26aufirst%3DL.%2BP.%26aulast%3DHouk%26aufirst%3DB.%2BE.%26aulast%3DFakih%26aufirst%3DM.%2BG.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DB.%2BH.%26aulast%3DPrice%26aufirst%3DT.%2BJ.%26aulast%3DFalchook%26aufirst%3DG.%2BS.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DKuo%26aufirst%3DJ.%26aulast%3DGovindan%26aufirst%3DR.%26aulast%3DHong%26aufirst%3DD.%2BS.%26aulast%3DOuyang%26aufirst%3DW.%26aulast%3DHenary%26aufirst%3DH.%26aulast%3DArvedson%26aufirst%3DT.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DLipford%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520clinical%2520KRAS%2528G12C%2529%2520inhibitor%2520AMG%2520510%2520drives%2520anti-tumour%2520immunity%26jtitle%3DNature%26date%3D2019%26volume%3D575%26spage%3D217%26epage%3D223%26doi%3D10.1038%2Fs41586-019-1694-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wijeratne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reutter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furness, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zia-Ebrahimi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavitt, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelow, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Horn, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barda, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engler, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalmers, M. J.</span></span> <span> </span><span class="NLM_article-title">Chemical proteomic characterization of a covalent KRASG12C inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00110</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00110" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvVeisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=557-562&author=A.+Wijeratneauthor=J.+Xiaoauthor=C.+Reutterauthor=K.+W.+Furnessauthor=R.+Leonauthor=M.+Zia-Ebrahimiauthor=R.+N.+Cavittauthor=J.+M.+Strelowauthor=R.+D.+Van+Hornauthor=S.-B.+Pengauthor=D.+A.+Bardaauthor=T.+A.+Englerauthor=M.+J.+Chalmers&title=Chemical+proteomic+characterization+of+a+covalent+KRASG12C+inhibitor&doi=10.1021%2Facsmedchemlett.8b00110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor</span></div><div class="casAuthors">Wijeratne, Aruna; Xiao, Junpeng; Reutter, Christopher; Furness, Kelly W.; Leon, Rebecca; Zia-Ebrahimi, Mohammad; Cavitt, Rachel N.; Strelow, John M.; Van Horn, Robert D.; Peng, Sheng-Bin; Barda, David A.; Engler, Thomas A.; Chalmers, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">557-562</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The KRASG12C protein product is an attractive, yet challenging, target for small mol. inhibition.  One option for therapeutic intervention is to design small mol. ligands capable of binding to and inactivating KRASG12C via formation of a covalent bond to the sulfhydryl group of cysteine 12.  In order to better understand the cellular off-target interactions of Compd. I, a covalent KRASG12C inhibitor, we have completed a series of complementary chem. proteomics expts. in H358 cells.  A new thiol reactive probe (TRP) was designed and used to construct a cellular target occupancy assay for KRASG12C.  In addn., the thiol reactive probes allowed us to profile potential off-target interactions of Compd. I with over 3200 cysteine residues.  In order to complement the TRP data we designed Compd. II, an alkyne contg. version of Compd. I, to serve as bait in competitive chem. proteomics expts.  Herein, we describe and compare data from both the TRP and the click chem. probe pull down expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp215tWumE2SrVg90H21EOLACvtfcHk0lgGpj_elfqjiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvVeisrw%253D&md5=e95db80896d3bd29efaaf0ce541c760e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00110%26sid%3Dliteratum%253Aachs%26aulast%3DWijeratne%26aufirst%3DA.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DReutter%26aufirst%3DC.%26aulast%3DFurness%26aufirst%3DK.%2BW.%26aulast%3DLeon%26aufirst%3DR.%26aulast%3DZia-Ebrahimi%26aufirst%3DM.%26aulast%3DCavitt%26aufirst%3DR.%2BN.%26aulast%3DStrelow%26aufirst%3DJ.%2BM.%26aulast%3DVan%2BHorn%26aufirst%3DR.%2BD.%26aulast%3DPeng%26aufirst%3DS.-B.%26aulast%3DBarda%26aufirst%3DD.%2BA.%26aulast%3DEngler%26aufirst%3DT.%2BA.%26aulast%3DChalmers%26aufirst%3DM.%2BJ.%26atitle%3DChemical%2520proteomic%2520characterization%2520of%2520a%2520covalent%2520KRASG12C%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D557%26epage%3D562%26doi%3D10.1021%2Facsmedchemlett.8b00110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hallin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calinisan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briere, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudhakar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowcut, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkard, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigers, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Banet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlicek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velastagui, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierobon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patricoin, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassidy, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybkin, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lito, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span> <span> </span><span class="NLM_article-title">The KRASG12C inhibitor, MRTX849, provides insights toward therapeutic susceptibility of KRAS mutant cancers in mouse models and patients</span>. <i>Canc. Discov.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.cd-19-1167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1158%2F2159-8290.CD-19-1167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=31658955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A280%3ADC%252BB3Mjitl2jtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=54-71&author=J.+Hallinauthor=L.+D.+Engstromauthor=L.+Hargisauthor=A.+Calinisanauthor=R.+Arandaauthor=D.+M.+Briereauthor=N.+Sudhakarauthor=V.+Bowcutauthor=B.+R.+Baerauthor=J.+A.+Ballardauthor=M.+R.+Burkardauthor=J.+B.+Fellauthor=J.+P.+Fischerauthor=G.+P.+Vigersauthor=Y.+Xueauthor=S.+Gattoauthor=J.+Fernandez-Banetauthor=A.+Pavlicekauthor=K.+Velastaguiauthor=R.+C.+Chaoauthor=J.+Bartonauthor=M.+Pierobonauthor=E.+Baldelliauthor=E.+F.+Patricoinauthor=D.+P.+Cassidyauthor=M.+A.+Marxauthor=I.+I.+Rybkinauthor=M.+L.+Johnsonauthor=S.-H.+I.+Ouauthor=P.+Litoauthor=K.+P.+Papadopoulosauthor=P.+A.+J%C3%A4nneauthor=P.+Olsonauthor=J.+G.+Christensen&title=The+KRASG12C+inhibitor%2C+MRTX849%2C+provides+insights+toward+therapeutic+susceptibility+of+KRAS+mutant+cancers+in+mouse+models+and+patients&doi=10.1158%2F2159-8290.cd-19-1167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients</span></div><div class="casAuthors">Hallin Jill; Engstrom Lars D; Hargis Lauren; Calinisan Andrew; Aranda Ruth; Briere David M; Sudhakar Niranjan; Bowcut Vickie; Velastagui Karen; Chao Richard C; Barton Jeremy; Marx Matthew A; Olson Peter; Christensen James G; Baer Brian R; Ballard Joshua A; Burkard Michael R; Fell Jay B; Fischer John P; Vigers Guy P; Xue Yaohua; Lito Piro; Gatto Sole; Fernandez-Banet Julio; Pavlicek Adam; Pierobon Mariaelena; Baldelli Elisa; Patricoin Emanuel F 3rd; Cassidy Douglas P; Janne Pasi A; Rybkin Igor I; Johnson Melissa L; Ou Sai-Hong Ignatius; Papadopoulos Kyriakos P</div><div class="citationInfo"><span class="NLM_cas:title">Cancer discovery</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-71</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Despite decades of research, efforts to directly target KRAS have been challenging.  MRTX849 was identified as a potent, selective, and covalent KRAS(G12C) inhibitor that exhibits favorable drug-like properties, selectively modifies mutant cysteine 12 in GDP-bound KRAS(G12C), and inhibits KRAS-dependent signaling.  MRTX849 demonstrated pronounced tumor regression in 17 of 26 (65%) KRAS(G12C)-positive cell line- and patient-derived xenograft models from multiple tumor types, and objective responses have been observed in patients with KRAS(G12C)-positive lung and colon adenocarcinomas.  Comprehensive pharmacodynamic and pharmacogenomic profiling in sensitive and partially resistant nonclinical models identified mechanisms implicated in limiting antitumor activity including KRAS nucleotide cycling and pathways that induce feedback reactivation and/or bypass KRAS dependence.  These factors included activation of receptor tyrosine kinases (RTK), bypass of KRAS dependence, and genetic dysregulation of cell cycle.  Combinations of MRTX849 with agents that target RTKs, mTOR, or cell cycle demonstrated enhanced response and marked tumor regression in several tumor models, including MRTX849-refractory models.  SIGNIFICANCE: The discovery of MRTX849 provides a long-awaited opportunity to selectively target KRAS(G12C) in patients.  The in-depth characterization of MRTX849 activity, elucidation of response and resistance mechanisms, and identification of effective combinations provide new insight toward KRAS dependence and the rational development of this class of agents.See related commentary by Klempner and Hata, p. 20.This article is highlighted in the In This Issue feature, p. 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2TUtaXPf8uHl8icjszYl0fW6udTcc2eaR3NHJMP1ebrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mjitl2jtA%253D%253D&md5=49d361ac110c002732933f302220049d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-19-1167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-19-1167%26sid%3Dliteratum%253Aachs%26aulast%3DHallin%26aufirst%3DJ.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHargis%26aufirst%3DL.%26aulast%3DCalinisan%26aufirst%3DA.%26aulast%3DAranda%26aufirst%3DR.%26aulast%3DBriere%26aufirst%3DD.%2BM.%26aulast%3DSudhakar%26aufirst%3DN.%26aulast%3DBowcut%26aufirst%3DV.%26aulast%3DBaer%26aufirst%3DB.%2BR.%26aulast%3DBallard%26aufirst%3DJ.%2BA.%26aulast%3DBurkard%26aufirst%3DM.%2BR.%26aulast%3DFell%26aufirst%3DJ.%2BB.%26aulast%3DFischer%26aufirst%3DJ.%2BP.%26aulast%3DVigers%26aufirst%3DG.%2BP.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DGatto%26aufirst%3DS.%26aulast%3DFernandez-Banet%26aufirst%3DJ.%26aulast%3DPavlicek%26aufirst%3DA.%26aulast%3DVelastagui%26aufirst%3DK.%26aulast%3DChao%26aufirst%3DR.%2BC.%26aulast%3DBarton%26aufirst%3DJ.%26aulast%3DPierobon%26aufirst%3DM.%26aulast%3DBaldelli%26aufirst%3DE.%26aulast%3DPatricoin%26aufirst%3DE.%2BF.%26aulast%3DCassidy%26aufirst%3DD.%2BP.%26aulast%3DMarx%26aufirst%3DM.%2BA.%26aulast%3DRybkin%26aufirst%3DI.%2BI.%26aulast%3DJohnson%26aufirst%3DM.%2BL.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DLito%26aufirst%3DP.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DOlson%26aufirst%3DP.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DThe%2520KRASG12C%2520inhibitor%252C%2520MRTX849%252C%2520provides%2520insights%2520toward%2520therapeutic%2520susceptibility%2520of%2520KRAS%2520mutant%2520cancers%2520in%2520mouse%2520models%2520and%2520patients%26jtitle%3DCanc.%2520Discov.%26date%3D2020%26volume%3D10%26spage%3D54%26epage%3D71%26doi%3D10.1158%2F2159-8290.cd-19-1167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">Mild and General Palladium-Catalyzed Synthesis of Methyl Ethers Enabled by Palladacycle Precatalyst</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3998</span>, <span class="refDoi"> DOI: 10.1021/ol401796v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol401796v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFKgurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=3998&author=C.+W.+Cheungauthor=S.+L.+Buchwald&title=Mild+and+General+Palladium-Catalyzed+Synthesis+of+Methyl+Ethers+Enabled+by+Palladacycle+Precatalyst&doi=10.1021%2Fol401796v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Mild and General Palladium-Catalyzed Synthesis of Methyl Aryl Ethers Enabled by the Use of a Palladacycle Precatalyst</span></div><div class="casAuthors">Cheung, Chi Wai; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3998-4001</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A general method for the Pd-catalyzed coupling of methanol with (hetero)aryl halides is described.  The reactions proceed under mild conditions with a wide range of aryl and heteroaryl halides to give Me aryl ethers in high yield.  E.g., in presence of palladacycle precatalyst I (L = tBuBrettPhos) and the ligand tBuBrettPhos, arylation of MeOH by 4-Me3CC6H4Cl gave 93% 4-Me3CC6H4OMe.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJNZIu1ifO97Vg90H21EOLACvtfcHk0lhBTy_mkpmR-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFKgurzL&md5=de17e9bf376136d0ca7d801928032e7e</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fol401796v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol401796v%26sid%3Dliteratum%253Aachs%26aulast%3DCheung%26aufirst%3DC.%2BW.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DMild%2520and%2520General%2520Palladium-Catalyzed%2520Synthesis%2520of%2520Methyl%2520Ethers%2520Enabled%2520by%2520Palladacycle%2520Precatalyst%26jtitle%3DOrg.%2520Lett.%26date%3D2013%26volume%3D15%26spage%3D3998%26doi%3D10.1021%2Fol401796v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit28a"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fors, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">A single phosphine ligand allows palladium-catalyzed intermolecular C-O bond formation with secondary and primary alcohols</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">9943</span>, <span class="refDoi"> DOI: 10.1002/anie.201104361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1002%2Fanie.201104361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFKhs7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=9943&author=X.+Wuauthor=B.+P.+Forsauthor=S.+L.+Buchwald&title=A+single+phosphine+ligand+allows+palladium-catalyzed+intermolecular+C-O+bond+formation+with+secondary+and+primary+alcohols&doi=10.1002%2Fanie.201104361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A Single Phosphine Ligand Allows Palladium-Catalyzed Intermolecular C-O Bond Formation with Secondary and Primary Alcohols</span></div><div class="casAuthors">Wu, Xiaoxing; Fors, Brett P.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">9943-9947, S9943/1-S9943/134</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">An efficient, general palladium catalyst for C-O bond-forming reactions of secondary and primary alcs. with a range of aryl halides has been developed using RockPhos ligand I.  Heteroaryl halides, and, for the first time, electron-rich aryl halides can be coupled with secondary alcs.  A diverse set of substrate combinations are possible with just a single ligand, thus obviating the need to survey multiple ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1rRsKbYpjabVg90H21EOLACvtfcHk0lhBTy_mkpmR-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFKhs7jE&md5=00f2f016dd227483158dacc2e24fb614</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1002%2Fanie.201104361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201104361%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%26aulast%3DFors%26aufirst%3DB.%2BP.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DA%2520single%2520phosphine%2520ligand%2520allows%2520palladium-catalyzed%2520intermolecular%2520C-O%2520bond%2520formation%2520with%2520secondary%2520and%2520primary%2520alcohols%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2011%26volume%3D50%26spage%3D9943%26doi%3D10.1002%2Fanie.201104361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit28b"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maligres, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krska, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreier, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raheem, I. T.</span></span> <span> </span><span class="NLM_article-title">C-O cross-coupling of activated aryl and heteroaryl halides with aliphatic alcohols</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">9071</span>, <span class="refDoi"> DOI: 10.1002/anie.201203460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1002%2Fanie.201203460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFGhtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=9071&author=P.+E.+Maligresauthor=J.+Liauthor=S.+W.+Krskaauthor=J.+D.+Schreierauthor=I.+T.+Raheem&title=C-O+cross-coupling+of+activated+aryl+and+heteroaryl+halides+with+aliphatic+alcohols&doi=10.1002%2Fanie.201203460"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">C-O Cross-Coupling of Activated Aryl and Heteroaryl Halides with Aliphatic Alcohols</span></div><div class="casAuthors">Maligres, Peter E.; Li, Jing; Krska, Shane W.; Schreier, John D.; Raheem, Izzat T.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">9071-9074,S9071/1-S9071/21</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The authors describe a Pd/Josiphos catatyst system for alkoxylation of activated aryl and heteroaryl halides with primary, secondary, and select tertiary alcs.  E.g., in presence of [Pd2(dba)3] and ligand CyPF-tBu (I), C-O cross-coupling of 4-chloro-2-methylquinoline and PhCH2CH2OH gave 99% arom. ether 4-(2-phenylethoxy)-2-methylquinoline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqDUweMYyL3bVg90H21EOLACvtfcHk0liVU8UpBnnIzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFGhtLvN&md5=0888ab292ffa72853009ba5c64e71f4f</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1002%2Fanie.201203460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201203460%26sid%3Dliteratum%253Aachs%26aulast%3DMaligres%26aufirst%3DP.%2BE.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DKrska%26aufirst%3DS.%2BW.%26aulast%3DSchreier%26aufirst%3DJ.%2BD.%26aulast%3DRaheem%26aufirst%3DI.%2BT.%26atitle%3DC-O%2520cross-coupling%2520of%2520activated%2520aryl%2520and%2520heteroaryl%2520halides%2520with%2520aliphatic%2520alcohols%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2012%26volume%3D51%26spage%3D9071%26doi%3D10.1002%2Fanie.201203460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sureshbabu, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwanatha, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panguluri, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basavaprabhu</span></span> <span> </span><span class="NLM_article-title">Propanephosphonic acid anhydride (T3P®) - a benign reagent for diverse applications inclusive of large-scale synthesis</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1569</span>– <span class="NLM_lpage">1601</span>, <span class="refDoi"> DOI: 10.1055/s-0033-1338989</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1055%2Fs-0033-1338989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1ClsLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=1569-1601&author=V.+V.+Sureshbabuauthor=T.+M.+Vishwanathaauthor=N.+R.+Panguluriauthor=+Basavaprabhu&title=Propanephosphonic+acid+anhydride+%28T3P%C2%AE%29+-+a+benign+reagent+for+diverse+applications+inclusive+of+large-scale+synthesis&doi=10.1055%2Fs-0033-1338989"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Propanephosphonic acid anhydride (T3P). A benign reagent for diverse applications inclusive of large-scale synthesis</span></div><div class="casAuthors">Basavaprabhu; Vishwanatha, T. M.; Panguluri, Nageswara Rao; Sureshbabu, Vommina V.</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1569-1601</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">A review.  Propanephosphonic acid anhydride (T3P) is a prevailing coupling and dehydrating agent with many desirable properties which render it a reagent of choice for a plethora of reactions and, befittingly, its application in org. synthesis is rapidly increasing.  Since its introduction as a peptide coupling agent in 1980, the realm of applications of T3P expanded.  Currently its use showed a broad range of reactions, including condensation, functional group transformation, heterocycles prepn., rearrangements, and catalysis.  It offers several advantages over traditional reagents, such as high yield, chem. and optical purity, broad functional group tolerance and easy work-up.  The reagent is attractive for large-scale synthesis as well, and particularly so for multi-kilogram scale prepns. of drug mols.  This article reviewed the hitherto reported applications of T3P as a reagent in org. synthesis.  Focus is also placed on the use of T3P for large-scale synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYFQQPdkNefLVg90H21EOLACvtfcHk0liVU8UpBnnIzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1ClsLfE&md5=651a5f3c12c616d20c3ee00706b5b541</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1055%2Fs-0033-1338989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0033-1338989%26sid%3Dliteratum%253Aachs%26aulast%3DSureshbabu%26aufirst%3DV.%2BV.%26aulast%3DVishwanatha%26aufirst%3DT.%2BM.%26aulast%3DPanguluri%26aufirst%3DN.%2BR.%26aulast%3DBasavaprabhu%26atitle%3DPropanephosphonic%2520acid%2520anhydride%2520%2528T3P%25C2%25AE%2529%2520-%2520a%2520benign%2520reagent%2520for%2520diverse%2520applications%2520inclusive%2520of%2520large-scale%2520synthesis%26jtitle%3DSynthesis%26date%3D2013%26volume%3D45%26spage%3D1569%26epage%3D1601%26doi%3D10.1055%2Fs-0033-1338989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17','cit17a'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28','cit28a','cit28b'],'ref29':['cit29']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 50 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Hao Chen, Jeff B. Smaill, Tongzheng Liu, Ke Ding, <span class="NLM_string-name hlFld-ContribAuthor">Xiaoyun Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (23)
                                     , 14404-14424. <a href="https://doi.org/10.1021/acs.jmedchem.0c01312" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01312</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01312%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BInhibitors%252BDirectly%252BTargeting%252BKRAS%252Bas%252BAnticancer%252BTherapeutics%26aulast%3DChen%26aufirst%3DHao%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D28072020%26date%3D23112020%26volume%3D63%26issue%3D23%26spage%3D14404%26epage%3D14424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Keisuke Tokunaga, Mami Sato, Keiko Kuwata, Chizuru Miura, Hirokazu Fuchida, Naoya Matsunaga, Satoru Koyanagi, Shigehiro Ohdo, Naoya Shindo, <span class="NLM_string-name hlFld-ContribAuthor">Akio Ojida</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclobutane Carboxylic Amide as a Cysteine-Directed Strained Electrophile for Selective Targeting of Proteins. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2020,</strong> <em>142 </em>
                                    (43)
                                     , 18522-18531. <a href="https://doi.org/10.1021/jacs.0c07490" title="DOI URL">https://doi.org/10.1021/jacs.0c07490</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.0c07490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.0c07490%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DBicyclobutane%252BCarboxylic%252BAmide%252Bas%252Ba%252BCysteine-Directed%252BStrained%252BElectrophile%252Bfor%252BSelective%252BTargeting%252Bof%252BProteins%26aulast%3DTokunaga%26aufirst%3DKeisuke%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D12072020%26date%3D13102020%26volume%3D142%26issue%3D43%26spage%3D18522%26epage%3D18531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Adam Birkholz, David J. Kopecky, Laurie P. Volak, Michael D. Bartberger, Yuping Chen, Christopher M. Tegley, Tara Arvedson, John D. McCarter, Christopher Fotsch, <span class="NLM_string-name hlFld-ContribAuthor">Victor J. Cee</span>. </span><span class="cited-content_cbyCitation_article-title">Systematic Study of the Glutathione Reactivity of N-Phenylacrylamides: 2. Effects of Acrylamide Substitution. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 11602-11614. <a href="https://doi.org/10.1021/acs.jmedchem.0c00749" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00749</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00749%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSystematic%252BStudy%252Bof%252Bthe%252BGlutathione%252BReactivity%252Bof%252BN-Phenylacrylamides%25253A%252B2.%252BEffects%252Bof%252BAcrylamide%252BSubstitution%26aulast%3DBirkholz%26aufirst%3DAdam%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04052020%26date%3D09102020%26date%3D23092020%26volume%3D63%26issue%3D20%26spage%3D11602%26epage%3D11614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Michael J. Bond, Ling Chu, Dhanusha A. Nalawansha, Ke Li, <span class="NLM_string-name hlFld-ContribAuthor">Craig M. Crews</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs. </span><span class="cited-content_cbyCitation_journal-name">ACS Central Science</span><span> <strong>2020,</strong> <em>6 </em>
                                    (8)
                                     , 1367-1375. <a href="https://doi.org/10.1021/acscentsci.0c00411" title="DOI URL">https://doi.org/10.1021/acscentsci.0c00411</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscentsci.0c00411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscentsci.0c00411%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Central%2520Science%26atitle%3DTargeted%252BDegradation%252Bof%252BOncogenic%252BKRASG12C%252Bby%252BVHL-Recruiting%252BPROTACs%26aulast%3DBond%26aufirst%3DMichael%2BJ.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D07042020%26date%3D08072020%26volume%3D6%26issue%3D8%26spage%3D1367%26epage%3D1375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Elena De Vita, Maria Maneiro, <span class="NLM_string-name hlFld-ContribAuthor">Edward W. Tate</span>. </span><span class="cited-content_cbyCitation_article-title">The Missing Link between (Un)druggable and Degradable KRAS. </span><span class="cited-content_cbyCitation_journal-name">ACS Central Science</span><span> <strong>2020,</strong> <em>6 </em>
                                    (8)
                                     , 1281-1284. <a href="https://doi.org/10.1021/acscentsci.0c00920" title="DOI URL">https://doi.org/10.1021/acscentsci.0c00920</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscentsci.0c00920&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscentsci.0c00920%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Central%2520Science%26atitle%3DThe%252BMissing%252BLink%252Bbetween%252B%252528Un%252529druggable%252Band%252BDegradable%252BKRAS%26aulast%3DDe%2BVita%26aufirst%3DElena%26date%3D2020%26date%3D2020%26date%3D03082020%26volume%3D6%26issue%3D8%26spage%3D1281%26epage%3D1284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Peter Ertl, Eva Altmann, <span class="NLM_string-name hlFld-ContribAuthor">Jeffrey M. McKenna</span>. </span><span class="cited-content_cbyCitation_article-title">The Most Common Functional Groups in Bioactive Molecules and How Their Popularity Has Evolved over Time. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (15)
                                     , 8408-8418. <a href="https://doi.org/10.1021/acs.jmedchem.0c00754" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00754</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00754%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BMost%252BCommon%252BFunctional%252BGroups%252Bin%252BBioactive%252BMolecules%252Band%252BHow%252BTheir%252BPopularity%252BHas%252BEvolved%252Bover%252BTime%26aulast%3DErtl%26aufirst%3DPeter%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D05052020%26date%3D29072020%26date%3D14072020%26volume%3D63%26issue%3D15%26spage%3D8408%26epage%3D8418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ronen Gabizon, <span class="NLM_string-name hlFld-ContribAuthor">Nir London</span>. </span><span class="cited-content_cbyCitation_article-title">Hitting KRAS When It’s Down. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (13)
                                     , 6677-6678. <a href="https://doi.org/10.1021/acs.jmedchem.0c00785" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00785</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00785%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHitting%252BKRAS%252BWhen%252BIt%2525E2%252580%252599s%252BDown%26aulast%3DGabizon%26aufirst%3DRonen%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D09052020%26date%3D22062020%26volume%3D63%26issue%3D13%26spage%3D6677%26epage%3D6678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lorenz  Herdeis</span>, <span class="hlFld-ContribAuthor ">Daniel  Gerlach</span>, <span class="hlFld-ContribAuthor ">Darryl B.  McConnell</span>, <span class="hlFld-ContribAuthor ">Dirk  Kessler</span>. </span><span class="cited-content_cbyCitation_article-title">Stopping the beating heart of cancer: KRAS reviewed. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Structural Biology</span><span> <strong>2021,</strong> <em>71 </em>, 136-147. <a href="https://doi.org/10.1016/j.sbi.2021.06.013" title="DOI URL">https://doi.org/10.1016/j.sbi.2021.06.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.sbi.2021.06.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.sbi.2021.06.013%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Structural%2520Biology%26atitle%3DStopping%252Bthe%252Bbeating%252Bheart%252Bof%252Bcancer%25253A%252BKRAS%252Breviewed%26aulast%3DHerdeis%26aufirst%3DLorenz%26date%3D2021%26volume%3D71%26spage%3D136%26epage%3D147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Takamasa  Koga</span>, <span class="hlFld-ContribAuthor ">Kenichi  Suda</span>, <span class="hlFld-ContribAuthor ">Toshio  Fujino</span>, <span class="hlFld-ContribAuthor ">Shuta  Ohara</span>, <span class="hlFld-ContribAuthor ">Akira  Hamada</span>, <span class="hlFld-ContribAuthor ">Masaya  Nishino</span>, <span class="hlFld-ContribAuthor ">Masato  Chiba</span>, <span class="hlFld-ContribAuthor ">Masaki  Shimoji</span>, <span class="hlFld-ContribAuthor ">Toshiki  Takemoto</span>, <span class="hlFld-ContribAuthor ">Takeo  Arita</span>, <span class="hlFld-ContribAuthor ">Michael  Gmachl</span>, <span class="hlFld-ContribAuthor ">Marco H.  Hofmann</span>, <span class="hlFld-ContribAuthor ">Junichi  Soh</span>, <span class="hlFld-ContribAuthor ">Tetsuya  Mitsudomi</span>. </span><span class="cited-content_cbyCitation_article-title">KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments. </span><span class="cited-content_cbyCitation_journal-name">Journal of Thoracic Oncology</span><span> <strong>2021,</strong> <em>16 </em>
                                    (8)
                                     , 1321-1332. <a href="https://doi.org/10.1016/j.jtho.2021.04.015" title="DOI URL">https://doi.org/10.1016/j.jtho.2021.04.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jtho.2021.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jtho.2021.04.015%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Thoracic%2520Oncology%26atitle%3DKRAS%252BSecondary%252BMutations%252BThat%252BConfer%252BAcquired%252BResistance%252Bto%252BKRAS%252BG12C%252BInhibitors%25252C%252BSotorasib%252Band%252BAdagrasib%25252C%252Band%252BOvercoming%252BStrategies%25253A%252BInsights%252BFrom%252BIn%2525C2%2525A0Vitro%252BExperiments%26aulast%3DKoga%26aufirst%3DTakamasa%26date%3D2021%26volume%3D16%26issue%3D8%26spage%3D1321%26epage%3D1332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Severin  Thompson</span>, <span class="hlFld-ContribAuthor ">Andreas  Buckl</span>, <span class="hlFld-ContribAuthor ">Alexander G.  Dossetter</span>, <span class="hlFld-ContribAuthor ">Ed  Griffen</span>, <span class="hlFld-ContribAuthor ">Adrian  Gill</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em> </em><a href="https://doi.org/10.1080/13543776.2021.1952984" title="DOI URL">https://doi.org/10.1080/13543776.2021.1952984</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1952984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1952984%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DSmall%252Bmolecule%252BSon%252Bof%252BSevenless%252B1%252B%252528SOS1%252529%252Binhibitors%25253A%252Ba%252Breview%252Bof%252Bthe%252Bpatent%252Bliterature%26aulast%3DThompson%26aufirst%3DSeverin%26date%3D2021%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fandi  Sutanto</span>, <span class="hlFld-ContribAuthor ">Shabnam  Shaabani</span>, <span class="hlFld-ContribAuthor ">Rick  Oerlemans</span>, <span class="hlFld-ContribAuthor ">Deniz  Eris</span>, <span class="hlFld-ContribAuthor ">Pravin  Patil</span>, <span class="hlFld-ContribAuthor ">Mojgan  Hadian</span>, <span class="hlFld-ContribAuthor ">Meitian  Wang</span>, <span class="hlFld-ContribAuthor ">May Elizabeth  Sharpe</span>, <span class="hlFld-ContribAuthor ">Matthew R.  Groves</span>, <span class="hlFld-ContribAuthor ">Alexander  Dömling</span>. </span><span class="cited-content_cbyCitation_article-title">Combining High‐Throughput Synthesis and High‐Throughput Protein Crystallography for Accelerated Hit Identification. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2021,</strong> <em> </em><a href="https://doi.org/10.1002/ange.202105584" title="DOI URL">https://doi.org/10.1002/ange.202105584</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202105584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202105584%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DCombining%252BHigh%2525E2%252580%252590Throughput%252BSynthesis%252Band%252BHigh%2525E2%252580%252590Throughput%252BProtein%252BCrystallography%252Bfor%252BAccelerated%252BHit%252BIdentification%26aulast%3DSutanto%26aufirst%3DFandi%26date%3D2021%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fandi  Sutanto</span>, <span class="hlFld-ContribAuthor ">Shabnam  Shaabani</span>, <span class="hlFld-ContribAuthor ">Rick  Oerlemans</span>, <span class="hlFld-ContribAuthor ">Deniz  Eris</span>, <span class="hlFld-ContribAuthor ">Pravin  Patil</span>, <span class="hlFld-ContribAuthor ">Mojgan  Hadian</span>, <span class="hlFld-ContribAuthor ">Meitian  Wang</span>, <span class="hlFld-ContribAuthor ">May Elizabeth  Sharpe</span>, <span class="hlFld-ContribAuthor ">Matthew R.  Groves</span>, <span class="hlFld-ContribAuthor ">Alexander  Dömling</span>. </span><span class="cited-content_cbyCitation_article-title">Combining High‐Throughput Synthesis and High‐Throughput Protein Crystallography for Accelerated Hit Identification. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2021,</strong> <em>182 </em><a href="https://doi.org/10.1002/anie.202105584" title="DOI URL">https://doi.org/10.1002/anie.202105584</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202105584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202105584%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DCombining%252BHigh%2525E2%252580%252590Throughput%252BSynthesis%252Band%252BHigh%2525E2%252580%252590Throughput%252BProtein%252BCrystallography%252Bfor%252BAccelerated%252BHit%252BIdentification%26aulast%3DSutanto%26aufirst%3DFandi%26date%3D2021%26date%3D2021%26volume%3D182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Colin R.  Lindsay</span>, <span class="hlFld-ContribAuthor ">Marina C.  Garassino</span>, <span class="hlFld-ContribAuthor ">Ernest  Nadal</span>, <span class="hlFld-ContribAuthor ">Katarina  Öhrling</span>, <span class="hlFld-ContribAuthor ">Matthias  Scheffler</span>, <span class="hlFld-ContribAuthor ">Julien  Mazières</span>. </span><span class="cited-content_cbyCitation_article-title">On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Lung Cancer</span><span> <strong>2021,</strong> <em>893 </em><a href="https://doi.org/10.1016/j.lungcan.2021.07.005" title="DOI URL">https://doi.org/10.1016/j.lungcan.2021.07.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.lungcan.2021.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.lungcan.2021.07.005%26sid%3Dliteratum%253Aachs%26jtitle%3DLung%2520Cancer%26atitle%3DOn%252Btarget%25253A%252BRational%252Bapproaches%252Bto%252BKRAS%252Binhibition%252Bfor%252Btreatment%252Bof%252Bnon-small%252Bcell%252Blung%252Bcarcinoma%26aulast%3DLindsay%26aufirst%3DColin%2BR.%26date%3D2021%26volume%3D893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark M.  Awad</span>, <span class="hlFld-ContribAuthor ">Shengwu  Liu</span>, <span class="hlFld-ContribAuthor ">Igor I.  Rybkin</span>, <span class="hlFld-ContribAuthor ">Kathryn C.  Arbour</span>, <span class="hlFld-ContribAuthor ">Julien  Dilly</span>, <span class="hlFld-ContribAuthor ">Viola W.  Zhu</span>, <span class="hlFld-ContribAuthor ">Melissa L.  Johnson</span>, <span class="hlFld-ContribAuthor ">Rebecca S.  Heist</span>, <span class="hlFld-ContribAuthor ">Tejas  Patil</span>, <span class="hlFld-ContribAuthor ">Gregory J.  Riely</span>, <span class="hlFld-ContribAuthor ">Joseph O.  Jacobson</span>, <span class="hlFld-ContribAuthor ">Xiaoping  Yang</span>, <span class="hlFld-ContribAuthor ">Nicole S.  Persky</span>, <span class="hlFld-ContribAuthor ">David E.  Root</span>, <span class="hlFld-ContribAuthor ">Kristen E.  Lowder</span>, <span class="hlFld-ContribAuthor ">Hanrong  Feng</span>, <span class="hlFld-ContribAuthor ">Shannon S.  Zhang</span>, <span class="hlFld-ContribAuthor ">Kevin M.  Haigis</span>, <span class="hlFld-ContribAuthor ">Yin P.  Hung</span>, <span class="hlFld-ContribAuthor ">Lynette M.  Sholl</span>, <span class="hlFld-ContribAuthor ">Brian M.  Wolpin</span>, <span class="hlFld-ContribAuthor ">Julie  Wiese</span>, <span class="hlFld-ContribAuthor ">Jason  Christiansen</span>, <span class="hlFld-ContribAuthor ">Jessica  Lee</span>, <span class="hlFld-ContribAuthor ">Alexa B.  Schrock</span>, <span class="hlFld-ContribAuthor ">Lee P.  Lim</span>, <span class="hlFld-ContribAuthor ">Kavita  Garg</span>, <span class="hlFld-ContribAuthor ">Mark  Li</span>, <span class="hlFld-ContribAuthor ">Lars D.  Engstrom</span>, <span class="hlFld-ContribAuthor ">Laura  Waters</span>, <span class="hlFld-ContribAuthor ">J. David  Lawson</span>, <span class="hlFld-ContribAuthor ">Peter  Olson</span>, <span class="hlFld-ContribAuthor ">Piro  Lito</span>, <span class="hlFld-ContribAuthor ">Sai-Hong I.  Ou</span>, <span class="hlFld-ContribAuthor ">James G.  Christensen</span>, <span class="hlFld-ContribAuthor ">Pasi A.  Jänne</span>, <span class="hlFld-ContribAuthor ">Andrew J.  Aguirre</span>. </span><span class="cited-content_cbyCitation_article-title">Acquired Resistance to KRAS
              G12C
              Inhibition in Cancer. </span><span class="cited-content_cbyCitation_journal-name">New England Journal of Medicine</span><span> <strong>2021,</strong> <em>384 </em>
                                    (25)
                                     , 2382-2393. <a href="https://doi.org/10.1056/NEJMoa2105281" title="DOI URL">https://doi.org/10.1056/NEJMoa2105281</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1056/NEJMoa2105281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1056%2FNEJMoa2105281%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520England%2520Journal%2520of%2520Medicine%26atitle%3DAcquired%252BResistance%252Bto%252BKRAS%252BG12C%252BInhibition%252Bin%252BCancer%26aulast%3DAwad%26aufirst%3DMark%2BM.%26date%3D2021%26volume%3D384%26issue%3D25%26spage%3D2382%26epage%3D2393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Baoyuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Yan  Zhang</span>, <span class="hlFld-ContribAuthor ">Jiangwei  Zhang</span>, <span class="hlFld-ContribAuthor ">Ping  Liu</span>, <span class="hlFld-ContribAuthor ">Bo  Jiao</span>, <span class="hlFld-ContribAuthor ">Zaiqi  Wang</span>, <span class="hlFld-ContribAuthor ">Ruibao  Ren</span>. </span><span class="cited-content_cbyCitation_article-title">Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling. </span><span class="cited-content_cbyCitation_journal-name">Advanced Science</span><span> <strong>2021,</strong> <em> </em>, 2100250. <a href="https://doi.org/10.1002/advs.202100250" title="DOI URL">https://doi.org/10.1002/advs.202100250</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/advs.202100250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadvs.202100250%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Science%26atitle%3DFocal%252BAdhesion%252BKinase%252B%252528FAK%252529%252BInhibition%252BSynergizes%252Bwith%252BKRAS%252BG12C%252BInhibitors%252Bin%252BTreating%252BCancer%252Bthrough%252Bthe%252BRegulation%252Bof%252Bthe%252BFAK%2525E2%252580%252593YAP%252BSignaling%26aulast%3DZhang%26aufirst%3DBaoyuan%26date%3D2021%26date%3D2021%26spage%3D2100250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael J.  Bond</span>, <span class="hlFld-ContribAuthor ">Craig M.  Crews</span>. </span><span class="cited-content_cbyCitation_article-title">Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation. </span><span class="cited-content_cbyCitation_journal-name">RSC Chemical Biology</span><span> <strong>2021,</strong> <em>2 </em>
                                    (3)
                                     , 725-742. <a href="https://doi.org/10.1039/D1CB00011J" title="DOI URL">https://doi.org/10.1039/D1CB00011J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1CB00011J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1CB00011J%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Chemical%2520Biology%26atitle%3DProteolysis%252Btargeting%252Bchimeras%252B%252528PROTACs%252529%252Bcome%252Bof%252Bage%25253A%252Bentering%252Bthe%252Bthird%252Bdecade%252Bof%252Btargeted%252Bprotein%252Bdegradation%26aulast%3DBond%26aufirst%3DMichael%2BJ.%26date%3D2021%26date%3D2021%26volume%3D2%26issue%3D3%26spage%3D725%26epage%3D742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ronen  Gabizon</span>, <span class="hlFld-ContribAuthor ">Nir  London</span>. </span><span class="cited-content_cbyCitation_article-title">The rise of covalent proteolysis targeting chimeras. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2021,</strong> <em>62 </em>, 24-33. <a href="https://doi.org/10.1016/j.cbpa.2020.12.003" title="DOI URL">https://doi.org/10.1016/j.cbpa.2020.12.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2020.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2020.12.003%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DThe%252Brise%252Bof%252Bcovalent%252Bproteolysis%252Btargeting%252Bchimeras%26aulast%3DGabizon%26aufirst%3DRonen%26date%3D2021%26volume%3D62%26spage%3D24%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel A.  Erlanson</span>, <span class="hlFld-ContribAuthor ">Kevin R.  Webster</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting mutant KRAS. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2021,</strong> <em>62 </em>, 101-108. <a href="https://doi.org/10.1016/j.cbpa.2021.02.010" title="DOI URL">https://doi.org/10.1016/j.cbpa.2021.02.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2021.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2021.02.010%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DTargeting%252Bmutant%252BKRAS%26aulast%3DErlanson%26aufirst%3DDaniel%2BA.%26date%3D2021%26volume%3D62%26spage%3D101%26epage%3D108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shumei  Kato</span>, <span class="hlFld-ContribAuthor ">Jacob J.  Adashek</span>, <span class="hlFld-ContribAuthor ">Justin  Shaya</span>, <span class="hlFld-ContribAuthor ">Ryosuke  Okamura</span>, <span class="hlFld-ContribAuthor ">Rebecca E.  Jimenez</span>, <span class="hlFld-ContribAuthor ">Suzanna  Lee</span>, <span class="hlFld-ContribAuthor ">Jason K.  Sicklick</span>, <span class="hlFld-ContribAuthor ">Razelle  Kurzrock</span>. </span><span class="cited-content_cbyCitation_article-title">Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2021,</strong> <em>27 </em>
                                    (10)
                                     , 2792-2797. <a href="https://doi.org/10.1158/1078-0432.CCR-20-3761" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-20-3761</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-20-3761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-20-3761%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DConcomitant%252BMEK%252Band%252BCyclin%252BGene%252BAlterations%25253A%252BImplications%252Bfor%252BResponse%252Bto%252BTargeted%252BTherapeutics%26aulast%3DKato%26aufirst%3DShumei%26date%3D2021%26date%3D2021%26volume%3D27%26issue%3D10%26spage%3D2792%26epage%3D2797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Imran  Khan</span>, <span class="hlFld-ContribAuthor ">Catherine  MarElia-Bennet</span>, <span class="hlFld-ContribAuthor ">Julia  Lefler</span>, <span class="hlFld-ContribAuthor ">Mariyam  Zuberi</span>, <span class="hlFld-ContribAuthor ">Eric  Denbaum</span>, <span class="hlFld-ContribAuthor ">Akiko  Koide</span>, <span class="hlFld-ContribAuthor ">Dean M.  Connor</span>, <span class="hlFld-ContribAuthor ">Ann-Marie  Broome</span>, <span class="hlFld-ContribAuthor ">Thierry  Pécot</span>, <span class="hlFld-ContribAuthor ">Cynthia  Timmers</span>, <span class="hlFld-ContribAuthor ">Michael C.  Ostrowski</span>, <span class="hlFld-ContribAuthor ">Shohei  Koide</span>, <span class="hlFld-ContribAuthor ">John P.  O’Bryan</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the KRAS α4-α5 allosteric interface inhibits pancreatic cancer tumorigenesis. </span><span class="cited-content_cbyCitation_journal-name">Small GTPases</span><span> <strong>2021,</strong> <em>48 </em>, 1-14. <a href="https://doi.org/10.1080/21541248.2021.1906621" title="DOI URL">https://doi.org/10.1080/21541248.2021.1906621</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/21541248.2021.1906621&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F21541248.2021.1906621%26sid%3Dliteratum%253Aachs%26jtitle%3DSmall%2520GTPases%26atitle%3DTargeting%252Bthe%252BKRAS%252B%2525CE%2525B14-%2525CE%2525B15%252Ballosteric%252Binterface%252Binhibits%252Bpancreatic%252Bcancer%252Btumorigenesis%26aulast%3DKhan%26aufirst%3DImran%26date%3D2021%26date%3D2021%26volume%3D48%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael S.  Bodnarchuk</span>, <span class="hlFld-ContribAuthor ">Doyle J.  Cassar</span>, <span class="hlFld-ContribAuthor ">Jason G.  Kettle</span>, <span class="hlFld-ContribAuthor ">Graeme  Robb</span>, <span class="hlFld-ContribAuthor ">Richard A.  Ward</span>. </span><span class="cited-content_cbyCitation_article-title">Drugging the undruggable: a computational chemist's view of KRAS
              G12C. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (4)
                                     , 609-614. <a href="https://doi.org/10.1039/D1MD00055A" title="DOI URL">https://doi.org/10.1039/D1MD00055A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1MD00055A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1MD00055A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DDrugging%252Bthe%252Bundruggable%25253A%252Ba%252Bcomputational%252Bchemist%252527s%252Bview%252Bof%252BKRAS%252BG12C%26aulast%3DBodnarchuk%26aufirst%3DMichael%2BS.%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D4%26spage%3D609%26epage%3D614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marcus J. C.  Long</span>, <span class="hlFld-ContribAuthor ">Amogh  Kulkarni</span>, <span class="hlFld-ContribAuthor ">Yimon  Aye</span>. </span><span class="cited-content_cbyCitation_article-title">Can Precision Electrophile Signaling Make a Meaningful and Lasting Impression in Drug Design?. </span><span class="cited-content_cbyCitation_journal-name">ChemBioChem</span><span> <strong>2021,</strong> <em>344 </em><a href="https://doi.org/10.1002/cbic.202100051" title="DOI URL">https://doi.org/10.1002/cbic.202100051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbic.202100051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbic.202100051%26sid%3Dliteratum%253Aachs%26jtitle%3DChemBioChem%26atitle%3DCan%252BPrecision%252BElectrophile%252BSignaling%252BMake%252Ba%252BMeaningful%252Band%252BLasting%252BImpression%252Bin%252BDrug%252BDesign%25253F%26aulast%3DLong%26aufirst%3DMarcus%2BJ.%2BC.%26date%3D2021%26date%3D2021%26volume%3D344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carolina L.  Trkulja</span>, <span class="hlFld-ContribAuthor ">Oscar  Jungholm</span>, <span class="hlFld-ContribAuthor ">Max  Davidson</span>, <span class="hlFld-ContribAuthor ">Kent  Jardemark</span>, <span class="hlFld-ContribAuthor ">Monica M.  Marcus</span>, <span class="hlFld-ContribAuthor ">Jessica  Hägglund</span>, <span class="hlFld-ContribAuthor ">Anders  Karlsson</span>, <span class="hlFld-ContribAuthor ">Roger  Karlsson</span>, <span class="hlFld-ContribAuthor ">Joseph  Bruton</span>, <span class="hlFld-ContribAuthor ">Niklas  Ivarsson</span>, <span class="hlFld-ContribAuthor ">Sreesha P.  Srinivasa</span>, <span class="hlFld-ContribAuthor ">Alexandra  Cavallin</span>, <span class="hlFld-ContribAuthor ">Peder  Svensson</span>, <span class="hlFld-ContribAuthor ">Gavin D. M.  Jeffries</span>, <span class="hlFld-ContribAuthor ">Maria-Nefeli  Christakopoulou</span>, <span class="hlFld-ContribAuthor ">Anna  Reymer</span>, <span class="hlFld-ContribAuthor ">Anaswara  Ashok</span>, <span class="hlFld-ContribAuthor ">Gabriella  Willman</span>, <span class="hlFld-ContribAuthor ">Daniela  Papadia</span>, <span class="hlFld-ContribAuthor ">Emma  Johnsson</span>, <span class="hlFld-ContribAuthor ">Owe  Orwar</span>. </span><span class="cited-content_cbyCitation_article-title">Rational antibody design for undruggable targets using kinetically controlled biomolecular probes. </span><span class="cited-content_cbyCitation_journal-name">Science Advances</span><span> <strong>2021,</strong> <em>7 </em>
                                    (16)
                                     , eabe6397. <a href="https://doi.org/10.1126/sciadv.abe6397" title="DOI URL">https://doi.org/10.1126/sciadv.abe6397</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/sciadv.abe6397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fsciadv.abe6397%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Advances%26atitle%3DRational%252Bantibody%252Bdesign%252Bfor%252Bundruggable%252Btargets%252Busing%252Bkinetically%252Bcontrolled%252Bbiomolecular%252Bprobes%26aulast%3DTrkulja%26aufirst%3DCarolina%2BL.%26date%3D2021%26date%3D2021%26volume%3D7%26issue%3D16%26spage%3Deabe6397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jens  Köhler</span>, <span class="hlFld-ContribAuthor ">Pasi A.  Jänne</span>. </span><span class="cited-content_cbyCitation_article-title">If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (6)
                                     , 3025. <a href="https://doi.org/10.3390/ijms22063025" title="DOI URL">https://doi.org/10.3390/ijms22063025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22063025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22063025%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DIf%252BVirchow%252Band%252BEhrlich%252BHad%252BDreamt%252BTogether%25253A%252BWhat%252Bthe%252BFuture%252BHolds%252Bfor%252BKRAS-Mutant%252BLung%252BCancer%26aulast%3DK%25C3%25B6hler%26aufirst%3DJens%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D6%26spage%3D3025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sean T  Toenjes</span>, <span class="hlFld-ContribAuthor ">Mariam  Basilaia</span>, <span class="hlFld-ContribAuthor ">Jeffrey L  Gustafson</span>. </span><span class="cited-content_cbyCitation_article-title">Leveraging conformational control about a potential atropisomeric axis as a strategy in medical chemistry. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2021,</strong> <em>13 </em>
                                    (5)
                                     , 443-446. <a href="https://doi.org/10.4155/fmc-2020-0348" title="DOI URL">https://doi.org/10.4155/fmc-2020-0348</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2020-0348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2020-0348%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DLeveraging%252Bconformational%252Bcontrol%252Babout%252Ba%252Bpotential%252Batropisomeric%252Baxis%252Bas%252Ba%252Bstrategy%252Bin%252Bmedical%252Bchemistry%26aulast%3DToenjes%26aufirst%3DSean%2BT%26date%3D2021%26volume%3D13%26issue%3D5%26spage%3D443%26epage%3D446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuanzheng  Xiao</span>, <span class="hlFld-ContribAuthor ">Mengzhen  Lai</span>, <span class="hlFld-ContribAuthor ">Zilan  Song</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRASG12C inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>213 </em>, 113082. <a href="https://doi.org/10.1016/j.ejmech.2020.113082" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113082%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bpharmacological%252Bevaluation%252Bof%252Bbicyclic%252Band%252Btetracyclic%252Bpyridopyrimidinone%252Banalogues%252Bas%252Bnew%252BKRASG12C%252Binhibitors%26aulast%3DXiao%26aufirst%3DXuanzheng%26date%3D2021%26volume%3D213%26spage%3D113082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fiona M.  Healy</span>, <span class="hlFld-ContribAuthor ">Ian A.  Prior</span>, <span class="hlFld-ContribAuthor ">David J.  MacEwan</span>. </span><span class="cited-content_cbyCitation_article-title">The Importance of Ras in Drug Resistance in Cancer. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2021,</strong> <em> </em><a href="https://doi.org/10.1111/bph.15420" title="DOI URL">https://doi.org/10.1111/bph.15420</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.15420&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.15420%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DThe%252BImportance%252Bof%252BRas%252Bin%252BDrug%252BResistance%252Bin%252BCancer%26aulast%3DHealy%26aufirst%3DFiona%2BM.%26date%3D2021%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ruth  Nussinov</span>, <span class="hlFld-ContribAuthor ">Hyunbum  Jang</span>, <span class="hlFld-ContribAuthor ">Attila  Gursoy</span>, <span class="hlFld-ContribAuthor ">Ozlem  Keskin</span>, <span class="hlFld-ContribAuthor ">Vadim  Gaponenko</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of Nonfunctional Ras. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2021,</strong> <em>28 </em>
                                    (2)
                                     , 121-133. <a href="https://doi.org/10.1016/j.chembiol.2020.12.012" title="DOI URL">https://doi.org/10.1016/j.chembiol.2020.12.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2020.12.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2020.12.012%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DInhibition%252Bof%252BNonfunctional%252BRas%26aulast%3DNussinov%26aufirst%3DRuth%26date%3D2021%26volume%3D28%26issue%3D2%26spage%3D121%26epage%3D133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jose Carlos  Ruffinelli</span>, <span class="hlFld-ContribAuthor ">Cristina  Santos Vivas</span>, <span class="hlFld-ContribAuthor ">Rebeca  Sanz-Pamplona</span>, <span class="hlFld-ContribAuthor ">Victor  Moreno</span>. </span><span class="cited-content_cbyCitation_article-title">New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Gastroenterology & Hepatology</span><span> <strong>2021,</strong> <em>15 </em>
                                    (1)
                                     , 65-79. <a href="https://doi.org/10.1080/17474124.2021.1826305" title="DOI URL">https://doi.org/10.1080/17474124.2021.1826305</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17474124.2021.1826305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17474124.2021.1826305%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Gastroenterology%2520%2526%2520Hepatology%26atitle%3DNew%252Badvances%252Bin%252Bthe%252Bclinical%252Bmanagement%252Bof%252BRAS%252Band%252BBRAF%252Bmutant%252Bcolorectal%252Bcancer%252Bpatients%26aulast%3DRuffinelli%26aufirst%3DJose%2BCarlos%26date%3D2021%26date%3D2020%26volume%3D15%26issue%3D1%26spage%3D65%26epage%3D79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chen  Liu</span>, <span class="hlFld-ContribAuthor ">Hengyu  Lu</span>, <span class="hlFld-ContribAuthor ">Hongyun  Wang</span>, <span class="hlFld-ContribAuthor ">Alice  Loo</span>, <span class="hlFld-ContribAuthor ">Xiamei  Zhang</span>, <span class="hlFld-ContribAuthor ">Guizhi  Yang</span>, <span class="hlFld-ContribAuthor ">Colleen  Kowal</span>, <span class="hlFld-ContribAuthor ">Scott  Delach</span>, <span class="hlFld-ContribAuthor ">Ye  Wang</span>, <span class="hlFld-ContribAuthor ">Silvia  Goldoni</span>, <span class="hlFld-ContribAuthor ">William D.  Hastings</span>, <span class="hlFld-ContribAuthor ">Karrie  Wong</span>, <span class="hlFld-ContribAuthor ">Hui  Gao</span>, <span class="hlFld-ContribAuthor ">Matthew J.  Meyer</span>, <span class="hlFld-ContribAuthor ">Susan E.  Moody</span>, <span class="hlFld-ContribAuthor ">Matthew J.  LaMarche</span>, <span class="hlFld-ContribAuthor ">Jeffrey A.  Engelman</span>, <span class="hlFld-ContribAuthor ">Juliet A.  Williams</span>, <span class="hlFld-ContribAuthor ">Peter S.  Hammerman</span>, <span class="hlFld-ContribAuthor ">Tinya J.  Abrams</span>, <span class="hlFld-ContribAuthor ">Morvarid  Mohseni</span>, <span class="hlFld-ContribAuthor ">Giordano  Caponigro</span>, <span class="hlFld-ContribAuthor ">Huai-Xiang  Hao</span>. </span><span class="cited-content_cbyCitation_article-title">Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2021,</strong> <em>27 </em>
                                    (1)
                                     , 342-354. <a href="https://doi.org/10.1158/1078-0432.CCR-20-2718" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-20-2718</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-20-2718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-20-2718%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DCombinations%252Bwith%252BAllosteric%252BSHP2%252BInhibitor%252BTNO155%252Bto%252BBlock%252BReceptor%252BTyrosine%252BKinase%252BSignaling%26aulast%3DLiu%26aufirst%3DChen%26date%3D2021%26date%3D2020%26volume%3D27%26issue%3D1%26spage%3D342%26epage%3D354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elena De  Vita</span>. </span><span class="cited-content_cbyCitation_article-title">10 years into the resurgence of covalent drugs. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2021,</strong> <em>13 </em>
                                    (2)
                                     , 193-210. <a href="https://doi.org/10.4155/fmc-2020-0236" title="DOI URL">https://doi.org/10.4155/fmc-2020-0236</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2020-0236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2020-0236%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3D10%252Byears%252Binto%252Bthe%252Bresurgence%252Bof%252Bcovalent%252Bdrugs%26aulast%3DVita%26aufirst%3DElena%2BDe%26date%3D2021%26volume%3D13%26issue%3D2%26spage%3D193%26epage%3D210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wai Cheung  Chan</span>, <span class="hlFld-ContribAuthor ">Shabnam  Sharifzadeh</span>, <span class="hlFld-ContribAuthor ">Sara J.  Buhrlage</span>, <span class="hlFld-ContribAuthor ">Jarrod A.  Marto</span>. </span><span class="cited-content_cbyCitation_article-title">Chemoproteomic methods for covalent drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2021,</strong> <em>10 </em><a href="https://doi.org/10.1039/D1CS00231G" title="DOI URL">https://doi.org/10.1039/D1CS00231G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1CS00231G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1CS00231G%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DChemoproteomic%252Bmethods%252Bfor%252Bcovalent%252Bdrug%252Bdiscovery%26aulast%3DChan%26aufirst%3DWai%2BCheung%26date%3D2021%26date%3D2021%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">György M.  Keserű</span>, <span class="hlFld-ContribAuthor ">Daniel A.  Erlanson</span>. </span><span class="cited-content_cbyCitation_article-title">The future of covalent inhibition. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 267-284. <a href="https://doi.org/10.1016/bs.armc.2020.10.003" title="DOI URL">https://doi.org/10.1016/bs.armc.2020.10.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.armc.2020.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.armc.2020.10.003%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252Bfuture%252Bof%252Bcovalent%252Binhibition%26aulast%3DKeser%25C5%25B1%26aufirst%3DGy%25C3%25B6rgy%2BM.%26date%3D2021%26spage%3D267%26epage%3D284%26pub%3DElsevier%26atitle%3DThe%252BDesign%252Bof%252BCovalent-Based%252BInhibitors%26date%3D2021%26volume%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claire  McWhirter</span>. </span><span class="cited-content_cbyCitation_article-title">Kinetic mechanisms of covalent inhibition. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-31. <a href="https://doi.org/10.1016/bs.armc.2020.11.001" title="DOI URL">https://doi.org/10.1016/bs.armc.2020.11.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.armc.2020.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.armc.2020.11.001%26sid%3Dliteratum%253Aachs%26atitle%3DKinetic%252Bmechanisms%252Bof%252Bcovalent%252Binhibition%26aulast%3DMcWhirter%26aufirst%3DClaire%26date%3D2021%26spage%3D1%26epage%3D31%26pub%3DElsevier%26atitle%3DThe%252BDesign%252Bof%252BCovalent-Based%252BInhibitors%26date%3D2021%26volume%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lyn H.  Jones</span>. </span><span class="cited-content_cbyCitation_article-title">Design of next-generation covalent inhibitors: Targeting residues beyond cysteine. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 95-134. <a href="https://doi.org/10.1016/bs.armc.2020.10.001" title="DOI URL">https://doi.org/10.1016/bs.armc.2020.10.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.armc.2020.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.armc.2020.10.001%26sid%3Dliteratum%253Aachs%26atitle%3DDesign%252Bof%252Bnext-generation%252Bcovalent%252Binhibitors%25253A%252BTargeting%252Bresidues%252Bbeyond%252Bcysteine%26aulast%3DJones%26aufirst%3DLyn%2BH.%26date%3D2021%26spage%3D95%26epage%3D134%26pub%3DElsevier%26atitle%3DThe%252BDesign%252Bof%252BCovalent-Based%252BInhibitors%26date%3D2021%26volume%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amit  Shraga</span>, <span class="hlFld-ContribAuthor ">Efrat  Resnick</span>, <span class="hlFld-ContribAuthor ">Ronen  Gabizon</span>, <span class="hlFld-ContribAuthor ">Nir  London</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent fragment screening. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 243-265. <a href="https://doi.org/10.1016/bs.armc.2021.04.001" title="DOI URL">https://doi.org/10.1016/bs.armc.2021.04.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.armc.2021.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.armc.2021.04.001%26sid%3Dliteratum%253Aachs%26atitle%3DCovalent%252Bfragment%252Bscreening%26aulast%3DShraga%26aufirst%3DAmit%26date%3D2021%26spage%3D243%26epage%3D265%26pub%3DElsevier%26atitle%3DThe%252BDesign%252Bof%252BCovalent-Based%252BInhibitors%26date%3D2021%26volume%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Catherine A.  Hurd</span>, <span class="hlFld-ContribAuthor ">Paul  Brear</span>, <span class="hlFld-ContribAuthor ">Jefferson  Revell</span>, <span class="hlFld-ContribAuthor ">Sarah  Ross</span>, <span class="hlFld-ContribAuthor ">Helen R.  Mott</span>, <span class="hlFld-ContribAuthor ">Darerca  Owen</span>. </span><span class="cited-content_cbyCitation_article-title">Affinity maturation of the RLIP76 Ral binding domain to inform the design of stapled peptides targeting the Ral GTPases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biological Chemistry</span><span> <strong>2021,</strong> <em>296 </em>, 100101. <a href="https://doi.org/10.1074/jbc.RA120.015735" title="DOI URL">https://doi.org/10.1074/jbc.RA120.015735</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/jbc.RA120.015735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fjbc.RA120.015735%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biological%2520Chemistry%26atitle%3DAffinity%252Bmaturation%252Bof%252Bthe%252BRLIP76%252BRal%252Bbinding%252Bdomain%252Bto%252Binform%252Bthe%252Bdesign%252Bof%252Bstapled%252Bpeptides%252Btargeting%252Bthe%252BRal%252BGTPases%26aulast%3DHurd%26aufirst%3DCatherine%2BA.%26date%3D2021%26volume%3D296%26spage%3D100101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Atanu  Chakraborty</span>. </span><span class="cited-content_cbyCitation_article-title">KRASG12C inhibitor: combing for combination. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Society Transactions</span><span> <strong>2020,</strong> <em>48 </em>
                                    (6)
                                     , 2691-2701. <a href="https://doi.org/10.1042/BST20200473" title="DOI URL">https://doi.org/10.1042/BST20200473</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1042/BST20200473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1042%2FBST20200473%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Society%2520Transactions%26atitle%3DKRASG12C%252Binhibitor%25253A%252Bcombing%252Bfor%252Bcombination%26aulast%3DChakraborty%26aufirst%3DAtanu%26date%3D2020%26date%3D2020%26volume%3D48%26issue%3D6%26spage%3D2691%26epage%3D2701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zoltán  Orgován</span>, <span class="hlFld-ContribAuthor ">György M.  Keserű</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule inhibitors of RAS proteins with oncogenic mutations. </span><span class="cited-content_cbyCitation_journal-name">Cancer and Metastasis Reviews</span><span> <strong>2020,</strong> <em>39 </em>
                                    (4)
                                     , 1107-1126. <a href="https://doi.org/10.1007/s10555-020-09911-9" title="DOI URL">https://doi.org/10.1007/s10555-020-09911-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10555-020-09911-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10555-020-09911-9%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520and%2520Metastasis%2520Reviews%26atitle%3DSmall%252Bmolecule%252Binhibitors%252Bof%252BRAS%252Bproteins%252Bwith%252Boncogenic%252Bmutations%26aulast%3DOrgov%25C3%25A1n%26aufirst%3DZolt%25C3%25A1n%26date%3D2020%26date%3D2020%26volume%3D39%26issue%3D4%26spage%3D1107%26epage%3D1126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fernando C.  Baltanás</span>, <span class="hlFld-ContribAuthor ">Natasha  Zarich</span>, <span class="hlFld-ContribAuthor ">Jose M.  Rojas-Cabañeros</span>, <span class="hlFld-ContribAuthor ">Eugenio  Santos</span>. </span><span class="cited-content_cbyCitation_article-title">SOS GEFs in health and disease. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - Reviews on Cancer</span><span> <strong>2020,</strong> <em>1874 </em>
                                    (2)
                                     , 188445. <a href="https://doi.org/10.1016/j.bbcan.2020.188445" title="DOI URL">https://doi.org/10.1016/j.bbcan.2020.188445</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbcan.2020.188445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbcan.2020.188445%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520Reviews%2520on%2520Cancer%26atitle%3DSOS%252BGEFs%252Bin%252Bhealth%252Band%252Bdisease%26aulast%3DBaltan%25C3%25A1s%26aufirst%3DFernando%2BC.%26date%3D2020%26volume%3D1874%26issue%3D2%26spage%3D188445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicolas  Bery</span>, <span class="hlFld-ContribAuthor ">Ami  Miller</span>, <span class="hlFld-ContribAuthor ">Terry  Rabbitts</span>. </span><span class="cited-content_cbyCitation_article-title">A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2020,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-020-17022-w" title="DOI URL">https://doi.org/10.1038/s41467-020-17022-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-020-17022-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-020-17022-w%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DA%252Bpotent%252BKRAS%252Bmacromolecule%252Bdegrader%252Bspecifically%252Btargeting%252Btumours%252Bwith%252Bmutant%252BKRAS%26aulast%3DBery%26aufirst%3DNicolas%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kinga  Nyíri</span>, <span class="hlFld-ContribAuthor ">Gergely  Koppány</span>, <span class="hlFld-ContribAuthor ">Beáta G.  Vértessy</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based inhibitor design of mutant RAS proteins—a paradigm shift. </span><span class="cited-content_cbyCitation_journal-name">Cancer and Metastasis Reviews</span><span> <strong>2020,</strong> <em>39 </em>
                                    (4)
                                     , 1091-1105. <a href="https://doi.org/10.1007/s10555-020-09914-6" title="DOI URL">https://doi.org/10.1007/s10555-020-09914-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10555-020-09914-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10555-020-09914-6%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520and%2520Metastasis%2520Reviews%26atitle%3DStructure-based%252Binhibitor%252Bdesign%252Bof%252Bmutant%252BRAS%252Bproteins%2525E2%252580%252594a%252Bparadigm%252Bshift%26aulast%3DNy%25C3%25ADri%26aufirst%3DKinga%26date%3D2020%26date%3D2020%26volume%3D39%26issue%3D4%26spage%3D1091%26epage%3D1105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dongsung  Kim</span>, <span class="hlFld-ContribAuthor ">Jenny Yaohua  Xue</span>, <span class="hlFld-ContribAuthor ">Piro  Lito</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients. </span><span class="cited-content_cbyCitation_journal-name">Cell</span><span> <strong>2020,</strong> <em>183 </em>
                                    (4)
                                     , 850-859. <a href="https://doi.org/10.1016/j.cell.2020.09.044" title="DOI URL">https://doi.org/10.1016/j.cell.2020.09.044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cell.2020.09.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cell.2020.09.044%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%26atitle%3DTargeting%252BKRAS%252528G12C%252529%25253A%252BFrom%252BInhibitory%252BMechanism%252Bto%252BModulation%252Bof%252BAntitumor%252BEffects%252Bin%252BPatients%26aulast%3DKim%26aufirst%3DDongsung%26date%3D2020%26volume%3D183%26issue%3D4%26spage%3D850%26epage%3D859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mariyam  Zuberi</span>, <span class="hlFld-ContribAuthor ">Imran  Khan</span>, <span class="hlFld-ContribAuthor ">John P.  O'Bryan</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of RAS: proven and potential vulnerabilities. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Society Transactions</span><span> <strong>2020,</strong> <em>48 </em>
                                    (5)
                                     , 1831-1841. <a href="https://doi.org/10.1042/BST20190023" title="DOI URL">https://doi.org/10.1042/BST20190023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1042/BST20190023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1042%2FBST20190023%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Society%2520Transactions%26atitle%3DInhibition%252Bof%252BRAS%25253A%252Bproven%252Band%252Bpotential%252Bvulnerabilities%26aulast%3DZuberi%26aufirst%3DMariyam%26date%3D2020%26date%3D2020%26volume%3D48%26issue%3D5%26spage%3D1831%26epage%3D1841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Synthesis of MRTX849. </span><span class="cited-content_cbyCitation_journal-name">Synfacts</span><span> <strong>2020,</strong>,, 1017. <a href="https://doi.org/10.1055/s-0040-1705872" title="DOI URL">https://doi.org/10.1055/s-0040-1705872</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/s-0040-1705872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fs-0040-1705872%26sid%3Dliteratum%253Aachs%26jtitle%3DSynfacts%26atitle%3DSynthesis%252Bof%252BMRTX849%26date%3D2020%26date%3D2020%26volume%3D16%26issue%3D09%26spage%3D1017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roberto Carmagnani  Pestana</span>, <span class="hlFld-ContribAuthor ">Shiraj  Sen</span>, <span class="hlFld-ContribAuthor ">Brian P.  Hobbs</span>, <span class="hlFld-ContribAuthor ">David S.  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Histology-agnostic drug development — considering issues beyond the tissue. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Clinical Oncology</span><span> <strong>2020,</strong> <em>17 </em>
                                    (9)
                                     , 555-568. <a href="https://doi.org/10.1038/s41571-020-0384-0" title="DOI URL">https://doi.org/10.1038/s41571-020-0384-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41571-020-0384-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41571-020-0384-0%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Clinical%2520Oncology%26atitle%3DHistology-agnostic%252Bdrug%252Bdevelopment%252B%2525E2%252580%252594%252Bconsidering%252Bissues%252Bbeyond%252Bthe%252Btissue%26aulast%3DPestana%26aufirst%3DRoberto%2BCarmagnani%26date%3D2020%26date%3D2020%26volume%3D17%26issue%3D9%26spage%3D555%26epage%3D568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Badi El  Osta</span>, <span class="hlFld-ContribAuthor ">Suresh S.  Ramalingam</span>. </span><span class="cited-content_cbyCitation_article-title">RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC. </span><span class="cited-content_cbyCitation_journal-name">JTO Clinical and Research Reports</span><span> <strong>2020,</strong> <em>1 </em>
                                    (3)
                                     , 100050. <a href="https://doi.org/10.1016/j.jtocrr.2020.100050" title="DOI URL">https://doi.org/10.1016/j.jtocrr.2020.100050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jtocrr.2020.100050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jtocrr.2020.100050%26sid%3Dliteratum%253Aachs%26jtitle%3DJTO%2520Clinical%2520and%2520Research%2520Reports%26atitle%3DRET%252BFusion%25253A%252BJoining%252Bthe%252BRanks%252Bof%252BTargetable%252BMolecular%252BDrivers%252Bin%252BNSCLC%26aulast%3DOsta%26aufirst%3DBadi%2BEl%26date%3D2020%26volume%3D1%26issue%3D3%26spage%3D100050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lisa  Goebel</span>, <span class="hlFld-ContribAuthor ">Matthias P.  Müller</span>, <span class="hlFld-ContribAuthor ">Roger S.  Goody</span>, <span class="hlFld-ContribAuthor ">Daniel  Rauh</span>. </span><span class="cited-content_cbyCitation_article-title">KRasG12C inhibitors in clinical trials: a short historical perspective. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2020,</strong> <em>11 </em>
                                    (7)
                                     , 760-770. <a href="https://doi.org/10.1039/D0MD00096E" title="DOI URL">https://doi.org/10.1039/D0MD00096E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00096E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00096E%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DKRasG12C%252Binhibitors%252Bin%252Bclinical%252Btrials%25253A%252Ba%252Bshort%252Bhistorical%252Bperspective%26aulast%3DGoebel%26aufirst%3DLisa%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D7%26spage%3D760%26epage%3D770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fatma H.  Al-Awadhi</span>, <span class="hlFld-ContribAuthor ">Hendrik  Luesch</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting eukaryotic proteases for natural products-based drug development. </span><span class="cited-content_cbyCitation_journal-name">Natural Product Reports</span><span> <strong>2020,</strong> <em>37 </em>
                                    (6)
                                     , 827-860. <a href="https://doi.org/10.1039/C9NP00060G" title="DOI URL">https://doi.org/10.1039/C9NP00060G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9NP00060G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9NP00060G%26sid%3Dliteratum%253Aachs%26jtitle%3DNatural%2520Product%2520Reports%26atitle%3DTargeting%252Beukaryotic%252Bproteases%252Bfor%252Bnatural%252Bproducts-based%252Bdrug%252Bdevelopment%26aulast%3DAl-Awadhi%26aufirst%3DFatma%2BH.%26date%3D2020%26date%3D2020%26volume%3D37%26issue%3D6%26spage%3D827%26epage%3D860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qizhang  Li</span>, <span class="hlFld-ContribAuthor ">Zhiying  Wang</span>, <span class="hlFld-ContribAuthor ">Qiang  Zheng</span>, <span class="hlFld-ContribAuthor ">Sen  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2. </span><span class="cited-content_cbyCitation_journal-name">Computational and Structural Biotechnology Journal</span><span> <strong>2020,</strong> <em>18 </em>, 2200-2208. <a href="https://doi.org/10.1016/j.csbj.2020.08.016" title="DOI URL">https://doi.org/10.1016/j.csbj.2020.08.016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.csbj.2020.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.csbj.2020.08.016%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520and%2520Structural%2520Biotechnology%2520Journal%26atitle%3DPotential%252Bclinical%252Bdrugs%252Bas%252Bcovalent%252Binhibitors%252Bof%252Bthe%252Bpriming%252Bproteases%252Bof%252Bthe%252Bspike%252Bprotein%252Bof%252BSARS-CoV-2%26aulast%3DLi%26aufirst%3DQizhang%26date%3D2020%26volume%3D18%26spage%3D2200%26epage%3D2208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0033.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structural comparison of compound <b>1</b> to clinical development candidate <b>MRTX849</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0008.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Compound <b>1</b> and the deshydroxy analogue <b>7</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0009.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray crystal structure of compound <b>7</b> bound to KRAS<sup>G12C</sup> with 2.27 Å resolution, hydrogens added for clarity (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6USX">6USX</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0010.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray crystal structure of compound <b>12a</b> bound to KRAS<sup>G12C</sup> with 2.03 Å resolution, surface pose (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6USZ">6USZ</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0011.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. PK/PD of Compounds <b>18</b> and <b>19</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0012.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Antitumor Efficacy of Compounds <b>18</b> and <b>19</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0013.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Comparison of inherent GSH reactivity to GST-mediated GSH metabolism in the human liver cytosol for a diverse set of tetrahydropyridopyrimidines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0014.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Correlation of CL values for the tetrahydropyridopyrimidine series between GSTA1-1-mediated metabolism and human liver cytosol.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0015.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Correlation of CL values for the tetrahydropyridopyrimidine series between GSTP1-1-mediated metabolism and HWB stability.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0002.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. X-ray crystal structure of <b>MRTX849</b> bound to KRAS<sup>G12C</sup> with 1.94 Å resolution, hydrogens added for clarity (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UT0">6UT0</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0003.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> determination for <b>MRTX849</b>. Data represent the mean <i>k</i><sub>obs</sub> measured from three experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0004.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. <b>MRTX849</b>-targeted proteins identified by MS-based proteomic cysteine profiling.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0005.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Click chemistry target identification in NCI-H358 cells using compound <b>24</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0006.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. PK/PD of <b>MRTX849</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0007.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Antitumor Efficacy of <b>MRTX849</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compound <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) (i) urea, NaOEt/EtOH, 80 °C, 21 h, 62%; (ii) POCl<sub>3</sub>, 110 °C, 12 h, 60%; (b) (i) Boc-piperazine, DIEA, DMSO, 55 °C, 10 h, 80%; (ii) (<i>S</i>)-(1-methylpyrrolidin-2-yl)methanol, BINAP, Pd(OAc)<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, tol. 110 °C, 6 h, 90%; (c) (i) Pd(OH)<sub>2</sub>, H<sub>2,</sub> MeOH, 40 °C, 24 h, 94%; (ii) 3-(benzyloxy)-1-bromonaphthalene, RuPhos, Pd<sub>2</sub>(dba)<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, tol., 110 °C, 70%; (d) (i) Pd/C, H<sub>2</sub>, MeOH; (ii) HCl, MeCN, 0.5 h; (iii) acryloyl anhydride, DCM, DIEA, −50 °C, 12%.</p></p></figure><figure data-id="sch2" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Representative Synthetic Route to the Indazole Analogues <b>2–6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) (i) Pd(OH)<sub>2</sub>, H<sub>2</sub>, MeOH, 40 °C, 24 h, 94%; (ii) bromo-5-methyl-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-indazole, RuPhos, Pd<sub>2</sub>(dba)<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, tol., 110 °C, 12 h, 70%; (b) (i) TFA, DCM, 1 h; (ii) acryloyl anhydride, DCM, DIEA, −40 °C, 49%.</p></p></figure><figure data-id="sch3" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compound <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) (i) Pd(OH)<sub>2</sub>, H<sub>2</sub>, MeOH, 40 °C, 24 h, 94%; (ii) 1-bromonaphthalene, Pd<sub>2</sub>(dba)<sub>3</sub>, RuPhos, Cs<sub>2</sub>CO<sub>3</sub>, tol., 90 °C, 8 h, 87%; (b) (i) HCl, MeCN, HCl/dioxane, 30 min, 0 °C; (ii) acryloyl anhydride, DCM, DIEA, −40 °C, 10 min, 14% over 2 steps.</p></p></figure><figure data-id="sch4" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Representative Synthesis of Substituted Piperazines <b>8–13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) NaOMe/MeOH 0 → 25 °C, 30 min, 92%; (b) (<i>S</i>)-(1-methylpyrrolidin-2-yl)methanol, BINAP, Pd(OAc)<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, tol., 110 °C, 8 h, 83%; (c) Pd(OH)<sub>2</sub>/C, H<sub>2,</sub> MeOH, 40 °C 48 h, 90%; (d) 1-bromonaphthalene, Pd<sub>2</sub>(dba)<sub>3</sub>, RuPhos, Cs<sub>2</sub>CO<sub>3</sub>, tol., 90 °C, 12 h, 64%; (e) (i) EtSH, NaH, DMF, 1 h (ii) DCM, TEA, 4 Å MS, Tf<sub>2</sub>O, −40 °C, 22%; (f) (i) (<i>S</i>)-2-(piperazin-2-yl)acetonitrile, DIEA, DMA; (ii) acryloyl anhydride, DCM, DIEA, 0 °C, 1 h; (iii) SCF separation.</p></p></figure><figure data-id="sch5" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of 8-Substituted Naphthyl <b>14–17</b> and <b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) (i) H<sub>2</sub>, Pd(OH)<sub>2</sub>, MeOH, 40 °C; (ii) CbzCl, DCM DIEA, 0 °C 36%; (b) (i) methyl carbamimidothioate, NaOMe/MeOH, 30 °C, 12 h, 85%; (ii) DCM, TEA, Tf<sub>2</sub>O, −40 °C, 67%; (c) (i) (<i>S</i>)-2-(piperazin-2-yl)acetonitrile, DIEA, DMA, 80 °C, 83%; (d) (i) <i>m</i>-CPBA, DCM, 30 min, 89%; (ii) (<i>S</i>)-(1-methylpyrrolidin-2-yl)methanol, NaOtBu, tol., 0 °C, 6 h, 61%; (iii) Pd/C, H<sub>2</sub>, MeOH, 40 °C, 24 h, 71%; (e) (i) 8-methyl, 1-bromonaphthalene, XantPhos, Pd<sub>2</sub>(dba)<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, tol., 100 °C, 5 h, 59%; (ii) HCl diox/ACN, 30 min; (f) acryloyl anhydride, DCM, DIEA, −40 °C, 24%.</p></p></figure><figure data-id="sch6" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compound <b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) Pd<sub>2</sub>(dba)<sub>3</sub>, RuPhos, Cs<sub>2</sub>CO<sub>3</sub>, tol. 90 °C, 12 h, 53%; (b) (i) EtSH, NaH, DMF, 60 °C, 1.5 h, 94%; (ii) Tf<sub>2</sub>O, TEA, 4 Å MS, DCM, −40 °C, 30 min, 22%; (c) (<i>S</i>)-2-(piperazin-2-yl)acetonitrile, DIEA, DMA, rt, 15 min, 44%; (d) acryloyl chloride, DCM −40 °C, 10 min, 36%.</p></p></figure><figure data-id="sch7" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of the Clinical Candidate <b>20</b> (<b>MRTX849</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) 2-Fluoroprop-2-enoic acid, T3P, TEA, 0 °C, 30 min, 29%.</p></p></figure><figure data-id="sch8" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/medium/jm9b02052_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Click Chemistry Probe <b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.9b02052/20200701/images/large/jm9b02052_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02052&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and Conditions. (a) (i) ethyl 1-benzyl-3-oxopiperidine-4-carboxylate, NaOEt, EtOH; (ii) POCl<sub>3</sub>, CHCl<sub>3</sub>, 80 °C, 12 h, 71% over 2 steps; (b) (<i>S</i>)-2-(piperazin-2-yl)acetonitrile, DIEA, DMA, 80 °C, 3 h; Boc<sub>2</sub>O, 80 °C, 1 h, 85%; (c) (i) ACE-Cl, DCE, DIEA, 1 h, 0 °C; MeOH, 70 °C, 1 h, 82%; (ii) 8-chloro,1-bromonaphthalene, 4 Å MS, XantPhos, Pd<sub>2</sub>(dba)<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, tol., 110 °C, 12 h, 66%; (d) (i) <i>m</i>-CPBA, DCM, 30 min.; (ii) (<i>S</i>)-(1-(pent-4-yn-1-yl)pyrrolidin-2-yl)methanol, NaOtBu, tol., 4 Å MS, 0 °C, 30 min., 64%; (e) (i) TFA, DCM; (ii) 2-fluoroprop-2-enoic acid, EtOAc, T3P, TEA, 0 °C, 30 min., 24%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i46">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02410" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02410" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 29 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bos, J.</span></span> <span> </span><span class="NLM_article-title">Ras oncogenes in human cancer: a review</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">4682</span>– <span class="NLM_lpage">4689</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=2547513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADyaL1MXltlWksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1989&pages=4682-4689&author=J.+Bos&title=Ras+oncogenes+in+human+cancer%3A+a+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Ras oncogenes in human cancer:  a review</span></div><div class="casAuthors">Bos, Johannes L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4682-9</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">A review with 98 refs. with emphasis on current knowledge of the role mutant ras genes play in human tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-UKTWAA6IXLVg90H21EOLACvtfcHk0liUEYSNJ0dNpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXltlWksL4%253D&md5=248025343f490785d0272d4b5e636df2</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBos%26aufirst%3DJ.%26atitle%3DRas%2520oncogenes%2520in%2520human%2520cancer%253A%2520a%2520review%26jtitle%3DCancer%2520Res.%26date%3D1989%26volume%3D49%26spage%3D4682%26epage%3D4689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jarvis, L.</span></span> <span> </span><span class="NLM_article-title">Have drug hunters finally cracked KRAS?</span>. <i>Chem. Eng. News</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">33</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2016&pages=28-33&author=L.+Jarvis&title=Have+drug+hunters+finally+cracked+KRAS%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJarvis%26aufirst%3DL.%26atitle%3DHave%2520drug%2520hunters%2520finally%2520cracked%2520KRAS%253F%26jtitle%3DChem.%2520Eng.%2520News%26date%3D2016%26volume%3D94%26spage%3D28%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">John, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohmen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feuerstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittinghofer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goody, R. S.</span></span> <span> </span><span class="NLM_article-title">Kinetics of interaction of nucleotides with nucleotide-free H-ras p21</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">6058</span>– <span class="NLM_lpage">6065</span>, <span class="refDoi"> DOI: 10.1021/bi00477a025</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00477a025" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADyaK3cXktF2lt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1990&pages=6058-6065&author=J.+Johnauthor=R.+Sohmenauthor=J.+Feuersteinauthor=R.+Linkeauthor=A.+Wittinghoferauthor=R.+S.+Goody&title=Kinetics+of+interaction+of+nucleotides+with+nucleotide-free+H-ras+p21&doi=10.1021%2Fbi00477a025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetics of interaction of nucleotides with nucleotide-free H-ras p21</span></div><div class="casAuthors">John, Jacob; Sohmen, Roland; Feuerstein, Juergen; Linke, Rosita; Wittinghofer, Alfred; Goody, Roger S.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">6058-65</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">A method is described for the convenient prepn. of substantial quantities of nucleotide-free H-ras p21 protein or of 1:1 complexes with nucleotides other than GDP.  The nucleotide-free protein was used for kinetic studies of the binding of GDP and GTP, making use of the fluorescent analogs 3'-(methylanthraniloyl)-2'-deoxy-GDP and -GTP.  Stopped-flow studies have led to the formulation of a 2-step binding mechanism for both GDP and GTP, involving initial rapid but weak binding of the nucleotide followed by a relatively slow (10-20 s-1 at 25°; 3-5 s-1 at 5°) quasi-irreversible isomerization reaction.  By use of a nonequil. competition method, guanosine and GMP have been shown to interact weakly but significantly with p21 (dissocn. consts. of 153 and 29 μM, resp.).  The presence of guanosine or GMP at the active site of p21 leads to a marked stabilization of p21 against denaturation when compared with the nucleotide- and nucleoside-free protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ_yMxte1CZrVg90H21EOLACvtfcHk0lih78AWWRXMAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXktF2lt7o%253D&md5=069c7f0ba9b6691bd6368b8a079161a9</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fbi00477a025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00477a025%26sid%3Dliteratum%253Aachs%26aulast%3DJohn%26aufirst%3DJ.%26aulast%3DSohmen%26aufirst%3DR.%26aulast%3DFeuerstein%26aufirst%3DJ.%26aulast%3DLinke%26aufirst%3DR.%26aulast%3DWittinghofer%26aufirst%3DA.%26aulast%3DGoody%26aufirst%3DR.%2BS.%26atitle%3DKinetics%2520of%2520interaction%2520of%2520nucleotides%2520with%2520nucleotide-free%2520H-ras%2520p21%26jtitle%3DBiochemistry%26date%3D1990%26volume%3D29%26spage%3D6058%26epage%3D6065%26doi%3D10.1021%2Fbi00477a025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matikas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mistriotis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgoulias, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotsakis, A.</span></span> <span> </span><span class="NLM_article-title">Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity</span>. <i>Crit. Rev. Oncol. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2016.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1016%2Fj.critrevonc.2016.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=28109399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A280%3ADC%252BC1c7nvFersg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2017&pages=1-12&author=A.+Matikasauthor=D.+Mistriotisauthor=V.+Georgouliasauthor=A.+Kotsakis&title=Targeting+KRAS+mutated+non-small+cell+lung+cancer%3A+A+history+of+failures+and+a+future+of+hope+for+a+diverse+entity&doi=10.1016%2Fj.critrevonc.2016.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity</span></div><div class="casAuthors">Matikas Alexios; Mistriotis Dimitrios; Georgoulias Vasilios; Kotsakis Athanasios</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lung cancer remains the leading cause of cancer-related deaths in both men and women.  However, the discovery of several oncogenic driver mutations and the development of immune checkpoint inhibitors resulted in improved clinical outcomes for most patients.  Although activating KRAS mutations are the most common recurring molecular events in lung adenocarcinoma, little progress has been made during the past decades with no new agents being approved for this indication.  The elucidation of the underlying biology of this diverse patient subgroup offers great potential and renewed hope regarding the rational development, rigorous evaluation and subsequent approval of novel targeted agents and combinations which will effectively suppress compensatory escape routes and the emergence of resistance, issues that have plagued previous attempts.  Here, we review in a structured manner all aspects of KRAS positive non-small cell lung cancer, including the molecular biology, clinicopathologic characteristics, the prognostic and predictive value of KRAS mutations, as well as previous and contemporary approaches towards the treatment of this elusive target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQYoTBLJyPLwhWfpMXQLRstfW6udTcc2eZP-E8zP1minrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7nvFersg%253D%253D&md5=1a6d423366e389c294cf507f378e0096</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2016.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2016.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DMatikas%26aufirst%3DA.%26aulast%3DMistriotis%26aufirst%3DD.%26aulast%3DGeorgoulias%26aufirst%3DV.%26aulast%3DKotsakis%26aufirst%3DA.%26atitle%3DTargeting%2520KRAS%2520mutated%2520non-small%2520cell%2520lung%2520cancer%253A%2520A%2520history%2520of%2520failures%2520and%2520a%2520future%2520of%2520hope%2520for%2520a%2520diverse%2520entity%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2017%26volume%3D110%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.critrevonc.2016.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Vega, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armenia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatila, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitriadow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantheti, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saghafinia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foltz, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shmulevich, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heins, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochoa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandoth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahceci, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dervishi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dogrusoz, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laird, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Way, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iavarone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazar, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammer, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tward, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Allen, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherniack, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciriello, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, N.</span></span> <span> </span><span class="NLM_article-title">Oncogenic signaling pathways in the cancer genone atlas</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">337</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1016%2Fj.cell.2018.03.035" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2018&pages=321-337&author=F.+Sanchez-Vegaauthor=M.+Minaauthor=J.+Armeniaauthor=W.+K.+Chatilaauthor=A.+Lunaauthor=K.+C.+Laauthor=S.+Dimitriadowauthor=D.+L.+Liuauthor=H.+S.+Kanthetiauthor=S.+Saghafiniaauthor=D.+Chakravartyauthor=F.+Daianauthor=Q.+Gaoauthor=M.+H.+Baileyauthor=W.+W.+Liangauthor=S.+M.+Foltzauthor=I.+Shmulevichauthor=L.+Dingauthor=Z.+Heinsauthor=A.+Ochoaauthor=B.+Grossauthor=J.+Gaoauthor=H.+Zhangauthor=R.+Kundraauthor=C.+Kandothauthor=I.+Bahceciauthor=L.+Dervishiauthor=U.+Dogrusozauthor=W.+Zhouauthor=H.+Shenauthor=P.+W.+Lairdauthor=G.+P.+Wayauthor=C.+S.+Greeneauthor=H.+Liangauthor=Y.+Xiaoauthor=C.+Wangauthor=A.+Iavaroneauthor=A.+H.+Bergerauthor=T.+G.+Bivonaauthor=A.+J.+Lazarauthor=G.+D.+Hammerauthor=T.+Giordanoauthor=L.+N.+Kwongauthor=G.+McArthurauthor=C.+Huangauthor=A.+D.+Twardauthor=M.+J.+Frederickauthor=F.+McCormickauthor=M.+Meyersonauthor=E.+M.+Van+Allenauthor=A.+D.+Cherniackauthor=G.+Cirielloauthor=C.+Sanderauthor=N.+Schultz&title=Oncogenic+signaling+pathways+in+the+cancer+genone+atlas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Vega%26aufirst%3DF.%26aulast%3DMina%26aufirst%3DM.%26aulast%3DArmenia%26aufirst%3DJ.%26aulast%3DChatila%26aufirst%3DW.%2BK.%26aulast%3DLuna%26aufirst%3DA.%26aulast%3DLa%26aufirst%3DK.%2BC.%26aulast%3DDimitriadow%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DD.%2BL.%26aulast%3DKantheti%26aufirst%3DH.%2BS.%26aulast%3DSaghafinia%26aufirst%3DS.%26aulast%3DChakravarty%26aufirst%3DD.%26aulast%3DDaian%26aufirst%3DF.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DBailey%26aufirst%3DM.%2BH.%26aulast%3DLiang%26aufirst%3DW.%2BW.%26aulast%3DFoltz%26aufirst%3DS.%2BM.%26aulast%3DShmulevich%26aufirst%3DI.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DHeins%26aufirst%3DZ.%26aulast%3DOchoa%26aufirst%3DA.%26aulast%3DGross%26aufirst%3DB.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DKundra%26aufirst%3DR.%26aulast%3DKandoth%26aufirst%3DC.%26aulast%3DBahceci%26aufirst%3DI.%26aulast%3DDervishi%26aufirst%3DL.%26aulast%3DDogrusoz%26aufirst%3DU.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DLaird%26aufirst%3DP.%2BW.%26aulast%3DWay%26aufirst%3DG.%2BP.%26aulast%3DGreene%26aufirst%3DC.%2BS.%26aulast%3DLiang%26aufirst%3DH.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DIavarone%26aufirst%3DA.%26aulast%3DBerger%26aufirst%3DA.%2BH.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26aulast%3DLazar%26aufirst%3DA.%2BJ.%26aulast%3DHammer%26aufirst%3DG.%2BD.%26aulast%3DGiordano%26aufirst%3DT.%26aulast%3DKwong%26aufirst%3DL.%2BN.%26aulast%3DMcArthur%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DTward%26aufirst%3DA.%2BD.%26aulast%3DFrederick%26aufirst%3DM.%2BJ.%26aulast%3DMcCormick%26aufirst%3DF.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DVan%2BAllen%26aufirst%3DE.%2BM.%26aulast%3DCherniack%26aufirst%3DA.%2BD.%26aulast%3DCiriello%26aufirst%3DG.%26aulast%3DSander%26aufirst%3DC.%26aulast%3DSchultz%26aufirst%3DN.%26atitle%3DOncogenic%2520signaling%2520pathways%2520in%2520the%2520cancer%2520genone%2520atlas%26jtitle%3DCell%26date%3D2018%26volume%3D172%26spage%3D321%26epage%3D337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simanshu, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissley, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, F.</span></span> <span> </span><span class="NLM_article-title">Ras proteins and their regulators in human disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.06.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1016%2Fj.cell.2017.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=28666118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSqsLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2017&pages=17-33&author=D.+K.+Simanshuauthor=D.+V.+Nissleyauthor=F.+McCormick&title=Ras+proteins+and+their+regulators+in+human+disease&doi=10.1016%2Fj.cell.2017.06.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">RAS Proteins and their regulators in human disease</span></div><div class="casAuthors">Simanshu, Dhirendra K.; Nissley, Dwight V.; McCormick, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-33</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  RAS proteins are binary switches, cycling between ON and OFF states during signal transduction.  These switches are normally tightly controlled, but in RAS-related diseases, such as cancer, RASopathies, and many psychiatric disorders, mutations in the RAS genes or their regulators render RAS proteins persistently active.  The structural basis of the switch and many of the pathways that RAS controls are well known, but the precise mechanisms by which RAS proteins function are less clear.  All RAS biol. occurs in membranes: a precise understanding of RAS' interaction with membranes is essential to understand RAS action and to intervene in RAS-driven diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoH9cHufj4FLVg90H21EOLACvtfcHk0ljraGHBy2A1Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSqsLfP&md5=638a0c0efac88f2873c352715e332a92</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DSimanshu%26aufirst%3DD.%2BK.%26aulast%3DNissley%26aufirst%3DD.%2BV.%26aulast%3DMcCormick%26aufirst%3DF.%26atitle%3DRas%2520proteins%2520and%2520their%2520regulators%2520in%2520human%2520disease%26jtitle%3DCell%26date%3D2017%26volume%3D170%26spage%3D17%26epage%3D33%26doi%3D10.1016%2Fj.cell.2017.06.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ledford, H.</span></span> <span> </span><span class="NLM_article-title">Cancer: The Ras renaissance</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>520</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.1038/520278a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1038%2F520278a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=25877186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsF2gsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=520&publication_year=2015&pages=278-280&author=H.+Ledford&title=Cancer%3A+The+Ras+renaissance&doi=10.1038%2F520278a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer: The Ras renaissance</span></div><div class="casAuthors">Ledford, Heidi</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">520</span>
        (<span class="NLM_cas:issue">7547</span>),
    <span class="NLM_cas:pages">278-280</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Thirty years of pursuit have failed to yield a drug to take on one of the deadliest families of cancer-causing proteins.  Now some researchers are taking another shot.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9ZmQoGf5hfbVg90H21EOLACvtfcHk0ljraGHBy2A1Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsF2gsb0%253D&md5=bb8dc94e579a028675392e3002b61684</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2F520278a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F520278a%26sid%3Dliteratum%253Aachs%26aulast%3DLedford%26aufirst%3DH.%26atitle%3DCancer%253A%2520The%2520Ras%2520renaissance%26jtitle%3DNature%26date%3D2015%26volume%3D520%26spage%3D278%26epage%3D280%26doi%3D10.1038%2F520278a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span> <span> </span><span class="NLM_article-title">Drugging RAS: Know the enemy</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">1158</span>– <span class="NLM_lpage">1163</span>, <span class="refDoi"> DOI: 10.1126/science.aam7622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1126%2Fscience.aam7622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=28302824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktFOmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2017&pages=1158-1163&author=B.+Papkeauthor=C.+J.+Der&title=Drugging+RAS%3A+Know+the+enemy&doi=10.1126%2Fscience.aam7622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging RAS: Know the enemy</span></div><div class="casAuthors">Papke, Bjoern; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">6330</span>),
    <span class="NLM_cas:pages">1158-1163</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  The three RAS oncogenes make up the most frequently mutated gene family in human cancer.  The well-validated role of mutationally activated RAS genes in driving cancer development and growth has stimulated comprehensive efforts to develop therapeutic strategies to block mutant RAS function for cancer treatment.  Disappointingly, despite more than three decades of research effort, clin. effective anti-RAS therapies have remained elusive, prompting a perception that RAS may be undruggable.  However, with a greater appreciation of the complexities of RAS that thwarted past efforts, and armed with new technologies and directions, the field is experiencing renewed excitement that mutant RAS may finally be conquered.  Here the authors summarize where these efforts stand.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhrMhg-D4EM7Vg90H21EOLACvtfcHk0ljraGHBy2A1Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktFOmtrY%253D&md5=ce9da51019033a624c765ef2507bac2e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1126%2Fscience.aam7622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aam7622%26sid%3Dliteratum%253Aachs%26aulast%3DPapke%26aufirst%3DB.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DDrugging%2520RAS%253A%2520Know%2520the%2520enemy%26jtitle%3DScience%26date%3D2017%26volume%3D355%26spage%3D1158%26epage%3D1163%26doi%3D10.1126%2Fscience.aam7622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ostrem, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sos, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>503</i></span>,  <span class="NLM_fpage">548</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1038/nature12796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1038%2Fnature12796" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=24256730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGqs7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=503&publication_year=2013&pages=548-551&author=J.+M.+Ostremauthor=U.+Petersauthor=M.+L.+Sosauthor=J.+A.+Wellsauthor=K.+M.+Shokat&title=K-Ras+%28G12C%29+inhibitors+allosterically+control+GTP+affinity+and+effector+interactions&doi=10.1038%2Fnature12796"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions</span></div><div class="casAuthors">Ostrem, Jonathan M.; Peters, Ulf; Sos, Martin L.; Wells, James A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">503</span>
        (<span class="NLM_cas:issue">7477</span>),
    <span class="NLM_cas:pages">548-551</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Somatic mutations in the small GTPase K-Ras are the most common activating lesions found in human cancer, and are generally assocd. with poor response to std. therapies.  Efforts to target this oncogene directly have faced difficulties owing to its picomolar affinity for GTP/GDP and the absence of known allosteric regulatory sites.  Oncogenic mutations result in functional activation of Ras family proteins by impairing GTP hydrolysis.  With diminished regulation by GTPase activity, the nucleotide state of Ras becomes more dependent on relative nucleotide affinity and concn.  This gives GTP an advantage over GDP and increases the proportion of active GTP-bound Ras.  Here we report the development of small mols. that irreversibly bind to a common oncogenic mutant, K-Ras(G12C).  These compds. rely on the mutant cysteine for binding and therefore do not affect the wild-type protein.  Crystallog. studies reveal the formation of a new pocket that is not apparent in previous structures of Ras, beneath the effector binding switch-II region.  Binding of these inhibitors to K-Ras(G12C) disrupts both switch-I and switch-II, subverting the native nucleotide preference to favor GDP over GTP and impairing binding to Raf.  Our data provide structure-based validation of a new allosteric regulatory site on Ras that is targetable in a mutant-specific manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokkgcVXuBn_rVg90H21EOLACvtfcHk0lhrfzPoECIREw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGqs7jO&md5=27c1e7d8ef6b7e4b2919e9f00a073923</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature12796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12796%26sid%3Dliteratum%253Aachs%26aulast%3DOstrem%26aufirst%3DJ.%2BM.%26aulast%3DPeters%26aufirst%3DU.%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DWells%26aufirst%3DJ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DK-Ras%2520%2528G12C%2529%2520inhibitors%2520allosterically%2520control%2520GTP%2520affinity%2520and%2520effector%2520interactions%26jtitle%3DNature%26date%3D2013%26volume%3D503%26spage%3D548%26epage%3D551%26doi%3D10.1038%2Fnature12796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ostrem, J. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design</span>. <i>Nat. Rev. Drug Discov.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">771</span>– <span class="NLM_lpage">785</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1038%2Fnrd.2016.139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=27469033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Gisb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=771-785&author=J.+M.+L.+Ostremauthor=K.+M.+Shokat&title=Direct+small-molecule+inhibitors+of+KRAS%3A+from+structural+insights+to+mechanism-based+design&doi=10.1038%2Fnrd.2016.139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design</span></div><div class="casAuthors">Ostrem, Jonathan M. L.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">771-785</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">KRAS is the most frequently mutated oncogene in human cancer.  In addn. to holding this distinction, unsuccessful attempts to target this protein have led to the characterization of RAS as 'undruggable'.  However, recent advances in technol. and novel approaches to drug discovery have renewed hope that a direct KRAS inhibitor may be on the horizon.  In this Review, we provide an in-depth anal. of the structure, dynamics, mutational activation and inactivation, and signalling mechanisms of RAS.  From this perspective, we then consider potential mechanisms of action for effective RAS inhibitors.  Finally, we examine each of the many recent reports of direct RAS inhibitors and discuss promising avenues for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBobrhZLF3V7Vg90H21EOLACvtfcHk0lhrfzPoECIREw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Gisb%252FK&md5=b0832c7ef45cc0555e11c59baccc5abd</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.139%26sid%3Dliteratum%253Aachs%26aulast%3DOstrem%26aufirst%3DJ.%2BM.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DDirect%2520small-molecule%2520inhibitors%2520of%2520KRAS%253A%2520from%2520structural%2520insights%2520to%2520mechanism-based%2520design%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discov.%26date%3D2016%26volume%3D15%26spage%3D771%26epage%3D785%26doi%3D10.1038%2Fnrd.2016.139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janes, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babbar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firdaus, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darjania, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, Y. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarieh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ely, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucharski, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brehmer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanak, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu-Lowe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patricelli, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">578</span>– <span class="NLM_lpage">589.e17</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2018.01.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1016%2Fj.cell.2018.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=29373830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislyisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2018&pages=578-589.e17&author=M.+R.+Janesauthor=J.+Zhangauthor=L.-S.+Liauthor=R.+Hansenauthor=U.+Petersauthor=X.+Guoauthor=Y.+Chenauthor=A.+Babbarauthor=S.+J.+Firdausauthor=L.+Darjaniaauthor=J.+Fengauthor=J.+H.+Chenauthor=S.+Liauthor=S.+Liauthor=Y.+O.+Longauthor=C.+Thachauthor=Y.+Liuauthor=A.+Zariehauthor=T.+Elyauthor=J.+M.+Kucharskiauthor=L.+V.+Kesslerauthor=T.+Wuauthor=K.+Yuauthor=Y.+Wangauthor=Y.+Yaoauthor=X.+Dengauthor=P.+P.+Zarrinkarauthor=D.+Brehmerauthor=D.+Dhanakauthor=M.+V.+Lorenziauthor=D.+Hu-Loweauthor=M.+P.+Patricelliauthor=P.+Renauthor=Y.+Liu&title=Targeting+KRAS+mutant+cancers+with+a+covalent+G12C-specific+inhibitor&doi=10.1016%2Fj.cell.2018.01.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor</span></div><div class="casAuthors">Janes, Matthew R.; Zhang, Jingchuan; Li, Lian-Sheng; Hansen, Rasmus; Peters, Ulf; Guo, Xin; Chen, Yuching; Babbar, Anjali; Firdaus, Sarah J.; Darjania, Levan; Feng, Jun; Chen, Jeffrey H.; Li, Shuangwei; Li, Shisheng; Long, Yun O.; Thach, Carol; Liu, Yuan; Zarieh, Ata; Ely, Tess; Kucharski, Jeff M.; Kessler, Linda V.; Wu, Tao; Yu, Ke; Wang, Yi; Yao, Yvonne; Deng, Xiaohu; Zarrinkar, Patrick P.; Brehmer, Dirk; Dhanak, Dashyant; Lorenzi, Matthew V.; Hu-Lowe, Dana; Patricelli, Matthew P.; Ren, Pingda; Liu, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">578-589.e17</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">KRASG12C was recently identified to be potentially druggable by allele-specific covalent targeting of Cys 12 in vicinity to an inducible allosteric switch II pocket (S-IIP).  Success of this approach requires active cycling of KRASG12C between its active-GTP and inactive-GDP conformations as accessibility of the S-IIP is restricted only to the GDP-bound state.  This strategy proved feasible for inhibiting mutant KRAS in vitro; however, it is uncertain whether this approach would translate to in vivo.  Here, the authors describe structure-based design and identification of ARS-1620, a covalent compd. with high potency and selectivity for KRASG12C.  ARS-1620 achieves rapid and sustained in vivo target occupancy to induce tumor regression.  The authors use ARS-1620 to dissect oncogenic KRAS dependency and demonstrate that monolayer culture formats significantly underestimate KRAS dependency in vivo.  This study provides in vivo evidence that mutant KRAS can be selectively targeted and reveals ARS-1620 as representing a new generation of KRASG12C-specific inhibitors with promising therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVmv4KAl4_dLVg90H21EOLACvtfcHk0ljl8mMpWCucBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislyisb8%253D&md5=d0883bde981b51e41a794179ffae87be</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DJanes%26aufirst%3DM.%2BR.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.-S.%26aulast%3DHansen%26aufirst%3DR.%26aulast%3DPeters%26aufirst%3DU.%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DBabbar%26aufirst%3DA.%26aulast%3DFirdaus%26aufirst%3DS.%2BJ.%26aulast%3DDarjania%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DY.%2BO.%26aulast%3DThach%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZarieh%26aufirst%3DA.%26aulast%3DEly%26aufirst%3DT.%26aulast%3DKucharski%26aufirst%3DJ.%2BM.%26aulast%3DKessler%26aufirst%3DL.%2BV.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DBrehmer%26aufirst%3DD.%26aulast%3DDhanak%26aufirst%3DD.%26aulast%3DLorenzi%26aufirst%3DM.%2BV.%26aulast%3DHu-Lowe%26aufirst%3DD.%26aulast%3DPatricelli%26aufirst%3DM.%2BP.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DTargeting%2520KRAS%2520mutant%2520cancers%2520with%2520a%2520covalent%2520G12C-specific%2520inhibitor%26jtitle%3DCell%26date%3D2018%26volume%3D172%26spage%3D578%26epage%3D589.e17%26doi%3D10.1016%2Fj.cell.2018.01.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patricelli, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucharski, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ely, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firdaus, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babbar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state</span>. <i>Canc. Discov.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">329</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.cd-15-1105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1158%2F2159-8290.CD-15-1105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=26739882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVyru7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=316-329&author=M.+P.+Patricelliauthor=M.+R.+Janesauthor=L.-S.+Liauthor=R.+Hansenauthor=U.+Petersauthor=L.+V.+Kesslerauthor=Y.+Chenauthor=J.+M.+Kucharskiauthor=J.+Fengauthor=T.+Elyauthor=J.+H.+Chenauthor=S.+J.+Firdausauthor=A.+Babbarauthor=P.+Renauthor=Y.+Liu&title=Selective+inhibition+of+oncogenic+KRAS+output+with+small+molecules+targeting+the+inactive+state&doi=10.1158%2F2159-8290.cd-15-1105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State</span></div><div class="casAuthors">Patricelli, Matthew P.; Janes, Matthew R.; Li, Lian-Sheng; Hansen, Rasmus; Peters, Ulf; Kessler, Linda V.; Chen, Yuching; Kucharski, Jeff M.; Feng, Jun; Ely, Tess; Chen, Jeffrey H.; Firdaus, Sarah J.; Babbar, Anjali; Ren, Pingda; Liu, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">316-329</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">KRAS gain-of-function mutations occur in approx. 30% of all human cancers.  Despite more than 30 years of KRAS-focused research and development efforts, no targeted therapy has been discovered for cancers with KRAS mutations.  Here, we describe ARS-853, a selective, covalent inhibitor of KRASG12C that inhibits mutant KRAS-driven signaling by binding to the GDP-bound oncoprotein and preventing activation.  Based on the rates of engagement and inhibition obsd. for ARS-853, along with a mutant-specific mass spectrometry-based assay for assessing KRAS activation status, we show that the nucleotide state of KRASG12C is in a state of dynamic flux that can be modulated by upstream signaling factors.  These studies provide convincing evidence that the KRASG12C mutation generates a "hyperexcitable" rather than a "statically active" state and that targeting the inactive, GDP-bound form is a promising approach for generating novel anti-RAS therapeutics.  Significance: A cell-active, mutant-specific, covalent inhibitor of KRASG12C is described that targets the GDP-bound, inactive state and prevents subsequent activation.  Using this novel compd., we demonstrate that KRASG12C oncoprotein rapidly cycles bound nucleotide and responds to upstream signaling inputs to maintain a highly active state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJJA-9IIHeN7Vg90H21EOLACvtfcHk0ljl8mMpWCucBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVyru7s%253D&md5=41db2f02006e8f0be7a9bb47354addcd</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-1105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-1105%26sid%3Dliteratum%253Aachs%26aulast%3DPatricelli%26aufirst%3DM.%2BP.%26aulast%3DJanes%26aufirst%3DM.%2BR.%26aulast%3DLi%26aufirst%3DL.-S.%26aulast%3DHansen%26aufirst%3DR.%26aulast%3DPeters%26aufirst%3DU.%26aulast%3DKessler%26aufirst%3DL.%2BV.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DKucharski%26aufirst%3DJ.%2BM.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DEly%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DFirdaus%26aufirst%3DS.%2BJ.%26aulast%3DBabbar%26aufirst%3DA.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DSelective%2520inhibition%2520of%2520oncogenic%2520KRAS%2520output%2520with%2520small%2520molecules%2520targeting%2520the%2520inactive%2520state%26jtitle%3DCanc.%2520Discov.%26date%3D2016%26volume%3D6%26spage%3D316%26epage%3D329%26doi%3D10.1158%2F2159-8290.cd-15-1105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lito, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">604</span>– <span class="NLM_lpage">608</span>, <span class="refDoi"> DOI: 10.1126/science.aad6204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1126%2Fscience.aad6204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=26841430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhsl2jt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2016&pages=604-608&author=P.+Litoauthor=M.+Solomonauthor=L.-S.+Liauthor=R.+Hansenauthor=N.+Rosen&title=Allele-specific+inhibitors+inactivate+mutant+KRAS+G12C+by+a+trapping+mechanism&doi=10.1126%2Fscience.aad6204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism</span></div><div class="casAuthors">Lito, Piro; Solomon, Martha; Li, Lian-Sheng; Hansen, Rasmus; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">6273</span>),
    <span class="NLM_cas:pages">604-608</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">It is thought that KRAS oncoproteins are constitutively active because their guanosine triphosphatase (GTPase) activity is disabled.  Consequently, drugs targeting the inactive or GDP-bound conformation are not expected to be effective.  We describe a mechanism that enables such drugs to inhibit KRASG12C signaling and cancer cell growth.  Inhibition requires intact GTPase activity and occurs because drug-bound KRASG12C is insusceptible to nucleotide exchange factors and thus trapped in its inactive state.  Indeed, mutants completely lacking GTPase activity and those promoting exchange reduced the potency of the drug.  Suppressing nucleotide exchange activity downstream of various tyrosine kinases enhanced KRASG12C inhibition, whereas its potentiation had the opposite effect.  These findings reveal that KRASG12C undergoes nucleotide cycling in cancer cells and provide a basis for developing effective therapies to treat KRASG12C-driven cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK3AbqEZO6k7Vg90H21EOLACvtfcHk0ljl8mMpWCucBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhsl2jt78%253D&md5=22a47908ac0146822ecf19f5d0c952de</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscience.aad6204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aad6204%26sid%3Dliteratum%253Aachs%26aulast%3DLito%26aufirst%3DP.%26aulast%3DSolomon%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DL.-S.%26aulast%3DHansen%26aufirst%3DR.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DAllele-specific%2520inhibitors%2520inactivate%2520mutant%2520KRAS%2520G12C%2520by%2520a%2520trapping%2520mechanism%26jtitle%3DScience%26date%3D2016%26volume%3D351%26spage%3D604%26epage%3D608%26doi%3D10.1126%2Fscience.aad6204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhana, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briere, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkard, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chicarelli, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudino, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicken, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinklin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mejia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savechenkov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudhakar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigers, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecca, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of tetrahydropyridopyrimidines as irreversible covalent inhibitors of KRAS-G12C with in vivo activity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1230</span>– <span class="NLM_lpage">1234</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00382</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00382" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFagurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1230-1234&author=J.+B.+Fellauthor=J.+P.+Fischerauthor=B.+R.+Baerauthor=J.+Ballardauthor=J.+F.+Blakeauthor=K.+Bouhanaauthor=B.+J.+Brandhuberauthor=D.+M.+Briereauthor=L.+E.+Burgessauthor=M.+R.+Burkardauthor=H.+Chiangauthor=M.+J.+Chicarelliauthor=K.+Davidsonauthor=J.+J.+Gaudinoauthor=J.+Hallinauthor=L.+Hansonauthor=K.+Heeauthor=E.+J.+Hickenauthor=R.+J.+Hinklinauthor=M.+A.+Marxauthor=M.+J.+Mejiaauthor=P.+Olsonauthor=P.+Savechenkovauthor=N.+Sudhakarauthor=T.+P.+Tangauthor=G.+P.+Vigersauthor=H.+Zeccaauthor=J.+G.+Christensen&title=Discovery+of+tetrahydropyridopyrimidines+as+irreversible+covalent+inhibitors+of+KRAS-G12C+with+in+vivo+activity&doi=10.1021%2Facsmedchemlett.8b00382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity</span></div><div class="casAuthors">Fell, Jay B.; Fischer, John P.; Baer, Brian R.; Ballard, Joshua; Blake, James F.; Bouhana, Karyn; Brandhuber, Barbara J.; Briere, David M.; Burgess, Laurence E.; Burkard, Michael R.; Chiang, Harrah; Chicarelli, Mark J.; Davidson, Kevin; Gaudino, John J.; Hallin, Jill; Hanson, Lauren; Hee, Kenneth; Hicken, Erik J.; Hinklin, Ronald J.; Marx, Matthew A.; Mejia, Macedonio J.; Olson, Peter; Savechenkov, Pavel; Sudhakar, Niranjan; Tang, Tony P.; Vigers, Guy P.; Zecca, Henry; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1230-1234</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">KRAS is the most frequently mutated driver oncogene in human cancer, and KRAS mutations are commonly assocd. with poor prognosis and resistance to std. treatment.  The ability to effectively target and block the function of mutated KRAS has remained elusive despite decades of research.  Recent findings have demonstrated that directly targeting KRAS-G12C with electrophilic small mols. that covalently modify the mutated codon 12 cysteine is feasible.  We have discovered a series of tetrahydropyridopyrimidines as irreversible covalent inhibitors of KRAS-G12C with in vivo activity.  The PK/PD and efficacy of compd. 13 will be highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGs80kLXd9TbVg90H21EOLACvtfcHk0lilUHxHvSpL6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFagurfP&md5=f40ea2037c92c98dd84e907ebdcb4af6</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00382%26sid%3Dliteratum%253Aachs%26aulast%3DFell%26aufirst%3DJ.%2BB.%26aulast%3DFischer%26aufirst%3DJ.%2BP.%26aulast%3DBaer%26aufirst%3DB.%2BR.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DBouhana%26aufirst%3DK.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DBriere%26aufirst%3DD.%2BM.%26aulast%3DBurgess%26aufirst%3DL.%2BE.%26aulast%3DBurkard%26aufirst%3DM.%2BR.%26aulast%3DChiang%26aufirst%3DH.%26aulast%3DChicarelli%26aufirst%3DM.%2BJ.%26aulast%3DDavidson%26aufirst%3DK.%26aulast%3DGaudino%26aufirst%3DJ.%2BJ.%26aulast%3DHallin%26aufirst%3DJ.%26aulast%3DHanson%26aufirst%3DL.%26aulast%3DHee%26aufirst%3DK.%26aulast%3DHicken%26aufirst%3DE.%2BJ.%26aulast%3DHinklin%26aufirst%3DR.%2BJ.%26aulast%3DMarx%26aufirst%3DM.%2BA.%26aulast%3DMejia%26aufirst%3DM.%2BJ.%26aulast%3DOlson%26aufirst%3DP.%26aulast%3DSavechenkov%26aufirst%3DP.%26aulast%3DSudhakar%26aufirst%3DN.%26aulast%3DTang%26aufirst%3DT.%2BP.%26aulast%3DVigers%26aufirst%3DG.%2BP.%26aulast%3DZecca%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DDiscovery%2520of%2520tetrahydropyridopyrimidines%2520as%2520irreversible%2520covalent%2520inhibitors%2520of%2520KRAS-G12C%2520with%2520in%2520vivo%2520activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D1230%26epage%3D1234%26doi%3D10.1021%2Facsmedchemlett.8b00382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berenbom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, L.</span></span> <span> </span><span class="NLM_article-title">Biochemical Studies of Toxic Agents. 3. The Isolation of 1- and 2-Naphthyl-sulphuric acid and 1- and 2-naphthylglucaronide from the urine of rats dosed with 1- and 2-naphthol</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">1951</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1042/bj0490165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1042%2Fbj0490165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=14858304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADyaG38XjsFWl" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1951&pages=165-169&author=M.+Berenbomauthor=L.+Young&title=Biochemical+Studies+of+Toxic+Agents.+3.+The+Isolation+of+1-+and+2-Naphthyl-sulphuric+acid+and+1-+and+2-naphthylglucaronide+from+the+urine+of+rats+dosed+with+1-+and+2-naphthol&doi=10.1042%2Fbj0490165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical studies of toxic agents. III. The isolation of 1- and 2-naphthylsulfuric acid and 1- and 2-naphthylglucuronide from the urine of rats dosed with 1- and 2-naphthol</span></div><div class="casAuthors">Berenbom, M.; Young, L.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">1951</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">165-9</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    </div><div class="casAbstract">cf. C.A. 45, 764a.  Rats were injected subcutaneously with 1- and 2-naphthol.  The substances pass out into the urine, and are also conjugated and excreted as the corresponding H2SO4 and glucuronide compounds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkN9FLUzdPJ7Vg90H21EOLACvtfcHk0lilUHxHvSpL6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG38XjsFWl&md5=8b904c9981da86dc81d0ce290c662061</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1042%2Fbj0490165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj0490165%26sid%3Dliteratum%253Aachs%26aulast%3DBerenbom%26aufirst%3DM.%26aulast%3DYoung%26aufirst%3DL.%26atitle%3DBiochemical%2520Studies%2520of%2520Toxic%2520Agents.%25203.%2520The%2520Isolation%2520of%25201-%2520and%25202-Naphthyl-sulphuric%2520acid%2520and%25201-%2520and%25202-naphthylglucaronide%2520from%2520the%2520urine%2520of%2520rats%2520dosed%2520with%25201-%2520and%25202-naphthol%26jtitle%3DBiochem.%2520J.%26date%3D1951%26volume%3D49%26spage%3D165%26epage%3D169%26doi%3D10.1042%2Fbj0490165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirado-Rives, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span> <span> </span><span class="NLM_article-title">Energetics of displacing water molecules from protein binding sites: consequences for ligand optimization</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">15403</span>– <span class="NLM_lpage">15411</span>, <span class="refDoi"> DOI: 10.1021/ja906058w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja906058w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFOiu7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=15403-15411&author=J.+Michelauthor=J.+Tirado-Rivesauthor=W.+L.+Jorgensen&title=Energetics+of+displacing+water+molecules+from+protein+binding+sites%3A+consequences+for+ligand+optimization&doi=10.1021%2Fja906058w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Energetics of Displacing Water Molecules from Protein Binding Sites: Consequences for Ligand Optimization</span></div><div class="casAuthors">Michel, Julien; Tirado-Rives, Julian; Jorgensen, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">15403-15411</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A strategy in drug design is to consider enhancing the affinity of lead mols. with structural modifications that displace water mols. from a protein binding site.  Because success of the approach is uncertain, clarification of the assocd. energetics was sought in cases where similar structural modifications yield qual. different outcomes.  Specifically, free-energy perturbation calcns. were carried out in the context of Monte Carlo statistical mechanics simulations to investigate ligand series that feature displacement of ordered water mols. in the binding sites of scytalone dehydratase, p38-αMAP kinase, and EGFR kinase.  The change in affinity for a ligand modification is found to correlate with the ease of displacement of the ordered water mol.  However, as in the EGFR example, the binding affinity may diminish if the free-energy increase due to the removal of the bound water mol. is not more than compensated by the addnl. interactions of the water-displacing moiety.  For accurate computation of the effects of ligand modifications, a complete thermodn. anal. is shown to be needed.  It requires identification of the location of water mols. in the protein-ligand interface and evaluation of the free-energy changes assocd. with their removal and with the introduction of the ligand modification.  Direct modification of the ligand in free-energy calcns. is likely to trap the ordered mol. and provide misleading guidance for lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoULCMKgzc8SLVg90H21EOLACvtfcHk0lgfAmJv9YcSeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFOiu7%252FI&md5=598676ea350be074bc2adea75eae9948</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fja906058w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja906058w%26sid%3Dliteratum%253Aachs%26aulast%3DMichel%26aufirst%3DJ.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26atitle%3DEnergetics%2520of%2520displacing%2520water%2520molecules%2520from%2520protein%2520binding%2520sites%253A%2520consequences%2520for%2520ligand%2520optimization%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D15403%26epage%3D15411%26doi%3D10.1021%2Fja906058w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marx, M.</span>; <span class="NLM_string-name">Baer, B. R.</span>; <span class="NLM_string-name">Ballard, J.</span>; <span class="NLM_string-name">Blake, J. F.</span>; <span class="NLM_string-name">Bouhana, K.</span>; <span class="NLM_string-name">Briere, D. M.</span>; <span class="NLM_string-name">Burgess, L. E.</span>; <span class="NLM_string-name">Burkard, M. R.</span>; <span class="NLM_string-name">Chiang, H.</span>; <span class="NLM_string-name">Chicarelli, M. J.</span>; <span class="NLM_string-name">Christensen, J. G.</span>; <span class="NLM_string-name">Cook, A. W.</span>; <span class="NLM_string-name">Fischer, J. P.</span>; <span class="NLM_string-name">Hallin, J.</span>; <span class="NLM_string-name">Mejia, M. J.</span>; <span class="NLM_string-name">Olson, P.</span>; <span class="NLM_string-name">Rodriguez, M.</span>; <span class="NLM_string-name">Savenchenkov, P.</span>; <span class="NLM_string-name">Sudhakar, N.</span>; <span class="NLM_string-name">Tang, T. P.</span>; <span class="NLM_string-name">Vigers, G. P.</span>; <span class="NLM_string-name">Fell, J. B.</span></span> <span> </span><span class="NLM_article-title">Structure based drug discovery of MRTX1257, a selective, covalent KRAS G12C inhibitor with oral activity in animal models of cancer</span>.  <i>AACR Targeting RAS-Driven Cancers</i>, <span class="NLM_year">2018</span>, <span class="NLM_publisher-loc">San Diego CA</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=M.+Marx&author=B.+R.+Baer&author=J.+Ballard&author=J.+F.+Blake&author=K.+Bouhana&author=D.+M.+Briere&author=L.+E.+Burgess&author=M.+R.+Burkard&author=H.+Chiang&author=M.+J.+Chicarelli&author=J.+G.+Christensen&author=A.+W.+Cook&author=J.+P.+Fischer&author=J.+Hallin&author=M.+J.+Mejia&author=P.+Olson&author=M.+Rodriguez&author=P.+Savenchenkov&author=N.+Sudhakar&author=T.+P.+Tang&author=G.+P.+Vigers&author=J.+B.+Fell&title=Structure+based+drug+discovery+of+MRTX1257%2C+a+selective%2C+covalent+KRAS+G12C+inhibitor+with+oral+activity+in+animal+models+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DMarx%26aufirst%3DM.%26atitle%3DStructure%2520based%2520drug%2520discovery%2520of%2520MRTX1257%252C%2520a%2520selective%252C%2520covalent%2520KRAS%2520G12C%2520inhibitor%2520with%2520oral%2520activity%2520in%2520animal%2520models%2520of%2520cancer%26jtitle%3DAACR%2520Targeting%2520RAS-Driven%2520Cancers%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hallin, J.</span>; <span class="NLM_string-name">Aranda, R.</span>; <span class="NLM_string-name">Baer, B. R.</span>; <span class="NLM_string-name">Burkard, M. R.</span>; <span class="NLM_string-name">Calinisan, A.</span>; <span class="NLM_string-name">Chiang, H.</span>; <span class="NLM_string-name">Engstrom, L. D.</span>; <span class="NLM_string-name">Fell, J. B.</span>; <span class="NLM_string-name">Marx, M. A.</span>; <span class="NLM_string-name">Olson, P.</span>; <span class="NLM_string-name">Christensen, J. G.</span></span> <span> </span><span class="NLM_article-title">Insight towards therapeutic susceptibility of KRAS mutant cancers from MRTX1257; A prototype selective inhibitor of KRAS G12C</span>.  <i>AACR Targeting RAS-Driven Cancers</i>, <span class="NLM_year">2018</span>, <span class="NLM_publisher-loc">San Diego CA</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=J.+Hallin&author=R.+Aranda&author=B.+R.+Baer&author=M.+R.+Burkard&author=A.+Calinisan&author=H.+Chiang&author=L.+D.+Engstrom&author=J.+B.+Fell&author=M.+A.+Marx&author=P.+Olson&author=J.+G.+Christensen&title=Insight+towards+therapeutic+susceptibility+of+KRAS+mutant+cancers+from+MRTX1257%3B+A+prototype+selective+inhibitor+of+KRAS+G12C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DHallin%26aufirst%3DJ.%26atitle%3DInsight%2520towards%2520therapeutic%2520susceptibility%2520of%2520KRAS%2520mutant%2520cancers%2520from%2520MRTX1257%253B%2520A%2520prototype%2520selective%2520inhibitor%2520of%2520KRAS%2520G12C%26jtitle%3DAACR%2520Targeting%2520RAS-Driven%2520Cancers%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahmood, I.</span></span> <span> </span><span class="NLM_article-title">Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development</span>. <i>Adv. Drug Deliv. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1177</span>– <span class="NLM_lpage">1192</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2007.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1016%2Fj.addr.2007.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=17826864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1amsL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2007&pages=1177-1192&author=I.+Mahmood&title=Application+of+allometric+principles+for+the+prediction+of+pharmacokinetics+in+human+and+veterinary+drug+development&doi=10.1016%2Fj.addr.2007.05.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development</span></div><div class="casAuthors">Mahmood, Iftekhar</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1177-1192</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The concept of correlating pharmacokinetic parameters with body wt. (termed as pharmacokinetic interspecies scaling) from different animal species has become a useful tool in drug development.  Interspecies scaling is based on the power function, where the body wt. of the species is plotted against the pharmacokinetic parameter of interest.  Clearance, vol. of distribution, and elimination half-life are the three most frequently extrapolated pharmacokinetic parameters.  The predicted pharmacokinetic parameter clearance can be used for estg. a first-in-human dose.  Over the years, many approaches have been suggested to improve the prediction of aforementioned pharmacokinetic parameters in humans from animal data.  A literature review indicates that there are different degrees of success with different methods for different drugs.  Interspecies scaling is also a very useful tool in veterinary medicine.  The knowledge of pharmacokinetics in veterinary medicine is important for dosage selection, particularly in the treatment of large animals such as horses, camels, elephants, or other large zoo animals.  Despite the potential for extrapolation error, the reality is that interspecies scaling is needed across many veterinary practice situations, and therefore will be used.  For this reason, it is important to consider mechanisms for reducing the risk of extrapolation errors that can seriously affect animal safety and therapeutic response.  Overall, although interspecies scaling requires continuous refinement and better understanding, the rationale approach of interspecies scaling has a lot of potential during the drug development process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrG8VANcfYx7Vg90H21EOLACvtfcHk0lg_55vS8B5Ipw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1amsL7F&md5=387ebd60e0e0573306734851ac5b05b9</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2007.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2007.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DMahmood%26aufirst%3DI.%26atitle%3DApplication%2520of%2520allometric%2520principles%2520for%2520the%2520prediction%2520of%2520pharmacokinetics%2520in%2520human%2520and%2520veterinary%2520drug%2520development%26jtitle%3DAdv.%2520Drug%2520Deliv.%2520Rev.%26date%3D2007%26volume%3D59%26spage%3D1177%26epage%3D1192%26doi%3D10.1016%2Fj.addr.2007.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, T.</span></span> <span> </span><span class="NLM_article-title">Physiological parameters in laboratory animals and humans</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1093</span>– <span class="NLM_lpage">1095</span>, <span class="refDoi"> DOI: 10.1023/a:1018943613122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1023%2Fa%3A1018943613122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=8378254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A280%3ADyaK3szptFaqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1993&pages=1093-1095&author=B.+Daviesauthor=T.+Morris&title=Physiological+parameters+in+laboratory+animals+and+humans&doi=10.1023%2Fa%3A1018943613122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Physiological parameters in laboratory animals and humans</span></div><div class="casAuthors">Davies B; Morris T</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1093-5</span>
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDDwka3A6hEYYPsCkJIw00fW6udTcc2eaqhxAQkaJRVbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3szptFaqsg%253D%253D&md5=094cdd17306b58cc17c8cf4fd5db9927</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1023%2Fa%3A1018943613122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252Fa%253A1018943613122%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DB.%26aulast%3DMorris%26aufirst%3DT.%26atitle%3DPhysiological%2520parameters%2520in%2520laboratory%2520animals%2520and%2520humans%26jtitle%3DPharm.%2520Res.%26date%3D1993%26volume%3D10%26spage%3D1093%26epage%3D1095%26doi%3D10.1023%2Fa%3A1018943613122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, M.</span></span> <span> </span><span class="NLM_article-title">The role of extrahepatic metabolism in the pharmacokinetics of the targeted covalent inhibitors afatinib, ibrutinib, and neratinib</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">384</span>, <span class="refDoi"> DOI: 10.1124/dmd.114.061424</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1124%2Fdmd.114.061424" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=25504185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1OmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=375-384&author=Y.+Shibataauthor=M.+Chiba&title=The+role+of+extrahepatic+metabolism+in+the+pharmacokinetics+of+the+targeted+covalent+inhibitors+afatinib%2C+ibrutinib%2C+and+neratinib&doi=10.1124%2Fdmd.114.061424"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The role of extrahepatic metabolism in the pharmacokinetics of the targeted covalent inhibitors afatinib, ibrutinib, and neratinib</span></div><div class="casAuthors">Shibata, Yoshihiro; Chiba, Masato</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">375-384, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Despite the fact that much progress has been made recently in the development of targeted covalent inhibitors (TCIs), their pharmacokinetics (PK) have not been well characterized in the light of extrahepatic clearance (CLextH) by glutathione (GSH)/glutathione S-transferase (GST)-dependent conjugation attributable to the unique electrophilic structure (e.g., acrylamide moiety) of TCI compds.  In the present study, CLextH values were examd. in rat, dog, and monkey to predict the contribution of CLextH to the PK of the TCIs afatinib, ibrutinib, and neratinib in humans.  Afatinib and neratinib both underwent extensive conjugation with GSH in buffer and cytosol fractions of liver and kidney, whereas ibrutinib showed much lower reactivity/susceptibility to GSH/GST-dependent conjugation.  The CLextH in each species was calcd. from the difference between obsd. total body clearance and predicted hepatic clearance (CLH) in cryopreserved hepatocytes suspended in 100% serum of the corresponding species.  The power-based simple allometry relating the CLextH for the unbound compd. to animal body wt. was applicable across species for afatinib and neratinib (R2 ≥ 0.9) but not for ibrutinib (R2 = 0.04).  The predicted AUC after oral administration of afatinib and neratinib agreed reasonably closely with reported values in phase I dose-escalation studies.  Comparisons of CLextH and CLH predicted that CLextH largely detd. the PK of afatinib (>90% as a proportion of total body clearance) and neratinib (∼34%) in humans.  The present method can serve as one of the tools for the optimization of PK in humans at the discovery stage for the development of TCI candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquWC6d6e6DU7Vg90H21EOLACvtfcHk0lg_55vS8B5Ipw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1OmsrY%253D&md5=eaac67ce7cea5f2432c5144922ba3dd2</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1124%2Fdmd.114.061424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.114.061424%26sid%3Dliteratum%253Aachs%26aulast%3DShibata%26aufirst%3DY.%26aulast%3DChiba%26aufirst%3DM.%26atitle%3DThe%2520role%2520of%2520extrahepatic%2520metabolism%2520in%2520the%2520pharmacokinetics%2520of%2520the%2520targeted%2520covalent%2520inhibitors%2520afatinib%252C%2520ibrutinib%252C%2520and%2520neratinib%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26spage%3D375%26epage%3D384%26doi%3D10.1124%2Fdmd.114.061424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelevitz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zientek, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banfield, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorarensen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span> <span> </span><span class="NLM_article-title">Clearance prediction of targeted covalent inhibitors by in vitro-in vivo extrapolation of hepatic and extrapatic clearance mechanisms</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1124/dmd.116.072983</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1124%2Fdmd.116.072983" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=27784718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlSksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=1-7&author=L.+Leungauthor=X.+Yangauthor=T.+J.+Strelevitzauthor=J.+Montgomeryauthor=M.+F.+Brownauthor=M.+A.+Zientekauthor=C.+Banfieldauthor=A.+M.+Gilbertauthor=A.+Thorarensenauthor=M.+E.+Dowty&title=Clearance+prediction+of+targeted+covalent+inhibitors+by+in+vitro-in+vivo+extrapolation+of+hepatic+and+extrapatic+clearance+mechanisms&doi=10.1124%2Fdmd.116.072983"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Clearance prediction of targeted covalent inhibitors by in vitro-in vivo extrapolation of hepatic and extrahepatic clearance mechanisms</span></div><div class="casAuthors">Leung, Louis; Yang, Xin; Strelevitz, Timothy J.; Montgomery, Justin; Brown, Matthew F.; Zientek, Michael A.; Banfield, Christopher; Gilbert, Adam M.; Thorarensen, Atli; Dowty, Martin E.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The concept of target-specific covalent enzyme inhibitors appears attractive from both an efficacy and a selectivity viewpoint considering the potential for enhanced biochem. efficiency assocd. with an irreversible mechanism.  Aside from potential safety concerns, clearance prediction of covalent inhibitors represents a unique challenge due to the inclusion of nontraditional metabolic pathways of direct conjugation with glutathione (GSH) or via GSH S-transferase-mediated processes.  In this article, a novel pharmacokinetic algorithm was developed using a series of Pfizer kinase selective acrylamide covalent inhibitors based on their in vitro-in vivo extrapolation of systemic clearance in rats.  The algorithmencompasses the use of hepatocytes as an in vitro model for hepatic clearance due to oxidative metab. and GSH conjugation, and the use of whole blood as an in vitro surrogate for GSH conjugation in extrahepatic tissues.  Initial evaluations with clin. covalent inhibitors suggested that the scaling algorithm developed from rats may also be useful for human clearance prediction when species-specific parameters, such as hepatocyte and blood stability and blood binding, were considered.  With careful consideration of clearance mechanisms, the described in vitro-in vivo extrapolation approach may be useful to facilitate candidate optimization, selection, and prediction of human pharmacokinetic clearance during the discovery and development of targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvIMBCrCxzNLVg90H21EOLACvtfcHk0lgaUj57Fzg_dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlSksL4%253D&md5=8c8b918b087278b2025e0ae56a7abe37</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1124%2Fdmd.116.072983&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.116.072983%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DMontgomery%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DZientek%26aufirst%3DM.%2BA.%26aulast%3DBanfield%26aufirst%3DC.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DThorarensen%26aufirst%3DA.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26atitle%3DClearance%2520prediction%2520of%2520targeted%2520covalent%2520inhibitors%2520by%2520in%2520vitro-in%2520vivo%2520extrapolation%2520of%2520hepatic%2520and%2520extrapatic%2520clearance%2520mechanisms%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2017%26volume%3D45%26spage%3D1%26epage%3D7%26doi%3D10.1124%2Fdmd.116.072983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span> <span> </span><span class="NLM_article-title">A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9889</span>– <span class="NLM_lpage">9900</span>, <span class="refDoi"> DOI: 10.1021/jm5014659</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5014659" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKqu7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9889-9900&author=G.+Xiaauthor=W.+Chenauthor=J.+Zhangauthor=J.+Shaoauthor=Y.+Zhangauthor=W.+Huangauthor=L.+Zhangauthor=W.+Qiauthor=X.+Sunauthor=B.+Liauthor=Z.+Xiangauthor=C.+Maauthor=J.+Xuauthor=H.+Dengauthor=Y.+Liauthor=P.+Liauthor=H.+Miaoauthor=J.+Hanauthor=Y.+Liuauthor=J.+Shenauthor=Y.+Yu&title=A+chemical+tuned+strategy+to+develop+novel+irreversible+EGFR-TK+inhibitors+with+improved+safety+and+pharmacokinetic+profiles&doi=10.1021%2Fjm5014659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles</span></div><div class="casAuthors">Xia, Guangxin; Chen, Wenteng; Zhang, Jing; Shao, Jiaan; Zhang, Yong; Huang, Wei; Zhang, Leduo; Qi, Weixing; Sun, Xing; Li, Bojun; Xiang, Zhixiong; Ma, Chen; Xu, Jia; Deng, Hailin; Li, Yufeng; Li, Ping; Miao, Hong; Han, Jiansheng; Liu, Yanjun; Shen, Jingkang; Yu, Yongping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9889-9900</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Gatekeeper T790 M mutation in EGFR is the most prevalent factor underlying acquired resistance.  Acrylamide-bearing quinazoline derivs. are powerful irreversible inhibitors for overcoming resistance.  Nevertheless, concerns about the risk of nonspecific covalent modification have motivated the development of novel cysteine-targeting inhibitors.  In this paper, the authors demonstrate that fluoro-substituted olefins can be tuned to alter Michael addn. reactivity.  Incorporation of these olefins into the quinazoline templates produced potent EGFR inhibitors with improved safety and pharmacokinetic properties.  A lead compd. I was validated against EGFRWT, EGFRT790M as well as A431 and H1975 cancer cell lines.  Addnl., compd. I displayed a weaker inhibition against the EGFR-independent cancer cell line SW620 when compared with afatinib.  Oral administration of I at a dose of 30 mg/kg induced tumor regression in a murine-EGFRL858R/T790M driven H1975 xenograft model.  Also, I exhibited improved oral bioavailability and safety as well as favorable tissue distribution properties and enhanced brain uptake.  These findings provide the basis of a promising strategy toward the treatment of NSCLC patients with drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV-v8dZV3wkLVg90H21EOLACvtfcHk0lgaUj57Fzg_dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKqu7vF&md5=bc5ffd322783971a898d5c0fa62d261c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm5014659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5014659%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DMiao%26aufirst%3DH.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DY.%26atitle%3DA%2520chemical%2520tuned%2520strategy%2520to%2520develop%2520novel%2520irreversible%2520EGFR-TK%2520inhibitors%2520with%2520improved%2520safety%2520and%2520pharmacokinetic%2520profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9889%26epage%3D9900%26doi%3D10.1021%2Fjm5014659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of AZD9291 derivatives as selective and potent EGFRL<sup>858R/T790M</sup> inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.11.069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1016%2Fj.ejmech.2018.11.069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=30530173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKqsrfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2019&pages=367-380&author=B.+Zhaoauthor=Z.+Xiaoauthor=J.+Qiauthor=R.+Luoauthor=Z.+Lanauthor=Y.+Zhangauthor=X.+Huauthor=Q.+Tangauthor=P.+Zhengauthor=S.+Xuauthor=W.+Zhu&title=Design%2C+synthesis+and+biological+evaluation+of+AZD9291+derivatives+as+selective+and+potent+EGFRL858R%2FT790M+inhibitors&doi=10.1016%2Fj.ejmech.2018.11.069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of AZD9291 derivatives as selective and potent EGFRL858R/T790M inhibitors</span></div><div class="casAuthors">Zhao, Bingbing; Xiao, Zhen; Qi, Jianguo; Luo, Rong; Lan, Zhou; Zhang, Yanzhuo; Hu, Xiaohan; Tang, Qidong; Zheng, Pengwu; Xu, Shan; Zhu, Wufu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">367-380</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Third-generation epidermal growth factor receptor (EGFR)L858R/T790M inhibitors are still the main drugs for the treatment of advanced non-small cell lung cancer (NSCLC), and these drugs have achieved remarkable clin. efficacy.  However, there are still many patients suffering from drug-resistant mutations and drug side effects caused by NSCLC.  In this study, guided by the mol. simulation, we applied a structure-based drug design strategy (SBDD) and optimized the structure to obtain a series of potent and selective EGFRL858R/T790M inhibitors.  The most potent compd. 18e demonstrated excellent kinase inhibitory activity and selectivity for EGFRL858R/T790M double mutants and the IC50 value reached nanomolar level.  The selectivity of 18e against wild-type EGFR was near to 200-fold.  In addn., compd. 18e also inhibited H1975 cells proliferation at G2/M phase and induced apoptosis at a concn. of 0.25 μM, which makes it more valuable for potential lung cancer research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8TnKdjpJ_mLVg90H21EOLACvtfcHk0ljli9g_xn-Hiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKqsrfM&md5=c189aed9e39d21f36c80155ea2ea80a1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.11.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.11.069%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DXiao%26aufirst%3DZ.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DR.%26aulast%3DLan%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DQ.%26aulast%3DZheng%26aufirst%3DP.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DW.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520AZD9291%2520derivatives%2520as%2520selective%2520and%2520potent%2520EGFRL858R%252FT790M%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D163%26spage%3D367%26epage%3D380%26doi%3D10.1016%2Fj.ejmech.2018.11.069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babbar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">The reactivity driven biochemical mechanism of covalent KRAS(G12C) inhibitors</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1038/s41594-018-0061-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1038%2Fs41594-018-0061-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=29760531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKqu7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=454-462&author=R.+Hansenauthor=U.+Petersauthor=A.+Babbarauthor=Y.+Chenauthor=J.+Fengauthor=M.+R.+Janesauthor=L.-S.+Liauthor=P.+Renauthor=Y.+Liuauthor=P.+P.+Zarrinkar&title=The+reactivity+driven+biochemical+mechanism+of+covalent+KRAS%28G12C%29+inhibitors&doi=10.1038%2Fs41594-018-0061-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors</span></div><div class="casAuthors">Hansen, Rasmus; Peters, Ulf; Babbar, Anjali; Chen, Yuching; Feng, Jun; Janes, Matthew R.; Li, Lian-Sheng; Ren, Pingda; Liu, Yi; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">454-462</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Activating mutations in KRAS are among the most common tumor driver mutations.  Until recently, KRAS had been considered undruggable with small mols.; the discovery of the covalent KRASG12C inhibitors ARS-853 and ARS-1620 has demonstrated that it is feasible to inhibit KRAS with high potency in cells and animals.  Although the biol. activity of these inhibitors has been described, the biochem. mechanism of how the compds. achieve potent inhibition remained incompletely understood.  We now show that the activity of ARS-853 and ARS-1620 is primarily driven by KRAS-mediated catalysis of the chem. reaction with Cys12 in human KRASG12C, while the reversible binding affinity is weak, in the hundreds of micromolar or higher range.  The mechanism resolves how an induced, shallow and dynamic pocket not expected to support high-affinity binding of small mols. can nevertheless be targeted with potent inhibitors and may be applicable to other targets conventionally considered undruggable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrya_A4ZYnOu7Vg90H21EOLACvtfcHk0ljli9g_xn-Hiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKqu7nL&md5=b3f9198f55998306f3b881c256be22a9</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fs41594-018-0061-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-018-0061-5%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DR.%26aulast%3DPeters%26aufirst%3DU.%26aulast%3DBabbar%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DJanes%26aufirst%3DM.%2BR.%26aulast%3DLi%26aufirst%3DL.-S.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DThe%2520reactivity%2520driven%2520biochemical%2520mechanism%2520of%2520covalent%2520KRAS%2528G12C%2529%2520inhibitors%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D454%26epage%3D462%26doi%3D10.1038%2Fs41594-018-0061-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Canon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiki, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapaport, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osgood, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volak, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houk, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fakih, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neil, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falchook, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henary, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvedson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cee, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipford, J. R.</span></span> <span> </span><span class="NLM_article-title">The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>575</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1038/s41586-019-1694-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1038%2Fs41586-019-1694-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=31666701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitV2hsb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=575&publication_year=2019&pages=217-223&author=J.+Canonauthor=K.+Rexauthor=A.+Y.+Saikiauthor=C.+Mohrauthor=K.+Cookeauthor=D.+Bagalauthor=K.+Gaidaauthor=T.+Holtauthor=C.+G.+Knutsonauthor=N.+Koppadaauthor=B.+A.+Lanmanauthor=J.+Wernerauthor=A.+S.+Rapaportauthor=T.+San+Miguelauthor=R.+Ortizauthor=T.+Osgoodauthor=J.-R.+Sunauthor=X.+Zhuauthor=J.+D.+McCarterauthor=L.+P.+Volakauthor=B.+E.+Houkauthor=M.+G.+Fakihauthor=B.+H.+O%E2%80%99Neilauthor=T.+J.+Priceauthor=G.+S.+Falchookauthor=J.+Desaiauthor=J.+Kuoauthor=R.+Govindanauthor=D.+S.+Hongauthor=W.+Ouyangauthor=H.+Henaryauthor=T.+Arvedsonauthor=V.+J.+Ceeauthor=J.+R.+Lipford&title=The+clinical+KRAS%28G12C%29+inhibitor+AMG+510+drives+anti-tumour+immunity&doi=10.1038%2Fs41586-019-1694-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity</span></div><div class="casAuthors">Canon, Jude; Rex, Karen; Saiki, Anne Y.; Mohr, Christopher; Cooke, Keegan; Bagal, Dhanashri; Gaida, Kevin; Holt, Tyler; Knutson, Charles G.; Koppada, Neelima; Lanman, Brian A.; Werner, Jonathan; Rapaport, Aaron S.; San Miguel, Tisha; Ortiz, Roberto; Osgood, Tao; Sun, Ji-Rong; Zhu, Xiaochun; McCarter, John D.; Volak, Laurie P.; Houk, Brett E.; Fakih, Marwan G.; O'Neil, Bert H.; Price, Timothy J.; Falchook, Gerald S.; Desai, Jayesh; Kuo, James; Govindan, Ramaswamy; Hong, David S.; Ouyang, Wenjun; Henary, Haby; Arvedson, Tara; Cee, Victor J.; Lipford, J. Russell</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">575</span>
        (<span class="NLM_cas:issue">7781</span>),
    <span class="NLM_cas:pages">217-223</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">KRAS is the most frequently mutated oncogene in cancer and encodes a key signalling protein in tumors1,2.  The KRAS(G12C) mutant has a cysteine residue that has been exploited to design covalent inhibitors that have promising preclin. activity3-5.  Here we optimized a series of inhibitors, using novel binding interactions to markedly enhance their potency and selectivity.  Our efforts have led to the discovery of AMG 510, which is, to our knowledge, the first KRAS(G12C) inhibitor in clin. development.  In preclin. analyses, treatment with AMG 510 led to the regression of KRASG12C tumors and improved the anti-tumor efficacy of chemotherapy and targeted agents.  In immune-competent mice, treatment with AMG 510 resulted in a pro-inflammatory tumor microenvironment and produced durable cures alone as well as in combination with immune-checkpoint inhibitors.  Cured mice rejected the growth of isogenic KRASG12D tumors, which suggests adaptive immunity against shared antigens.  Furthermore, in clin. trials, AMG 510 demonstrated anti-tumor activity in the first dosing cohorts and represents a potentially transformative therapy for patients for whom effective treatments are lacking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTHdBftQfnhbVg90H21EOLACvtfcHk0ljli9g_xn-Hiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitV2hsb7F&md5=3819175980905976ba87ff545b9506e1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-1694-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-1694-1%26sid%3Dliteratum%253Aachs%26aulast%3DCanon%26aufirst%3DJ.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DSaiki%26aufirst%3DA.%2BY.%26aulast%3DMohr%26aufirst%3DC.%26aulast%3DCooke%26aufirst%3DK.%26aulast%3DBagal%26aufirst%3DD.%26aulast%3DGaida%26aufirst%3DK.%26aulast%3DHolt%26aufirst%3DT.%26aulast%3DKnutson%26aufirst%3DC.%2BG.%26aulast%3DKoppada%26aufirst%3DN.%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DWerner%26aufirst%3DJ.%26aulast%3DRapaport%26aufirst%3DA.%2BS.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DOrtiz%26aufirst%3DR.%26aulast%3DOsgood%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DJ.-R.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DVolak%26aufirst%3DL.%2BP.%26aulast%3DHouk%26aufirst%3DB.%2BE.%26aulast%3DFakih%26aufirst%3DM.%2BG.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DB.%2BH.%26aulast%3DPrice%26aufirst%3DT.%2BJ.%26aulast%3DFalchook%26aufirst%3DG.%2BS.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DKuo%26aufirst%3DJ.%26aulast%3DGovindan%26aufirst%3DR.%26aulast%3DHong%26aufirst%3DD.%2BS.%26aulast%3DOuyang%26aufirst%3DW.%26aulast%3DHenary%26aufirst%3DH.%26aulast%3DArvedson%26aufirst%3DT.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DLipford%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520clinical%2520KRAS%2528G12C%2529%2520inhibitor%2520AMG%2520510%2520drives%2520anti-tumour%2520immunity%26jtitle%3DNature%26date%3D2019%26volume%3D575%26spage%3D217%26epage%3D223%26doi%3D10.1038%2Fs41586-019-1694-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wijeratne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reutter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furness, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zia-Ebrahimi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavitt, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelow, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Horn, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barda, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engler, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalmers, M. J.</span></span> <span> </span><span class="NLM_article-title">Chemical proteomic characterization of a covalent KRASG12C inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00110</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00110" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvVeisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=557-562&author=A.+Wijeratneauthor=J.+Xiaoauthor=C.+Reutterauthor=K.+W.+Furnessauthor=R.+Leonauthor=M.+Zia-Ebrahimiauthor=R.+N.+Cavittauthor=J.+M.+Strelowauthor=R.+D.+Van+Hornauthor=S.-B.+Pengauthor=D.+A.+Bardaauthor=T.+A.+Englerauthor=M.+J.+Chalmers&title=Chemical+proteomic+characterization+of+a+covalent+KRASG12C+inhibitor&doi=10.1021%2Facsmedchemlett.8b00110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor</span></div><div class="casAuthors">Wijeratne, Aruna; Xiao, Junpeng; Reutter, Christopher; Furness, Kelly W.; Leon, Rebecca; Zia-Ebrahimi, Mohammad; Cavitt, Rachel N.; Strelow, John M.; Van Horn, Robert D.; Peng, Sheng-Bin; Barda, David A.; Engler, Thomas A.; Chalmers, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">557-562</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The KRASG12C protein product is an attractive, yet challenging, target for small mol. inhibition.  One option for therapeutic intervention is to design small mol. ligands capable of binding to and inactivating KRASG12C via formation of a covalent bond to the sulfhydryl group of cysteine 12.  In order to better understand the cellular off-target interactions of Compd. I, a covalent KRASG12C inhibitor, we have completed a series of complementary chem. proteomics expts. in H358 cells.  A new thiol reactive probe (TRP) was designed and used to construct a cellular target occupancy assay for KRASG12C.  In addn., the thiol reactive probes allowed us to profile potential off-target interactions of Compd. I with over 3200 cysteine residues.  In order to complement the TRP data we designed Compd. II, an alkyne contg. version of Compd. I, to serve as bait in competitive chem. proteomics expts.  Herein, we describe and compare data from both the TRP and the click chem. probe pull down expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp215tWumE2SrVg90H21EOLACvtfcHk0ljRukHFt8j_kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvVeisrw%253D&md5=e95db80896d3bd29efaaf0ce541c760e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00110%26sid%3Dliteratum%253Aachs%26aulast%3DWijeratne%26aufirst%3DA.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DReutter%26aufirst%3DC.%26aulast%3DFurness%26aufirst%3DK.%2BW.%26aulast%3DLeon%26aufirst%3DR.%26aulast%3DZia-Ebrahimi%26aufirst%3DM.%26aulast%3DCavitt%26aufirst%3DR.%2BN.%26aulast%3DStrelow%26aufirst%3DJ.%2BM.%26aulast%3DVan%2BHorn%26aufirst%3DR.%2BD.%26aulast%3DPeng%26aufirst%3DS.-B.%26aulast%3DBarda%26aufirst%3DD.%2BA.%26aulast%3DEngler%26aufirst%3DT.%2BA.%26aulast%3DChalmers%26aufirst%3DM.%2BJ.%26atitle%3DChemical%2520proteomic%2520characterization%2520of%2520a%2520covalent%2520KRASG12C%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D557%26epage%3D562%26doi%3D10.1021%2Facsmedchemlett.8b00110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hallin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calinisan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briere, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudhakar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowcut, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkard, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigers, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Banet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlicek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velastagui, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierobon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patricoin, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassidy, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybkin, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lito, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span> <span> </span><span class="NLM_article-title">The KRASG12C inhibitor, MRTX849, provides insights toward therapeutic susceptibility of KRAS mutant cancers in mouse models and patients</span>. <i>Canc. Discov.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.cd-19-1167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1158%2F2159-8290.CD-19-1167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=31658955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A280%3ADC%252BB3Mjitl2jtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=54-71&author=J.+Hallinauthor=L.+D.+Engstromauthor=L.+Hargisauthor=A.+Calinisanauthor=R.+Arandaauthor=D.+M.+Briereauthor=N.+Sudhakarauthor=V.+Bowcutauthor=B.+R.+Baerauthor=J.+A.+Ballardauthor=M.+R.+Burkardauthor=J.+B.+Fellauthor=J.+P.+Fischerauthor=G.+P.+Vigersauthor=Y.+Xueauthor=S.+Gattoauthor=J.+Fernandez-Banetauthor=A.+Pavlicekauthor=K.+Velastaguiauthor=R.+C.+Chaoauthor=J.+Bartonauthor=M.+Pierobonauthor=E.+Baldelliauthor=E.+F.+Patricoinauthor=D.+P.+Cassidyauthor=M.+A.+Marxauthor=I.+I.+Rybkinauthor=M.+L.+Johnsonauthor=S.-H.+I.+Ouauthor=P.+Litoauthor=K.+P.+Papadopoulosauthor=P.+A.+J%C3%A4nneauthor=P.+Olsonauthor=J.+G.+Christensen&title=The+KRASG12C+inhibitor%2C+MRTX849%2C+provides+insights+toward+therapeutic+susceptibility+of+KRAS+mutant+cancers+in+mouse+models+and+patients&doi=10.1158%2F2159-8290.cd-19-1167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients</span></div><div class="casAuthors">Hallin Jill; Engstrom Lars D; Hargis Lauren; Calinisan Andrew; Aranda Ruth; Briere David M; Sudhakar Niranjan; Bowcut Vickie; Velastagui Karen; Chao Richard C; Barton Jeremy; Marx Matthew A; Olson Peter; Christensen James G; Baer Brian R; Ballard Joshua A; Burkard Michael R; Fell Jay B; Fischer John P; Vigers Guy P; Xue Yaohua; Lito Piro; Gatto Sole; Fernandez-Banet Julio; Pavlicek Adam; Pierobon Mariaelena; Baldelli Elisa; Patricoin Emanuel F 3rd; Cassidy Douglas P; Janne Pasi A; Rybkin Igor I; Johnson Melissa L; Ou Sai-Hong Ignatius; Papadopoulos Kyriakos P</div><div class="citationInfo"><span class="NLM_cas:title">Cancer discovery</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-71</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Despite decades of research, efforts to directly target KRAS have been challenging.  MRTX849 was identified as a potent, selective, and covalent KRAS(G12C) inhibitor that exhibits favorable drug-like properties, selectively modifies mutant cysteine 12 in GDP-bound KRAS(G12C), and inhibits KRAS-dependent signaling.  MRTX849 demonstrated pronounced tumor regression in 17 of 26 (65%) KRAS(G12C)-positive cell line- and patient-derived xenograft models from multiple tumor types, and objective responses have been observed in patients with KRAS(G12C)-positive lung and colon adenocarcinomas.  Comprehensive pharmacodynamic and pharmacogenomic profiling in sensitive and partially resistant nonclinical models identified mechanisms implicated in limiting antitumor activity including KRAS nucleotide cycling and pathways that induce feedback reactivation and/or bypass KRAS dependence.  These factors included activation of receptor tyrosine kinases (RTK), bypass of KRAS dependence, and genetic dysregulation of cell cycle.  Combinations of MRTX849 with agents that target RTKs, mTOR, or cell cycle demonstrated enhanced response and marked tumor regression in several tumor models, including MRTX849-refractory models.  SIGNIFICANCE: The discovery of MRTX849 provides a long-awaited opportunity to selectively target KRAS(G12C) in patients.  The in-depth characterization of MRTX849 activity, elucidation of response and resistance mechanisms, and identification of effective combinations provide new insight toward KRAS dependence and the rational development of this class of agents.See related commentary by Klempner and Hata, p. 20.This article is highlighted in the In This Issue feature, p. 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2TUtaXPf8uHl8icjszYl0fW6udTcc2eZ5wdSyvqbsbbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mjitl2jtA%253D%253D&md5=49d361ac110c002732933f302220049d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-19-1167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-19-1167%26sid%3Dliteratum%253Aachs%26aulast%3DHallin%26aufirst%3DJ.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHargis%26aufirst%3DL.%26aulast%3DCalinisan%26aufirst%3DA.%26aulast%3DAranda%26aufirst%3DR.%26aulast%3DBriere%26aufirst%3DD.%2BM.%26aulast%3DSudhakar%26aufirst%3DN.%26aulast%3DBowcut%26aufirst%3DV.%26aulast%3DBaer%26aufirst%3DB.%2BR.%26aulast%3DBallard%26aufirst%3DJ.%2BA.%26aulast%3DBurkard%26aufirst%3DM.%2BR.%26aulast%3DFell%26aufirst%3DJ.%2BB.%26aulast%3DFischer%26aufirst%3DJ.%2BP.%26aulast%3DVigers%26aufirst%3DG.%2BP.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DGatto%26aufirst%3DS.%26aulast%3DFernandez-Banet%26aufirst%3DJ.%26aulast%3DPavlicek%26aufirst%3DA.%26aulast%3DVelastagui%26aufirst%3DK.%26aulast%3DChao%26aufirst%3DR.%2BC.%26aulast%3DBarton%26aufirst%3DJ.%26aulast%3DPierobon%26aufirst%3DM.%26aulast%3DBaldelli%26aufirst%3DE.%26aulast%3DPatricoin%26aufirst%3DE.%2BF.%26aulast%3DCassidy%26aufirst%3DD.%2BP.%26aulast%3DMarx%26aufirst%3DM.%2BA.%26aulast%3DRybkin%26aufirst%3DI.%2BI.%26aulast%3DJohnson%26aufirst%3DM.%2BL.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DLito%26aufirst%3DP.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DOlson%26aufirst%3DP.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DThe%2520KRASG12C%2520inhibitor%252C%2520MRTX849%252C%2520provides%2520insights%2520toward%2520therapeutic%2520susceptibility%2520of%2520KRAS%2520mutant%2520cancers%2520in%2520mouse%2520models%2520and%2520patients%26jtitle%3DCanc.%2520Discov.%26date%3D2020%26volume%3D10%26spage%3D54%26epage%3D71%26doi%3D10.1158%2F2159-8290.cd-19-1167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">Mild and General Palladium-Catalyzed Synthesis of Methyl Ethers Enabled by Palladacycle Precatalyst</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3998</span>, <span class="refDoi"> DOI: 10.1021/ol401796v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol401796v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFKgurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=3998&author=C.+W.+Cheungauthor=S.+L.+Buchwald&title=Mild+and+General+Palladium-Catalyzed+Synthesis+of+Methyl+Ethers+Enabled+by+Palladacycle+Precatalyst&doi=10.1021%2Fol401796v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Mild and General Palladium-Catalyzed Synthesis of Methyl Aryl Ethers Enabled by the Use of a Palladacycle Precatalyst</span></div><div class="casAuthors">Cheung, Chi Wai; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3998-4001</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A general method for the Pd-catalyzed coupling of methanol with (hetero)aryl halides is described.  The reactions proceed under mild conditions with a wide range of aryl and heteroaryl halides to give Me aryl ethers in high yield.  E.g., in presence of palladacycle precatalyst I (L = tBuBrettPhos) and the ligand tBuBrettPhos, arylation of MeOH by 4-Me3CC6H4Cl gave 93% 4-Me3CC6H4OMe.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJNZIu1ifO97Vg90H21EOLACvtfcHk0lg8yYvgxhdGSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFKgurzL&md5=de17e9bf376136d0ca7d801928032e7e</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fol401796v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol401796v%26sid%3Dliteratum%253Aachs%26aulast%3DCheung%26aufirst%3DC.%2BW.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DMild%2520and%2520General%2520Palladium-Catalyzed%2520Synthesis%2520of%2520Methyl%2520Ethers%2520Enabled%2520by%2520Palladacycle%2520Precatalyst%26jtitle%3DOrg.%2520Lett.%26date%3D2013%26volume%3D15%26spage%3D3998%26doi%3D10.1021%2Fol401796v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit28a"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fors, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">A single phosphine ligand allows palladium-catalyzed intermolecular C-O bond formation with secondary and primary alcohols</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">9943</span>, <span class="refDoi"> DOI: 10.1002/anie.201104361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1002%2Fanie.201104361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFKhs7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=9943&author=X.+Wuauthor=B.+P.+Forsauthor=S.+L.+Buchwald&title=A+single+phosphine+ligand+allows+palladium-catalyzed+intermolecular+C-O+bond+formation+with+secondary+and+primary+alcohols&doi=10.1002%2Fanie.201104361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A Single Phosphine Ligand Allows Palladium-Catalyzed Intermolecular C-O Bond Formation with Secondary and Primary Alcohols</span></div><div class="casAuthors">Wu, Xiaoxing; Fors, Brett P.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">9943-9947, S9943/1-S9943/134</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">An efficient, general palladium catalyst for C-O bond-forming reactions of secondary and primary alcs. with a range of aryl halides has been developed using RockPhos ligand I.  Heteroaryl halides, and, for the first time, electron-rich aryl halides can be coupled with secondary alcs.  A diverse set of substrate combinations are possible with just a single ligand, thus obviating the need to survey multiple ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1rRsKbYpjabVg90H21EOLACvtfcHk0lg8yYvgxhdGSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFKhs7jE&md5=00f2f016dd227483158dacc2e24fb614</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1002%2Fanie.201104361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201104361%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%26aulast%3DFors%26aufirst%3DB.%2BP.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DA%2520single%2520phosphine%2520ligand%2520allows%2520palladium-catalyzed%2520intermolecular%2520C-O%2520bond%2520formation%2520with%2520secondary%2520and%2520primary%2520alcohols%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2011%26volume%3D50%26spage%3D9943%26doi%3D10.1002%2Fanie.201104361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit28b"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maligres, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krska, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreier, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raheem, I. T.</span></span> <span> </span><span class="NLM_article-title">C-O cross-coupling of activated aryl and heteroaryl halides with aliphatic alcohols</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">9071</span>, <span class="refDoi"> DOI: 10.1002/anie.201203460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1002%2Fanie.201203460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFGhtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=9071&author=P.+E.+Maligresauthor=J.+Liauthor=S.+W.+Krskaauthor=J.+D.+Schreierauthor=I.+T.+Raheem&title=C-O+cross-coupling+of+activated+aryl+and+heteroaryl+halides+with+aliphatic+alcohols&doi=10.1002%2Fanie.201203460"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">C-O Cross-Coupling of Activated Aryl and Heteroaryl Halides with Aliphatic Alcohols</span></div><div class="casAuthors">Maligres, Peter E.; Li, Jing; Krska, Shane W.; Schreier, John D.; Raheem, Izzat T.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">9071-9074,S9071/1-S9071/21</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The authors describe a Pd/Josiphos catatyst system for alkoxylation of activated aryl and heteroaryl halides with primary, secondary, and select tertiary alcs.  E.g., in presence of [Pd2(dba)3] and ligand CyPF-tBu (I), C-O cross-coupling of 4-chloro-2-methylquinoline and PhCH2CH2OH gave 99% arom. ether 4-(2-phenylethoxy)-2-methylquinoline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqDUweMYyL3bVg90H21EOLACvtfcHk0lg8yYvgxhdGSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFGhtLvN&md5=0888ab292ffa72853009ba5c64e71f4f</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1002%2Fanie.201203460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201203460%26sid%3Dliteratum%253Aachs%26aulast%3DMaligres%26aufirst%3DP.%2BE.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DKrska%26aufirst%3DS.%2BW.%26aulast%3DSchreier%26aufirst%3DJ.%2BD.%26aulast%3DRaheem%26aufirst%3DI.%2BT.%26atitle%3DC-O%2520cross-coupling%2520of%2520activated%2520aryl%2520and%2520heteroaryl%2520halides%2520with%2520aliphatic%2520alcohols%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2012%26volume%3D51%26spage%3D9071%26doi%3D10.1002%2Fanie.201203460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sureshbabu, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwanatha, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panguluri, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basavaprabhu</span></span> <span> </span><span class="NLM_article-title">Propanephosphonic acid anhydride (T3P®) - a benign reagent for diverse applications inclusive of large-scale synthesis</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1569</span>– <span class="NLM_lpage">1601</span>, <span class="refDoi"> DOI: 10.1055/s-0033-1338989</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=10.1055%2Fs-0033-1338989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1ClsLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=1569-1601&author=V.+V.+Sureshbabuauthor=T.+M.+Vishwanathaauthor=N.+R.+Panguluriauthor=+Basavaprabhu&title=Propanephosphonic+acid+anhydride+%28T3P%C2%AE%29+-+a+benign+reagent+for+diverse+applications+inclusive+of+large-scale+synthesis&doi=10.1055%2Fs-0033-1338989"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Propanephosphonic acid anhydride (T3P). A benign reagent for diverse applications inclusive of large-scale synthesis</span></div><div class="casAuthors">Basavaprabhu; Vishwanatha, T. M.; Panguluri, Nageswara Rao; Sureshbabu, Vommina V.</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1569-1601</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">A review.  Propanephosphonic acid anhydride (T3P) is a prevailing coupling and dehydrating agent with many desirable properties which render it a reagent of choice for a plethora of reactions and, befittingly, its application in org. synthesis is rapidly increasing.  Since its introduction as a peptide coupling agent in 1980, the realm of applications of T3P expanded.  Currently its use showed a broad range of reactions, including condensation, functional group transformation, heterocycles prepn., rearrangements, and catalysis.  It offers several advantages over traditional reagents, such as high yield, chem. and optical purity, broad functional group tolerance and easy work-up.  The reagent is attractive for large-scale synthesis as well, and particularly so for multi-kilogram scale prepns. of drug mols.  This article reviewed the hitherto reported applications of T3P as a reagent in org. synthesis.  Focus is also placed on the use of T3P for large-scale synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYFQQPdkNefLVg90H21EOLACvtfcHk0lgS_FjiaE6CIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1ClsLfE&md5=651a5f3c12c616d20c3ee00706b5b541</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1055%2Fs-0033-1338989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0033-1338989%26sid%3Dliteratum%253Aachs%26aulast%3DSureshbabu%26aufirst%3DV.%2BV.%26aulast%3DVishwanatha%26aufirst%3DT.%2BM.%26aulast%3DPanguluri%26aufirst%3DN.%2BR.%26aulast%3DBasavaprabhu%26atitle%3DPropanephosphonic%2520acid%2520anhydride%2520%2528T3P%25C2%25AE%2529%2520-%2520a%2520benign%2520reagent%2520for%2520diverse%2520applications%2520inclusive%2520of%2520large-scale%2520synthesis%26jtitle%3DSynthesis%26date%3D2013%26volume%3D45%26spage%3D1569%26epage%3D1601%26doi%3D10.1055%2Fs-0033-1338989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6USX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6USX','PDB','6USX'); return false;">PDB: 6USX</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6USZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6USZ','PDB','6USZ'); return false;">PDB: 6USZ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UT0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UT0','PDB','6UT0'); return false;">PDB: 6UT0</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UTO" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UTO','PDB','6UTO'); return false;">PDB: 6UTO</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i42"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02052">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_80730"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b02052?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02052</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthetic experimental procedures, NMR spectra of final compounds, GSH reactivity data, metabolism of <b>MRTX849</b>, KRAS<sup>G12C</sup> target engagement, measurement of <i>K</i><sub>inact</sub>/<i>K</i><sub>I</sub>, metabolite identification in hepatocytes, NCI-H358 proteome cysteine selectivity assay, and click chemistry target identification and proteome selectivity and click chemistry target identification quantified protein list (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02052/suppl_file/jm9b02052_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02052/suppl_file/jm9b02052_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02052/suppl_file/jm9b02052_si_001.pdf">jm9b02052_si_001.pdf (7.92 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02052/suppl_file/jm9b02052_si_002.csv">jm9b02052_si_002.csv (2.39 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b02052&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-13%3BrequestedJournal%3Ajournal%3Ajmcmar%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b02052%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b02052" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a7fd0bc2e3cd6","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
